

Artificial Intelligence in Biomarker Discovery: Applications Across Medical Specialties

Authors:

Mobina Gheibi

Mazandaran University of Medical Sciences

Yasamin Rajabloo

Mashhad University of Medical Sciences

Yalda Alipour-Khabir

Ardabil University of Medical Sciences

Pouria Azami

Shiraz University of Medical Sciences

Sepideh Louia

Islamic Azad University, Central Tehran Branch

Tahmineh Ezazi Bojnordi

Iran University of Medical Sciences

Mahdi Javadian

University of Campania Luigi Vanvitelli

Masoud Jahanbakhsh Javid

Swansea University

Masih Kavian

Islamic Azad University, Tehran Dental Branch

Negar Rajabi

Azad University of Mashhad

Farbod Bigdeli

University of Texas at Arlington

Amir Ali Belbasi

University of Texas at Arlington

Shabnam Zolghadr Asli

Shiraz University of Medical Sciences

Sargol Assadi

University of Tehran

Fatemeh Ebrahimi

Shiraz University of Medical Sciences

Mostafa Ahangarian

Tarbiat Modares University

Negin Rabiei

Shiraz University of Medical Sciences

Fatemeh Mosayyebi

Babol University of Medical Sciences

Book Details:

Publisher: Kindle

Publication Date: August 2025

Language: English

Dimensions: 5 x 0.39 x 8 inches

© Kindle and PreferPub 2025

ISBN-13: 979-8298382267

This peer-reviewed book is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specially the rights of translation, reprinting, result of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

Contents

Chapter

1. AI in Biomarker Discovery for Renal Diseases
2. AI in Biomarker Discovery for Neurological Diseases
3. AI in Biomarker Discovery for Gastrointestinal Diseases
4. AI in Biomarker Discovery for Cardiac Diseases
5. AI in Biomarker Discovery for Dermatological Diseases
6. AI in Biomarker Discovery for Oncology
7. AI in Biomarker Discovery for Oral Diseases
8. AI in Biomarker Discovery for Infectious Diseases
9. AI in Biomarker Discovery for Rheumatological Diseases
10. AI in Biomarker Discovery for Other Diseases

1. AI IN BIOMARKER DISCOVERY FOR RENAL DISEASES

Background

Renal diseases encompass a broad spectrum of conditions that impair kidney structure and function, ultimately affecting the body's ability to maintain homeostasis. The timely identification of molecular and cellular biomarkers plays a pivotal role in diagnosing kidney disorders, monitoring disease progression, and tailoring personalized treatment strategies. Biomarkers can range from genetic and epigenetic alterations to proteins, metabolites, and imaging signatures. However, conventional biomarker discovery methods often face challenges such as high data complexity, heterogeneity among patient populations, and the difficulty of integrating multi-omics data. Artificial intelligence has emerged as a transformative tool in this domain, offering the ability to detect subtle patterns within large and diverse datasets, identify novel biomarker candidates, and validate them more efficiently than traditional methods. In renal disease research, AI has the potential to improve diagnostic accuracy, predict therapeutic response, and identify early indicators of disease progression that might otherwise remain hidden.

The Role of Biomarkers in Renal Disease Management

Biomarkers are measurable indicators of biological processes, pathogenic mechanisms, or responses to therapeutic interventions. In the context of renal diseases, biomarkers are essential for several purposes, including early detection of conditions such as chronic kidney disease, acute kidney injury, and glomerulonephritis, as well as prognostication and therapeutic monitoring. Protein biomarkers like cystatin C, neutrophil gelatinase-associated lipocalin, and kidney injury molecule-1 have been used in clinical settings, but their predictive accuracy may be limited when evaluated in isolation. The growing availability of multi-dimensional datasets, including transcriptomic, proteomic, metabolomic, and imaging data, demands computational methods capable of extracting meaningful patterns from high-dimensional, noisy, and often incomplete information. This is where AI methods excel, enabling the integration of various data types to generate comprehensive biomarker profiles that capture the complexity of renal pathophysiology.

Artificial Intelligence in Biomedical Data Analysis

Artificial intelligence refers to computational systems capable of performing tasks that traditionally require human intelligence, such

as pattern recognition, decision-making, and predictive modeling. In biomarker discovery, AI algorithms can process vast amounts of data, identify non-linear relationships, and uncover features that may elude conventional statistical methods. Machine learning, a subset of AI, encompasses techniques such as supervised learning for prediction, unsupervised learning for pattern discovery, and reinforcement learning for optimizing decision-making strategies. Deep learning, a branch of machine learning based on artificial neural networks with multiple layers, has demonstrated remarkable performance in image analysis, natural language processing, and multi-omics data integration. These capabilities are particularly valuable in renal research, where biomarkers often arise from complex interactions between genetic, molecular, and environmental factors.

Data Sources for AI-driven Biomarker Discovery

Successful AI applications in biomarker discovery rely on high-quality, well-curated datasets. In renal diseases, relevant data sources include electronic health records, laboratory measurements, genomic and transcriptomic datasets, proteomic and metabolomic profiles, and imaging studies such as ultrasound, computed tomography, and magnetic resonance imaging. Public repositories like The Cancer Genome Atlas,

the Genotype-Tissue Expression Project, and the NephroSeq database provide valuable resources for AI-driven research. However, the integration of data from multiple modalities presents significant challenges in terms of normalization, feature selection, and harmonization. AI techniques such as dimensionality reduction, feature embedding, and transfer learning can address these issues, enabling researchers to construct robust biomarker discovery pipelines that leverage diverse and complementary datasets.

Machine Learning Approaches for Biomarker Identification

Machine learning methods offer diverse strategies for identifying biomarkers in renal diseases. Supervised learning algorithms such as support vector machines, random forests, and gradient boosting machines can classify patients into disease subtypes or predict disease outcomes based on molecular profiles. These models rely on labeled datasets where the presence or absence of disease, or the severity of renal dysfunction, serves as the target variable. Unsupervised learning methods like hierarchical clustering, k-means clustering, and self-organizing maps can uncover hidden structure in data, identifying patient subgroups that share common biomarker signatures. Semi-supervised learning combines labeled and unlabeled data, a particularly useful approach in medical research where annotations

are often scarce or expensive to obtain. The choice of algorithm depends on factors such as data dimensionality, feature correlations, and interpretability requirements, all of which influence the reliability of the resulting biomarker candidates.

Deep Learning in Multi-omics Integration

Deep learning has gained significant traction in biomedical research due to its ability to learn complex representations from raw data without extensive manual feature engineering. In renal disease biomarker discovery, deep neural networks can integrate data from multiple omics layers, such as genomics, transcriptomics, proteomics, and metabolomics, to produce predictive models that capture the multifactorial nature of kidney disorders. Convolutional neural networks are particularly effective for image-based biomarker detection, such as identifying structural changes in kidney histology or radiology images. Recurrent neural networks and transformers can model temporal sequences, making them suitable for longitudinal biomarker monitoring in chronic kidney disease. Autoencoders and variational autoencoders enable dimensionality reduction and feature extraction across multi-modal datasets, facilitating the identification of latent variables that correlate strongly with disease

phenotypes.

AI in Imaging Biomarker Discovery for Renal Diseases

Medical imaging plays a critical role in diagnosing and monitoring renal diseases, providing insights into kidney morphology, vascularization, and tissue composition. AI techniques, particularly deep learning models, have demonstrated exceptional performance in analyzing imaging data for biomarker discovery. By training convolutional neural networks on annotated datasets, researchers can detect subtle texture variations, shape alterations, and intensity patterns that correlate with disease severity or progression. Radiomics, an emerging field that extracts quantitative features from medical images, combined with AI-driven feature selection, enables the identification of imaging biomarkers that can complement molecular and clinical markers. For example, texture analysis of computed tomography images can reveal microstructural alterations in kidney tissue that precede overt functional decline, offering a window for earlier intervention.

Challenges in AI-based Biomarker Discovery

Despite its potential, AI-based biomarker discovery in renal diseases faces several challenges. One major issue is the scarcity of large,

diverse, and well-annotated datasets, which can limit model generalizability and reproducibility. Data heterogeneity, resulting from differences in sample collection, processing, and measurement techniques, can introduce biases that affect biomarker reliability. Moreover, AI models, particularly deep learning architectures, are often criticized for their lack of interpretability, which can hinder clinical adoption. The risk of overfitting, where models capture noise instead of meaningful patterns, is another concern, especially when dealing with high-dimensional omics data. Addressing these challenges requires careful experimental design, rigorous validation procedures, and the development of interpretable AI models that can provide transparent reasoning behind their predictions.

Ethical and Regulatory Considerations

The application of AI in biomarker discovery raises important ethical and regulatory considerations. Patient privacy and data security are paramount, particularly when integrating multi-source datasets containing sensitive health information. Compliance with data protection regulations such as the General Data Protection Regulation and the Health Insurance Portability and Accountability Act is essential. Additionally, the potential for AI models to perpetuate existing biases in healthcare must be addressed, as imbalanced datasets

can lead to inequitable biomarker identification and risk stratification. Regulatory agencies are increasingly focusing on the validation and clinical translation of AI-derived biomarkers, emphasizing the need for reproducibility, transparency, and clinical relevance. Collaborative efforts between researchers, clinicians, ethicists, and regulators will be crucial to ensure that AI-driven biomarker discovery advances in a responsible and patient-centered manner.

AI for Longitudinal Biomarker Tracking in Renal Diseases

Longitudinal biomarker tracking involves monitoring changes in biomarker levels over time to understand disease progression, treatment response, and risk of complications. In renal diseases, such tracking is particularly important for conditions like chronic kidney disease, where subtle trends in molecular, imaging, or physiological parameters may precede significant clinical decline. AI algorithms, especially those designed for time-series analysis, can identify patterns in longitudinal data that are not apparent through manual inspection. Models such as recurrent neural networks, long short-term memory networks, and temporal convolutional networks can capture dependencies between past and present measurements, providing early warning signals for worsening kidney function. The integration of real-time monitoring devices,

such as wearable biosensors that track relevant physiological indicators, can further enhance the predictive power of AI-based longitudinal models. This approach holds promise for personalized care, as clinicians could receive alerts about significant biomarker deviations well before irreversible kidney damage occurs.

Personalized Medicine and AI-derived Biomarkers

The ultimate goal of biomarker discovery in renal diseases is to facilitate personalized medicine, where treatment strategies are tailored to the individual's molecular profile, disease stage, and comorbidities. AI-derived biomarkers can help stratify patients into subgroups that are more likely to respond to specific interventions, thereby avoiding unnecessary treatments and minimizing adverse effects. For example, a patient whose gene expression profile predicts a favorable response to a particular immunosuppressive therapy could be prioritized for that regimen, while others might benefit from alternative approaches. AI can also identify composite biomarker signatures that combine genetic, proteomic, and imaging data, offering a more holistic view of the patient's condition. This multi-dimensional personalization is particularly valuable in heterogeneous conditions such as lupus nephritis, diabetic nephropathy, and polycystic kidney disease, where different pathophysiological

mechanisms may underlie similar clinical presentations.

Case Studies of AI in Renal Biomarker Research

Several recent studies illustrate the potential of AI in renal biomarker discovery. In one investigation, researchers applied a deep learning framework to transcriptomic data from patients with diabetic kidney disease, identifying novel gene signatures that predicted progression to end-stage renal disease with higher accuracy than traditional clinical risk scores. Another example involved the use of radiomics combined with machine learning to analyze magnetic resonance imaging scans of kidney transplant recipients, enabling early detection of rejection episodes based on subtle tissue texture changes. A third study integrated proteomic and metabolomic data using AI-based feature selection to identify biomarkers associated with acute kidney injury in critically ill patients, providing a foundation for targeted therapeutic interventions. These case studies demonstrate that AI can not only accelerate biomarker discovery but also uncover associations that might be overlooked using conventional statistical techniques.

Integration of AI-derived Biomarkers into Clinical Workflows

The successful translation of AI-derived

biomarkers from research to routine clinical practice requires careful integration into existing workflows. This process begins with the validation of biomarkers in independent cohorts to confirm their reproducibility and clinical relevance. Once validated, these biomarkers can be incorporated into electronic health record systems, where AI-powered decision support tools can assist clinicians in interpreting results and making treatment decisions. Seamless integration also involves ensuring that biomarkers are measured using standardized and cost-effective assays that are feasible for routine clinical use. Education and training for healthcare professionals are essential to foster trust in AI-generated insights and to enable appropriate use. Furthermore, user-friendly interfaces that present biomarker information in an interpretable format can improve adoption and reduce the cognitive burden on clinicians.

The Role of Explainable AI in Biomarker Discovery

One of the main criticisms of AI in medicine is its perceived lack of interpretability. This issue is particularly important in biomarker discovery, where clinicians and researchers need to understand why a particular molecular signature has been identified as significant. Explainable AI techniques aim to make the decision-making process of AI models transparent, enabling users

to trace the contribution of individual features to the model's predictions. Methods such as SHAP (Shapley Additive Explanations), LIME (Local Interpretable Model-agnostic Explanations), and attention mechanisms in neural networks can provide insights into which variables drive the identification of a biomarker. In renal disease research, explainable AI can highlight specific genes, proteins, or imaging features that are most strongly associated with disease progression, thereby facilitating biological interpretation and guiding further experimental validation.

Collaborative Efforts and Data Sharing in AI-based Biomarker Research

The advancement of AI-driven biomarker discovery in renal diseases depends on collaborative efforts across institutions and disciplines. Data sharing initiatives that bring together clinical, molecular, and imaging data from diverse populations can enhance the robustness and generalizability of AI models. International consortia, public databases, and federated learning frameworks allow researchers to leverage large datasets without compromising patient privacy. Such collaborations also promote the development of standardized protocols for data collection, preprocessing, and annotation, reducing variability and bias in biomarker discovery. Moreover, partnerships between

academia, industry, and healthcare providers can accelerate the translation of AI-derived biomarkers into diagnostic tools, companion diagnostics for targeted therapies, and real-time monitoring systems for patient care.

Future Directions for AI in Renal Biomarker Discovery

The future of AI in biomarker discovery for renal diseases is likely to be shaped by several emerging trends. Multi-omics integration will continue to expand, incorporating not only genomics, transcriptomics, proteomics, and metabolomics, but also epigenomics, lipidomics, and microbiomics, to provide an even more comprehensive view of kidney biology. Advances in single-cell sequencing technologies will generate unprecedented resolution in understanding cellular heterogeneity, which AI can exploit to identify cell-type-specific biomarkers. Real-time data streams from wearable devices and remote monitoring tools will enable continuous biomarker tracking, supporting dynamic risk prediction and timely interventions. In addition, the rise of generative AI models may facilitate synthetic data generation to augment limited datasets, although careful validation will be necessary to ensure clinical reliability. Finally, interdisciplinary education programs will be critical to train a new generation of researchers fluent in both renal biology and AI methodologies,

ensuring that advances in computational techniques are grounded in biological relevance.

Conclusion

Artificial intelligence holds immense promise for revolutionizing biomarker discovery in renal diseases. By harnessing the power of machine learning, deep learning, and explainable AI, researchers can integrate diverse datasets, uncover hidden patterns, and identify biomarkers that improve diagnosis, prognostication, and treatment personalization. Although challenges such as data scarcity, heterogeneity, and interpretability remain, collaborative efforts and ongoing technological advances are steadily addressing these barriers. The ultimate impact of AI in this field will be measured not only by the novelty of the biomarkers it discovers but also by their successful translation into clinical practice, where they can directly improve patient outcomes. As AI technologies continue to evolve, their integration into renal research will likely shift the paradigm of kidney disease management from reactive to proactive, enabling earlier detection, more precise interventions, and better long-term prognosis for patients worldwide.

2. AI IN BIOMARKER DISCOVERY FOR NEUROLOGICAL DISEASES

Background

Neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, and amyotrophic lateral sclerosis remain significant global health concerns. These diseases are multifactorial, progressive, and challenging to treat effectively, particularly when diagnosis occurs at a late stage. One of the greatest challenges in neurology today is to identify credible methods for detecting these conditions earlier, tracking their progression over time, and predicting how patients will respond to treatment. In this context, biomarkers, which are biological indicators of the presence or progression of disease, play a crucial role. However, useful biomarkers are often difficult to identify. Traditional discovery methods tend to be slow, limited in scope, and poorly suited to managing the vast and complex datasets that have become available through advances in biomedical research.

Artificial intelligence (AI) has emerged in recent years as a transformative tool capable of analyzing massive datasets and detecting patterns that might otherwise go unnoticed,

thereby revolutionizing biomarker discovery for researchers. Machine learning (ML) and deep learning (DL) have demonstrated highly promising results in the analysis of high-dimensional data from diverse sources, including neuroimaging, genomics, proteomics, and electronic health records. For example, AI models have been used to examine MRI and PET scans to detect early indicators of neurodegeneration before the onset of clinical symptoms. Likewise, in molecular biology, AI can identify genes, proteins, or metabolic markers that are significantly associated with specific neurological disorders.

A particularly valuable advantage of AI in this field is its ability to integrate data from multiple, disparate sources. Neurological disorders often arise not from a single cause but from complex interactions among genetic, molecular, and environmental factors. AI can merge different types of data, such as imaging results and gene expression profiles, to provide a more comprehensive understanding of disease mechanisms. This integrated approach increases the likelihood of isolating meaningful biomarkers and facilitates the transition toward more personalized treatment strategies.

Nevertheless, implementing AI for biomarker discovery in neurology is not without its challenges. Issues related to data quality, the lack of standardized methodologies, and the difficulty

of interpreting model outputs must be addressed. Ethical considerations such as patient privacy, data security, and fairness are also of paramount importance. Moreover, the successful application of AI in this area requires close collaboration among neuroscientists, data scientists, clinicians, and bioinformaticians.

This paper explores the ways AI is currently being applied to discover biomarkers for neurological conditions, the techniques most suited to this purpose, and the obstacles that remain. Drawing on recent publications and case studies, it seeks to present a clear overview of the current state of the field and potential future directions. Ultimately, the objective is to demonstrate how AI can help transform the diagnosis and treatment of neurological disorders, enabling earlier detection, more accurate monitoring, and improved patient outcomes.

Biomarkers in Neurology: An Overview

Biomarkers can be derived from a variety of data modalities:

Molecular: Genomic, transcriptomic, proteomic, and metabolomic profiles

Imaging: MRI, PET, EEG, and MEG

Clinical and Behavioral: Motor examinations, cognitive assessments, and patient-reported outcomes

Wearable and Digital: Sensor data on gait, activity, sleep, and speech

The integration of these diverse data types can represent a transformative advancement in biomarker discovery. Artificial intelligence offers a scalable approach to manage such complexity by automating data processing, handling high-dimensional inputs efficiently, and accommodating a wide range of data types collected from large and diverse patient populations.

AI Approaches in Biomarker Discovery

Artificial intelligence techniques applied in biomarker research include:

Supervised Learning: Classification and regression models such as support vector machines, random forests, and logistic regression are used to differentiate between disease states based on labeled data.

Unsupervised Learning: Clustering techniques, including k-means and hierarchical clustering, and dimensionality reduction methods such as PCA and t-SNE, are employed to identify new patterns and subgroups.

Deep Learning: Convolutional neural networks, recurrent neural networks, and autoencoders are applied for analyzing image data, time-series data, and unstructured datasets.

Multi-modal Learning: Combines information from various sources to explain complex relationships.

Explainable AI: Models such as SHAP and LIME enhance interpretability, which is crucial for clinical adoption.

Use in Neurological Conditions

ALS

ALS, also known as amyotrophic lateral sclerosis, is the most common type of motor neuron disease affecting adults, leading to muscle weakness and ultimately resulting in respiratory failure. Improved methods for discovering and monitoring ALS are important because they allow doctors to detect the disease earlier and identify the most effective treatments. Researchers believe that analyzing several biological signatures at once may significantly enhance our ability to diagnose the condition and predict its progression in patients. At present, the application of artificial intelligence (AI) to large datasets is creating new opportunities for ALS research. These approaches can help identify novel biomarkers, monitor disease progression, and ultimately improve methods for diagnosis and treatment. AI is already being used to examine brain scans from ALS patients to gain insights into how the disease begins. For example, Behler and colleagues found that a specialized brain imaging method known

as diffusion tensor imaging (DTI) can track ALS progression by following the pattern of protein accumulation that occurs in four distinct stages throughout the nervous system. Using this technique, doctors can trace the progression of pTDP-43 protein in people with ALS. DTI also improves our understanding of how white matter deteriorates in ALS, particularly the damage to upper motor neurons. Behler's team combined DTI brain scans, eye-movement tests, and cognitive assessments from 245 ALS patients. By applying hierarchical clustering, a computational method, they identified four distinct patient groups, demonstrating why ALS affects individuals differently and how AI can classify patients based on their characteristics. Cognitive and eye movement tests allowed researchers to predict the rate of progression for each group. With AI, scientists were able to link changes in brain structure to brain function, enabling classification of disease stages for each patient and the creation of maps showing how ALS progresses.

In clinical practice, advances in sensor technology and computing have made measurements more sensitive and accurate, helping doctors detect early signs of ALS sooner. AI-powered imaging techniques have also significantly enhanced the processing and analysis of medical images. A good example is a specialized brain stimulation technique called threshold-tracking transcranial magnetic stimulation (TMS), which assesses how

brain circuits that control and enhance movement function in ALS patients. By using precisely timed stimulation, this technique reveals motor cortex abnormalities commonly found in ALS.

When brain and nervous system biomarkers are involved, ALS diagnosis becomes less invasive and more accurate. Combining electrical brain assessments with behavioral observations is especially beneficial when incorporating sensor technology. Kitaoka and colleagues developed an AI system using advanced object detection to record jaw movements in ALS mice. They observed that mice with tumors often ate more slowly, suggesting that such behavior could increase risk in diseased mice.

Nakamori and colleagues investigated whether analyzing swallowing sounds could be used to diagnose ALS in 24 patients, using electronic stethoscopes and AI. Their findings showed that this method performed as well as traditional swallowing tests, indicating that it could serve as an alternative diagnostic approach. Pancotti and collaborators designed a system to predict ALS progression using data from PRO-ACT, one of the world's largest ALS databases. They demonstrated that their model could accurately forecast the rate at which patient functional abilities would decline. With these biomarkers, doctors can monitor disease progression, evaluate treatment effectiveness, and potentially develop new clinical advances. It is anticipated that by using multiple

diagnostic markers and individualized treatments enhanced by AI, outcomes and quality of life will improve for people with ALS and related neurological diseases.

Alzheimer's Disease

Alzheimer's disease (AD) is a neurodegenerative disorder with several subtypes and varied clinical presentations. It is characterized by neurological changes that include the accumulation of amyloid-beta ($A\beta$) plaques. Researchers are searching for simple blood tests that could enable early detection of Alzheimer's. For many years, various approaches to blood testing have been investigated to identify early indicators. Recently, experts have found that several blood proteins, including $A\beta_{42/40}$, p-tau181, p-tau231, and p-tau217, can precisely monitor changes occurring in the brain. This progress suggests that doctors may one day be able to diagnose Alzheimer's through non-invasive methods. In addition, researchers are identifying lesser-studied blood substances that could assist in diagnosis.

Machine learning, a computational method that detects patterns in complex data, has proved particularly useful for this purpose. These tools have been applied to brain scans, nuclear medicine imaging, brain wave recordings, various memory tests, and even speech analysis. One promising approach uses machine learning to identify panels of metabolites, the small molecules

produced during the body's chemical processes, that together can signal Alzheimer's. Samples of cerebrospinal fluid (CSF), blood, saliva, and brain tissue have been studied to detect these features. Some scientists believe that blood metabolites may be as effective for detecting the disease as the currently used CSF tests. For instance, research comparing different computational approaches found that two specific metabolites, aspartate and dodecanedioate, were particularly effective in identifying the disease.

Rapid and accurate diagnosis of the specific type of dementia is crucial, especially as researchers develop treatments that may work best in the early stages. Despite promising research, no machine learning-based diagnostic tools are yet available for routine clinical use. Some researchers have grouped patients by their biomarker patterns and found that Alzheimer's may encompass several different disease processes. Five patient groups were identified in one study, with two groups showing brain changes distinct from typical Alzheimer's. One group displayed inflammation in the brain involving a biomarker known as YKL-40. While these findings are intriguing, further research is needed to understand how they may influence treatment.

Although CSF and imaging biomarkers are effective for predicting disease, their high cost and invasive procedures make non-invasive markers from bodily fluids such as blood, urine, feces,

saliva, or tears highly desirable. While accessibility issues limit their use, the reduced variability in CSF datasets makes them well-suited for discovering new markers. Once identified, the performance of these markers can be validated in other sample types, such as blood plasma. Eye imaging may also allow repeated, non-invasive monitoring for A β and tau deposits, thinning of neuronal layers, and vascular changes.

Most predictive biomarkers for Alzheimer's have been discovered using traditional research approaches and statistical methods. However, AI algorithms are increasingly being explored as alternative tools for prediction. Studies show that combining biomarkers from multiple sources, including CSF tests, brain imaging, and cognitive assessments, significantly improves the performance of AI models. Recently, researchers identified four patterns in which tau protein tends to spread among Alzheimer's patients. Integrating images from multiple brain imaging studies revealed disease patterns that traditional staging systems could not detect, as these systems are more effective at describing populations as a whole than at identifying individual differences. Importantly, datasets do not need to be highly complex to benefit from advanced AI tools. For example, researchers have used multi-level autoencoders, a type of neural network, to study changes in DNA methylation over time. Chen and colleagues found that simple autoencoder models

outperformed more complex convolutional neural networks, and the most relevant methylated sites were linked to biological pathways expected to be important in Alzheimer's disease.

Parkinson's Disease: AI analysis of voice, handwriting, and gait data has shown high accuracy in identifying early Parkinson's disease. Convolutional neural networks applied to DaTscan images and machine learning approaches using transcriptome data have revealed novel biomarker candidates, including important genes.

Multiple Sclerosis: Deep learning facilitates the segmentation of multiple sclerosis lesions on MRI scans. AI-driven feature selection and classification assist in identifying cerebrospinal fluid protein biomarkers and predicting relapses or treatment outcomes.

Epilepsy: AI has achieved high accuracy in detecting high-frequency oscillations and complex electrophysiological patterns in EEG data. These findings are essential for localizing epileptogenic zones and supporting seizure prediction through time-series analysis and deep learning models.

Challenges and Limitations

Despite promising advancements, several challenges remain. Data availability and quality issues, such as small and imbalanced datasets, increase the risk of overfitting. Interpretability

concerns, due to the opaque nature of black-box models, can reduce clinical trust. Variations in data collection and reporting hinder model generalizability. Privacy and ethical considerations arise with cross-institutional data sharing. Furthermore, many AI-discovered biomarkers lack validation in diverse populations.

Future Trajectories

Federated and transfer learning approaches enable collaborative model training across institutions without the need for direct data sharing. Digital biomarkers collected passively via smartphones and wearable devices provide opportunities for real-time, continuous monitoring. Integrative omics, which combines genetic, epigenetic, proteomic, and metabolomic data, supports comprehensive biomarker discovery. Large-scale clinical trials remain necessary to validate AI-discovered biomarkers for clinical use.

Conclusion

Artificial intelligence is transforming biomarker discovery in neurological diseases by enabling the analysis of complex, high-dimensional datasets. While challenges related to data quality, interpretability, and validation persist, ongoing advancements in algorithm design, data integration, and model transparency are bringing AI closer to clinical translation. The future of neurology lies in the integration of AI and

MOBINA GHEIBI

biomedicine, with the potential to enable earlier diagnoses, improve prognostication, and advance personalized treatment strategies.

ARTIFICIAL INTELLIGENCE IN BIOMARKER DISCOVERY: A...

3. AI IN BIOMARKER DISCOVERY FOR GASTROINTESTINAL DISEASES

Introduction

Gastrointestinal diseases encompass a wide range of disorders affecting the digestive tract, including inflammatory bowel diseases, gastrointestinal cancers, functional disorders, and liver-associated conditions. Early and accurate diagnosis of these conditions is critical for preventing complications and improving patient outcomes. Biomarkers play an essential role in this process by serving as measurable indicators of normal or pathogenic processes, as well as responses to therapeutic interventions. Despite advances in molecular biology, traditional biomarker discovery methods often fall short in capturing the complexity of gastrointestinal pathophysiology, which involves interactions among genetic, epigenetic, environmental, microbial, and immunological factors. Artificial intelligence has emerged as a transformative tool that can navigate these complexities by processing large and heterogeneous datasets, detecting hidden patterns, and identifying robust biomarker candidates. The application of AI in gastrointestinal disease research

ARTIFICIAL INTELLIGENCE IN BIOMARKER DISCOVERY: A...

offers the potential to refine diagnosis, predict disease progression, guide treatment selection, and monitor therapeutic responses with unprecedented precision.

The Importance of Biomarkers in Gastrointestinal Disease Management

In gastrointestinal medicine, biomarkers can range from molecular entities such as nucleic acids, proteins, and metabolites to imaging features and microbiome signatures. These indicators are essential for disease detection, prognosis assessment, and therapy monitoring. For example, fecal calprotectin is widely used to detect intestinal inflammation, while carcinoembryonic antigen serves as a tumor marker in colorectal cancer. However, single biomarkers often have limited sensitivity and specificity, leading to false positives or negatives that can delay appropriate treatment. The integration of multi-parametric data offers an opportunity to improve the accuracy of biomarker-based diagnostics. Artificial intelligence is uniquely suited for such integration, as it can handle high-dimensional data from genomics, proteomics, metabolomics, microbiome profiling, imaging studies, and clinical records. This capacity enables the development of multi-marker panels and predictive models that can more accurately

capture the complexity of gastrointestinal disorders.

Artificial Intelligence as a Catalyst for Biomedical Discovery

Artificial intelligence refers to computational methods capable of performing tasks that require human-like reasoning, learning, and decision-making. Within the biomarker discovery process, AI excels at recognizing subtle relationships in data that may be overlooked by conventional statistical approaches. Machine learning, a core subset of AI, encompasses supervised, unsupervised, and semi-supervised techniques that can be tailored to specific biomarker discovery goals. Deep learning, a more advanced subset of machine learning, leverages layered neural network architectures to automatically extract hierarchical features from raw data, making it particularly effective for complex and multi-modal datasets. In the context of gastrointestinal research, these capabilities allow AI to uncover previously unrecognized molecular signatures, correlate them with disease phenotypes, and generate predictive models that can be validated and deployed in clinical settings.

Sources of Data for AI- driven Biomarker Discovery in Gastrointestinal Diseases

High-quality and diverse datasets form the

foundation of AI-based biomarker discovery. In gastrointestinal diseases, these data sources include electronic health records containing patient histories and laboratory results, multi-omics datasets capturing genetic, transcriptomic, proteomic, metabolomic, and lipidomic information, as well as microbiome sequencing data. Medical imaging modalities such as endoscopy, computed tomography, magnetic resonance imaging, and ultrasound provide another rich source of information, with features that may be quantified through radiomics techniques. Additionally, large-scale clinical trials, patient registries, and public repositories such as The Cancer Genome Atlas and the Human Microbiome Project contribute valuable datasets. Integrating these heterogeneous sources poses challenges related to data harmonization, missing values, and batch effects. AI algorithms, through feature embedding, dimensionality reduction, and normalization techniques, can effectively address these challenges, enabling robust multi-modal biomarker discovery.

Machine Learning Approaches in Gastrointestinal Biomarker Research

Machine learning offers a diverse toolkit for biomarker identification in gastrointestinal diseases. Supervised learning models, including support vector machines, random forests, logistic

regression, and gradient boosting frameworks, can classify patients based on disease status or predict treatment outcomes using known biomarker profiles. Unsupervised learning approaches such as hierarchical clustering, principal component analysis, and non-negative matrix factorization are valuable for identifying novel disease subtypes or uncovering patterns within unlabeled datasets. Semi-supervised learning, which leverages both labeled and unlabeled data, is particularly useful in medical research where annotated datasets are often limited. The selection of an appropriate machine learning approach depends on factors such as the volume and quality of data, the dimensionality of features, and the interpretability requirements for clinical application.

Deep Learning for Multi-omics Integration in Gastrointestinal Diseases

Deep learning methods have demonstrated exceptional capabilities in integrating multi-omics data for biomarker discovery. By using architectures such as convolutional neural networks for imaging data, recurrent neural networks for sequential data, and fully connected feedforward networks for tabular data, deep learning enables comprehensive analysis across multiple data types. Autoencoders and variational autoencoders can compress high-

dimensional omics datasets into compact feature representations that retain critical biological information. In gastrointestinal disease research, such integrated models have been applied to combine genomic, transcriptomic, proteomic, and microbiome profiles to identify biomarkers that not only differentiate between disease and health but also stratify patients by disease stage, severity, and likely therapeutic response. The ability of deep learning to learn directly from raw data without extensive manual feature engineering streamlines the biomarker discovery process and can reveal relationships that might remain hidden with traditional methods.

AI in Imaging Biomarker Discovery for Gastrointestinal Disorders

Imaging is an integral component of gastrointestinal disease diagnosis and monitoring, particularly for cancers, inflammatory conditions, and structural abnormalities. AI has made significant strides in extracting quantitative biomarkers from medical images, a process known as radiomics. In gastrointestinal disorders, AI models can analyze endoscopic images to detect subtle mucosal changes indicative of early neoplasia or inflammatory activity. Convolutional neural networks can classify polyp types in colonoscopy images with accuracy comparable to expert endoscopists, supporting early detection and

intervention. Radiomic analysis of computed tomography or magnetic resonance imaging scans can quantify tumor heterogeneity, vascularity, and texture, providing imaging biomarkers that complement molecular and clinical indicators. Integrating these imaging-derived features with omics and clinical data through AI can enhance diagnostic precision and inform treatment planning.

The Role of the Microbiome in AI-based Biomarker Discovery

The gut microbiome plays a central role in gastrointestinal health and disease, influencing immune responses, metabolism, and epithelial integrity. Dysbiosis, or microbial imbalance, has been implicated in conditions such as inflammatory bowel disease, colorectal cancer, irritable bowel syndrome, and liver-related disorders. AI offers powerful methods for analyzing the complex, high-dimensional data generated by microbiome sequencing studies. Techniques such as random forests, neural networks, and network analysis can identify microbial taxa or community structures that serve as biomarkers for specific gastrointestinal conditions. Furthermore, AI can integrate microbiome profiles with host genetic, metabolomic, and proteomic data to identify composite biomarker signatures. These integrated biomarkers may improve diagnostic

accuracy, help predict disease flares, and provide insights into personalized dietary or probiotic interventions.

Challenges in AI-driven Gastrointestinal Biomarker Discovery

While AI presents numerous opportunities for biomarker discovery, several challenges must be addressed to ensure reliable and clinically useful outcomes. Data scarcity and imbalance remain common issues, particularly for rare gastrointestinal diseases or specific patient subpopulations. Variability in sample collection, processing, and measurement can introduce confounding factors that affect biomarker reproducibility. AI models, especially deep learning architectures, may suffer from overfitting when trained on limited datasets, resulting in poor generalization to new patient populations. Another concern is the interpretability of AI models, as clinicians require transparent reasoning for biomarker selection to support clinical decision-making. Addressing these challenges will require larger and more diverse datasets, standardization of methodologies, rigorous validation protocols, and the adoption of explainable AI techniques.

AI for Longitudinal Biomarker Tracking in

Gastrointestinal Diseases

Longitudinal biomarker tracking is crucial for understanding the progression of gastrointestinal diseases and the effects of treatment over time. Many conditions such as inflammatory bowel disease, chronic liver disease, and gastrointestinal cancers follow complex trajectories, with periods of stability interrupted by acute exacerbations or complications. Artificial intelligence can process time-series data from repeated laboratory tests, imaging studies, and microbiome analyses to identify subtle trends that precede clinical changes. Recurrent neural networks and temporal convolutional networks are well-suited for detecting patterns in sequential data, enabling early warnings for disease flare-ups or recurrence. This approach also supports adaptive treatment strategies, where therapy is adjusted based on evolving biomarker profiles. Integrating wearable and at-home testing devices that provide continuous or frequent measurements can further enhance longitudinal monitoring, making it possible to personalize disease management in real time.

Personalized Medicine Enabled by AI-derived Biomarkers

One of the most promising applications of AI in gastrointestinal biomarker discovery is the advancement of personalized medicine. By identifying biomarker profiles unique

to individual patients, AI allows for the customization of diagnostic and therapeutic approaches. In oncology, AI-derived molecular signatures can help predict which patients will respond to specific chemotherapy regimens or targeted agents, avoiding unnecessary side effects for those unlikely to benefit. In inflammatory bowel disease, predictive biomarker panels can identify patients at higher risk for aggressive disease, guiding early initiation of biologic therapies. Personalized medicine also extends to diet and lifestyle recommendations, as AI can integrate genetic, metabolic, and microbiome data to suggest individualized dietary plans aimed at modulating disease activity. This precision approach maximizes treatment effectiveness and minimizes unnecessary interventions.

Case Studies of AI in Gastrointestinal Biomarker Discovery

Several recent research efforts illustrate the potential of AI in advancing gastrointestinal biomarker discovery. In colorectal cancer research, machine learning models integrating genomic, epigenetic, and radiomic features have been used to predict treatment response and long-term survival with higher accuracy than conventional staging systems. In another study, convolutional neural networks analyzed colonoscopy images alongside histopathology

data to identify visual and molecular biomarkers associated with precancerous polyps, enabling earlier intervention. In inflammatory bowel disease, AI was applied to integrate transcriptomic data from mucosal biopsies with microbiome profiles, identifying novel combined biomarkers that correlated strongly with disease severity and response to anti-TNF therapy. These examples highlight how AI can bridge multiple domains of data to produce clinically relevant biomarkers with real-world impact.

Integrating AI-derived Biomarkers into Clinical Workflows

The translation of AI-discovered biomarkers into everyday clinical practice requires careful planning and validation. Biomarkers identified through AI must undergo rigorous testing in independent patient cohorts to confirm reproducibility. Once validated, these biomarkers can be embedded into clinical decision support systems that work alongside electronic health records, offering real-time guidance to healthcare providers. The integration process must be seamless, with clear visualization tools and straightforward interpretation to ensure clinician adoption. Practical considerations such as cost-effective assay development, compatibility with existing laboratory infrastructure, and standardization of measurement techniques are critical. Education and training for clinicians,

nurses, and laboratory personnel are also important for building confidence in AI-based tools and encouraging widespread use.

The Role of Explainable AI in Gastrointestinal Biomarker Research

Interpretability is a vital factor in building trust in AI-derived biomarkers. In gastrointestinal diseases, where biomarker discovery often involves combining complex genomic, imaging, and microbiome data, it is essential to understand how each feature contributes to the model's predictions. Explainable AI techniques such as SHAP values, feature importance scores, and visual saliency maps help demystify the decision-making process of machine learning models. For instance, in a model predicting colorectal cancer recurrence, explainable AI can highlight the specific gene expression patterns, imaging features, or microbial taxa most strongly associated with the prediction. This transparency aids in biological validation, improves clinician trust, and helps guide further research into the mechanisms underlying the discovered biomarkers.

Ethical and Regulatory Considerations in AI-based Biomarker Discovery

The application of AI in biomarker discovery

raises important ethical and regulatory issues. Patient privacy must be protected, especially when dealing with multi-source datasets that may contain sensitive health information. Compliance with legal frameworks such as the General Data Protection Regulation and the Health Insurance Portability and Accountability Act is essential. There is also the challenge of avoiding algorithmic bias, which can occur if datasets are not representative of the broader patient population. This bias could result in biomarkers that are less accurate for underrepresented groups, exacerbating healthcare disparities. Regulatory bodies are increasingly developing guidelines for the validation and clinical adoption of AI-based diagnostic tools, emphasizing the need for transparency, reproducibility, and evidence of clinical benefit before deployment.

Collaborative Research Models for AI in Gastrointestinal Diseases

Advancing AI-driven biomarker discovery requires strong collaboration between clinicians, data scientists, biostatisticians, and bioinformaticians. Multi-institutional consortia and data-sharing networks play a crucial role in assembling the large and diverse datasets needed for robust AI model development. Federated learning approaches offer a promising solution for enabling AI model training across multiple institutions without requiring direct sharing of

sensitive patient data. These collaborations can also help establish standardized protocols for data collection, annotation, and preprocessing, which are essential for minimizing bias and variability. Partnerships between academia, industry, and government agencies can accelerate the translation of research findings into commercial diagnostic assays and clinical tools.

Future Directions for AI in Gastrointestinal Biomarker Discovery

The future of AI in gastrointestinal biomarker research will likely be shaped by several important trends. Multi-omics integration will expand to include not only genomics, proteomics, and metabolomics but also epigenomics, lipidomics, and spatial transcriptomics, offering an even more detailed picture of disease biology. Advances in single-cell technologies will allow AI to identify biomarkers at the resolution of individual cells within tissue samples, revealing heterogeneity that bulk analyses may miss. The integration of real-time monitoring data from wearable sensors and home-based testing devices will support dynamic biomarker tracking and adaptive treatment strategies. Generative AI models may help simulate patient data to augment limited datasets, though such approaches will require careful validation. As these technologies mature, interdisciplinary training programs will be

necessary to prepare researchers who can navigate both the biomedical and computational aspects of biomarker discovery.

Conclusion

Artificial intelligence is poised to transform biomarker discovery in gastrointestinal diseases by integrating complex, multi-modal datasets to uncover clinically relevant indicators of disease presence, severity, and progression. Its capabilities extend beyond mere pattern recognition, enabling predictive modeling, personalized treatment planning, and real-time disease monitoring. Despite challenges related to data quality, interpretability, and regulatory approval, ongoing advances in AI algorithms, data integration techniques, and collaborative research frameworks are steadily addressing these issues. The ultimate measure of success will be the translation of AI-derived biomarkers into routine clinical practice, where they can improve early detection, refine prognostic assessments, and guide targeted interventions. As AI continues to evolve, it holds the potential to redefine the standard of care for patients with gastrointestinal diseases, ushering in a new era of precision medicine.

4. AI IN BIOMARKER DISCOVERY FOR CARDIAC DISEASES

Background

Cardiovascular diseases (CVDs) are a group of conditions that affect the heart and blood vessels, and they remain a major cause of illness and death worldwide. Early detection, accurate diagnosis, and timely treatment are essential for slowing the progression of these diseases and improving overall patient outcomes. Electrocardiography (ECG) and cardiac magnetic resonance imaging (CMR) are among the most effective diagnostic methods for detecting conditions such as ventricular dysfunction, aortic stenosis, and dilated cardiomyopathy. However, these advanced diagnostic approaches are typically used only in patients who present with symptoms. As a result, they cannot be applied to individuals without symptoms, leading to many cases going undetected until later stages, when outcomes are often much worse. Recent advancements in cardiac imaging and diagnostics have been greatly supported by artificial intelligence (AI), which has the potential to enhance diagnostic speed and accuracy, as well as the identification and treatment of cardiovascular diseases. The use of AI and machine learning models to analyze cardiac

biomarkers is becoming increasingly common. These biomarkers can provide valuable insights into cardiovascular health and risk assessment, enabling timely interventions before the onset of advanced stages of disease. Furthermore, by assessing blood flow and detecting structural anomalies in the heart and blood vessels, newer imaging modalities, such as ultrasound and optical coherence tomography (OCT), show promise for early detection of CVD. Research trends demonstrating an increasing emphasis on machine learning techniques in cardiovascular event detection highlight a shift toward proactive healthcare approaches. This trend underscores the importance of developing predictive algorithms capable of identifying early indicators of cardiovascular problems before they become clinically evident. With the ultimate aim of reducing the global burden of cardiovascular diseases, multidisciplinary collaboration and continuous research are essential for overcoming the challenges associated with validating biomarkers and incorporating these advanced technologies into established clinical practices. Cardiovascular diseases remain the leading cause of mortality worldwide, accounting for an estimated 18.6 million deaths annually. Traditional biomarkers such as troponin and BNP often lack sufficient sensitivity for detecting early-stage disease and for supporting personalized care. Artificial intelligence has emerged as a

transformative force in this field, enabling the integration of high-dimensional data from multi-omics, digital health sensors, and clinical records to identify novel biomarkers for early detection, risk stratification, and targeted interventions.

Biomarker Discovery Process

Through the identification, validation, and integration of measurable disease indicators, the multi-step biomarker discovery process aims to improve diagnosis and treatment, particularly in the context of cardiovascular diseases. This process is critical to the advancement of precision medicine, as it enables the customization of therapies according to the unique biomarkers of each patient.

Stages of Biomarker Discovery

The three main stages in the biomarker discovery process typically include initial detection, validation, and clinical integration. In the identification stage, researchers search for potential biomarkers within biological materials using various techniques, often relying on high-throughput technologies. Once discovered, biomarkers must undergo a rigorous validation process to ensure their accuracy and suitability for clinical use. This stage is vital to confirm that the biomarker can reliably reflect disease states or treatment responses.

Artificial Intelligence's Function

Artificial intelligence is transforming the process of biomarker discovery. By using machine learning and deep learning techniques to analyze large-scale biological data, researchers can now identify potential biomarkers with greater speed and precision. These AI methods can integrate multiple datasets, such as genomic, proteomic, and clinical records, to detect complex patterns and correlations that may indicate the presence of cardiovascular disorders. Furthermore, AI can strengthen the validation process by providing tools for explainable AI, which allow researchers to better understand and interpret the underlying factors influencing biomarker performance.

Challenges in Biomarker Validation

Despite technological advances, biomarker validation remains a significant challenge. A thorough approach is necessary to ensure that validated biomarkers are not only useful but also applicable across a variety of clinical contexts and populations. The multifactorial nature of cardiovascular diseases, influenced by both environmental and genetic factors, makes it more difficult to identify reliable biomarkers. Moreover, the shortage of validated biomarkers in cardiovascular medicine limits opportunities for pharmacogenomic applications aimed at personalizing treatment plans.

Artificial Intelligence in Biomarker Discovery

The recognition that artificial intelligence is transforming the search for cardiovascular disease biomarkers is steadily increasing. The application of AI techniques, particularly machine learning and deep learning, has enabled researchers to analyze complex biological datasets more effectively. This capability facilitates the discovery of novel biomarkers that have the potential to greatly enhance disease diagnosis and treatment.

AI Techniques in Biomarker Discovery

AI methods such as machine learning and deep learning provide powerful frameworks for processing vast amounts of biological data, including proteomic, metabolomic, and genomic datasets. These approaches enable the identification of correlations and patterns that may not be immediately detectable using conventional analytical techniques. These advanced computational tools assist researchers in accelerating the biomarker identification process and improving the accuracy of cardiovascular disease diagnosis.

Machine Learning Approaches

The use of machine learning in biomarker discovery involves a variety of techniques, including supervised, unsupervised, and

reinforcement learning. Supervised learning methods, such as support vector machines (SVMs) and artificial neural networks (ANNs), require labeled training data to classify and predict outcomes. These models are highly effective in analyzing and interpreting omics data, facilitating the identification of biomarkers for conditions such as myocardial infarction and heart failure. Unsupervised learning, in contrast, is primarily applied to uncover hidden patterns within data and does not require labeled datasets. This includes clustering methods, which are valuable for detecting novel biological markers and cellular subpopulations that may be linked to disease. Reinforcement learning, which combines elements of both supervised and unsupervised learning, improves model accuracy through trial-and-error strategies.

Explainable AI in Biomarker Discovery

The application of explainable AI (XAI) in biomarker development enhances the transparency of AI algorithms by clarifying the decision-making process. By revealing how specific predictions are generated, XAI fosters greater understanding and trust between researchers and clinicians. This is particularly critical in medical contexts where the implications of diagnostic tools may significantly affect patient care.

Challenges and Considerations

Despite the promising potential of AI in biomarker discovery, numerous challenges remain. Issues related to data privacy, ethical concerns, and the necessity for high-quality, representative training datasets are crucial and must be addressed to ensure the responsible and effective use of AI in healthcare. Moreover, AI models must undergo continuous refinement to accurately reflect the complexity of cardiovascular diseases.

Applications of AI in Cardiac Biomarker Discovery

Artificial intelligence is profoundly influencing the field of cardiovascular disease biomarker development. By applying machine learning and other AI-based methods, researchers are uncovering new biomarkers that enhance cardiac health monitoring, diagnosis, and prognosis.

Predictive Modeling

AI's capacity to develop robust predictive models has advanced cardiovascular risk assessment and patient outcome forecasting. Machine learning techniques, including deep learning and reinforcement learning, have been utilized to improve the accuracy of CVD classification and prediction. For example, predictive models can estimate the likelihood of acute episodes of hypertension or other cardiovascular events, thereby facilitating timely clinical interventions.

These models often incorporate advanced regularization and cross-validation techniques to prevent overfitting and to improve generalizability across diverse patient datasets.

Biomarker Identification

Identifying new biomarkers related to cardiac metabolism is essential for understanding and managing heart failure and other cardiovascular diseases, and AI algorithms have demonstrated strong capabilities in this area. Such biomarkers act as measurable indicators that assist in early diagnosis and guide treatment strategies by detecting early signs of metabolic dysfunction. By integrating extensive datasets that include genomic, proteomic, and medical imaging information, AI can offer a more comprehensive picture of cardiovascular health. This integration can reveal previously unknown metabolic pathways associated with cardiovascular conditions.

Clinical Translation and Implementation

Ensuring the seamless integration of AI-derived biomarkers into clinical practice remains a top priority. AI supports both the validation of biomarkers and their conversion into clinically meaningful data. By refining the connection between biomarkers and clinical outcomes, AI facilitates the development of precision medicine

strategies that improve diagnosis, treatment monitoring, and patient management. For these insights to be effectively applied in real-world healthcare settings, future work must focus on building models that are both interpretable and adaptable to various clinical environments.

Case Studies

Overview of AI Applications in Cardiac Biomarker Discovery

In the field of cardiac diseases, artificial intelligence has demonstrated considerable promise, especially in the discovery and validation of biomarkers. Numerous case studies have illustrated how AI algorithms can enhance diagnostic accuracy, predict patient outcomes, and inform treatment decisions for individuals with cardiovascular diseases.

AI-Enabled Electrocardiogram Analysis

A significant study investigated the application of AI-enabled electrocardiograms (ECGs) for identifying patients with low ejection fractions (EF). This randomized clinical study demonstrated that AI systems could accurately detect low EF and provide real-time data to assist physicians in the early diagnosis and treatment of heart failure. Such advancements in ECG technology have the potential to reduce the cognitive burden on medical professionals by offering

initial assessments and lowering the likelihood of misdiagnosis.

Predictive AI Model Performance

A comprehensive review of various predictive models used in cardiovascular disease (CVD) revealed that every study examined had at least one predictive performance metric. Key performance indicators included sensitivity or recall in 312 models, calibration plots in 90 models, and the C-index reported for 482 models. The review emphasized the importance of rigorous evaluation and validation of AI algorithms and found that many studies lacked critical reporting information. This deficiency could hinder the establishment of evidence-based practices in clinical settings.

External Validation of AI Tools

An AI-based tool for the automatic estimation of global longitudinal strain (LV-GLS) and left ventricular ejection fraction (LV-EF) was validated in a recent prospective cohort study. By comparing intraobserver and interobserver variability, the study underscored the importance of accuracy and reproducibility in AI-enabled assessments. It also demonstrated the clinical utility of AI in real-world settings by comparing AI-based measurements with conventional methods, reflecting how these technologies could be applied in practical clinical scenarios.

Integration Difficulties

Despite significant progress, integrating AI technologies into healthcare environments remains challenging. Concerns over data security, patient privacy, and the evolving legal framework continue to hinder the widespread adoption of AI solutions. In addition, the absence of standardized platforms for reporting predictions and the necessity for ongoing research into the broader effects of AI remain pressing issues. Addressing these challenges is critical to ensuring that AI applications comply with strict ethical standards, protect patient rights, and improve clinical outcomes.

Validation Processes for AI-Driven Biomarkers

Biomarker validation is a crucial preliminary step in applying artificial intelligence (AI) and machine learning (ML) to cardiovascular research. This process ensures that biomarkers consistently and accurately identify specific diseases or conditions, enabling their effective use in therapeutic settings.

Importance of Biomarker Validation

The validation of biomarkers is vital because it guarantees their reliability and accuracy, directly influencing clinical practice. Successful biomarker validation supports the development of precision medicine approaches, allowing for improved patient outcomes through targeted medications

and customized treatment plans. As AI and ML capabilities advance, their role in biomarker validation is expanding, particularly in refining the detection of precise biomarker signatures associated with different cardiac subtypes.

Advanced Computational Methods

The validation of biomarkers depends heavily on advanced computational methods and tools. These include machine learning algorithms for data analysis and pattern recognition, statistical modeling for hypothesis testing, and bioinformatics tools for feature extraction and data preprocessing. By integrating multi-omics data, these approaches provide a comprehensive understanding of how therapeutic interventions affect biological processes.

Stepwise Approach to Validation

A methodical, stepwise process is essential for biomarker validation. Following the initial selection and preprocessing of data, the evaluation of appropriate learning algorithms and assessment methods takes place. A robust validation plan should incorporate rigorous statistical analysis, the selection of diverse validation techniques, the identification of suitable data sources, and well-defined research objectives.

External Validation

External validation is a vital step in confirming

the clinical value of AI-driven biomarkers. It involves testing research findings on independent datasets to evaluate generalizability. A notable gap in the field is the lack of independent external validations for many models. Designing and conducting such studies is necessary to enhance the accuracy and reliability of AI-based biomarkers for CVD prediction.

Ethical Considerations

The application of AI in the search for cardiac biomarkers raises several ethical considerations aimed at safeguarding patient safety and data integrity.

Data Privacy and Security

Data privacy is one of the most pressing ethical concerns. AI systems often require access to sensitive patient information, which increases the risk of data breaches and the misuse of medical records. To reduce these risks, researchers must adhere to strict data protection regulations, such as the General Data Protection Regulation (GDPR) in the European Union. Measures such as pseudonymization, which removes personal identifiers from datasets, are essential for maintaining patient confidentiality.

Informed Consent

Informed consent is another critical ethical requirement. Patients must be made aware of who will have access to their medical and genetic

information and how AI systems will use it. Researchers must ensure that participants in AI-based studies fully understand the potential risks and benefits of their involvement and that their consent is given voluntarily.

Algorithmic Bias

Algorithmic bias presents a significant ethical challenge, particularly when AI models are trained on datasets that are not representative of the wider population. If the training data primarily reflects a specific demographic, the resulting models may generalize poorly, leading to disparities in diagnosis and treatment. To improve fairness and accuracy, researchers should ensure that AI models are trained using diverse datasets.

Transparency and Accountability

Transparency in AI algorithm development is essential to maintain trust among the public and healthcare professionals. Developers should openly share information about methodologies and results so that both patients and clinicians can understand the processes behind AI-generated decisions. This also involves disclosing potential conflicts of interest and taking responsibility for the outcomes of AI applications in clinical practice.

Ethical Research Practices

Ethical oversight plays a key role in AI-related research. Studies must be approved by the

appropriate ethics committees, and any protocol modifications that could affect participant safety should undergo formal review. Researchers should also commit to ongoing ethical education and remain informed about emerging challenges in the application of AI in healthcare.

Challenges in Integrating AI in Clinical Pathways

Several important challenges must be addressed to successfully incorporate AI into clinical pathways for cardiac biomarker identification.

Limited Knowledge and Usability

A significant concern is the limited knowledge among healthcare professionals regarding AI, which can make it more difficult to apply these tools effectively and consistently in clinical practice. Usability issues with AI systems and the challenge of integrating them into existing workflows present additional barriers, potentially reducing the quality of patient care.

Interpretability and Clinical Validation

One of the greatest barriers to AI adoption is the lack of interpretability in many AI models. If physicians cannot understand how an AI system arrived at its diagnosis or prediction, trust and effective use in practice are undermined. Furthermore, while many models perform well in controlled research environments, they often lack

adequate clinical validation in real-world settings, which can lead to discrepancies in performance.

Cost and Infrastructure Issues

Implementing AI technologies often involves substantial financial investment in infrastructure and resources, which can be a significant barrier, especially for resource-limited healthcare facilities. The need for robust technical infrastructure, interoperable systems, and comprehensive clinician training further complicates the integration process.

Ethical and Regulatory Challenges

Since AI systems in healthcare handle sensitive patient data, they raise concerns about privacy and security. The evolving regulatory framework for AI in medicine has introduced additional issues related to standardization, compliance, and ethics. While initiatives such as the National AI Initiative Office in the United States and the European Commission's Ethics Guidelines for Trustworthy AI are attempting to address these matters, comprehensive frameworks are still in development.

Bias and Generalization Issues

Bias in AI algorithms can result in unequal healthcare outcomes for different populations. Models trained on one demographic group may not perform effectively in another, raising concerns about fairness and equity in care

delivery.

Overreliance on AI

Another concern is the potential overreliance on AI, which could diminish the role of clinical intuition and human judgment. If medical professionals depend too heavily on AI recommendations, the quality of patient care could be compromised. Balancing AI assistance with human expertise is crucial for maintaining high standards in clinical decision-making.

AI-Driven Multi-Omics Biomarker Discovery

High-accuracy molecular signatures have been demonstrated by multimodal AI frameworks that integrate transcriptomics, genomics such as SNP data, and clinical records. These approaches have identified biomarkers including the ribosomal gene RPL36AP37 and the hemoglobin subunit HBA1 with exceptional predictive accuracy. Such biomarkers reveal underlying pathophysiological mechanisms, for example, HBA1 has been linked to hypoxia and oxidative stress, while RPL36AP37 implicates dysregulation in protein synthesis.

In computational biology, AI plays a significant role in identifying novel biomarker classes such as epigenetic markers including miRNAs and circRNAs, metabolomic profiles, and extracellular vesicles through multi-omics integration. In heart failure, AI has been shown to aid

in early risk prediction using metabolomic and proteomic signatures, in identifying drug targets, and in monitoring therapy response. Additionally, AI enables cross-disease biomarker translation, identifying immune-inflammatory markers such as CTSD, CEBPD, and CYP27A1 that predict coronary artery disease progression in patients with inflammatory bowel disease. This illustrates AI's ability to uncover shared pathological pathways such as neutrophil-mediated inflammation across comorbidities.

Digital Biomarkers and Sensing Technologies

Explainable AI has been applied to derive digital biomarkers from ECG data, using automated pipelines with unsupervised clustering and particle swarm optimization. This approach has identified novel markers such as T-wave multiscale entropy for arrhythmia risk, as well as established measures such as RR interval sample entropy. The use of explainable AI bridges the gap between algorithmic outputs and clinical interpretability, supporting the detection of preclinical cardiovascular disease.

Optical biosensors, enhanced with nanomaterials, aptamers, and saliva-based assays, have been developed for point-of-care testing. AI optimizes these devices for multiplexed detection of markers such as troponin and CRP, achieving high

sensitivity and enabling home-based monitoring. The expansion of AI-powered, digital-native biomarkers through wearables and smartphone applications is helping to democratize access to screening, particularly in underserved populations.

Lifestyle and Metabolic Interplay

AI has been applied to large-scale biobank datasets to identify dietary endotypes using latent profile analysis. These endotypes correlate with cardiovascular outcomes, such as a health-conscious profile associated with lower risks of heart failure and chronic kidney disease, and a sweet-tooth profile linked to higher risks of stroke and diabetes. Multi-omics analyses connect these dietary patterns to distinct metabolomic and proteomic signatures, including ketone bodies and leptin, supporting precision nutrition strategies in cardiovascular prevention.

Cross-Disciplinary Synergy

Insights from immunology demonstrate how AI can be used to discover biomarkers, predict treatment responses, and integrate mobile health data, approaches that can be translated to cardiovascular care for inflammatory biomarker panels in conditions such as myocarditis. Computational frameworks for biomarker discovery frequently involve feature selection techniques such as mRMR and RFE, classification

methods including XGBoost, SVM, and neural networks, and interpretability tools such as SHAP and LIME.

Challenges and Clinical Translation

Key challenges in AI-driven biomarker discovery include data heterogeneity, algorithmic bias, the need for clinical validation, and regulatory approval. Federated learning can help address data heterogeneity, while diverse cohort recruitment can reduce bias. Hybrid trial designs are essential for clinical validation, and alignment with regulatory frameworks is required for approval. Implementation pathways include point-of-care integration of biosensors, real-world evidence generation through wearable-based digital biomarkers, and precision prevention strategies such as dietary endotyping.

Conclusion

Artificial intelligence is redefining cardiac biomarker discovery through the integration of multi-omics, digital phenotyping, and cross-disciplinary innovation. From molecular markers such as HBA1 and CYP27A1 to ECG-derived features like T-wave entropy and dietary endotypes, AI is enabling a shift from reactive treatment toward precision prevention. Overcoming challenges in bias, validation, and equity will require collaborative frameworks that unite computational science, clinical practice, and

MOBINA GHEIBI

regulatory policy. As these technologies continue to mature, they will support earlier interventions, personalized management, and wider access to care, ultimately reducing the global burden of cardiovascular disease.

ARTIFICIAL INTELLIGENCE IN BIOMARKER DISCOVERY: A...

5. AI IN BIOMARKER DISCOVERY FOR DERMATOLOGICAL DISEASES

Background

Dermatological diseases encompass a vast array of conditions affecting the skin, hair, and nails, including inflammatory disorders, infectious diseases, autoimmune conditions, and skin cancers. Accurate diagnosis and monitoring of these diseases are often challenging due to the diversity of clinical presentations and overlapping features among different conditions. Biomarkers provide measurable indicators of pathological processes, enabling early detection, disease classification, prognosis assessment, and therapeutic monitoring. In dermatology, biomarkers can be derived from genetic profiles, circulating proteins, metabolites, immune signatures, and imaging features. However, traditional biomarker discovery approaches often struggle to integrate the vast and heterogeneous data generated by dermatological research. Artificial intelligence has emerged as a transformative tool in this field, offering the ability to handle large-scale, complex datasets, extract hidden patterns, and identify robust biomarker candidates that can improve both diagnostic accuracy and treatment

personalization.

The Importance of Biomarkers in Dermatological Diseases

Biomarkers in dermatology serve multiple purposes, from identifying disease presence to predicting progression and assessing treatment response. In conditions such as melanoma, non-melanoma skin cancers, psoriasis, and atopic dermatitis, biomarkers can guide clinical decisions and improve patient outcomes. For example, the expression levels of specific cytokines or immune cell populations can indicate the severity of inflammation in psoriasis, while genetic mutations in BRAF or NRAS can guide targeted therapy in melanoma. Yet, most single biomarkers have limited specificity and sensitivity when used in isolation, which can lead to misdiagnosis or inappropriate treatment selection. Integrating multiple biomarkers across molecular, cellular, and imaging domains offers the potential for more accurate and comprehensive disease assessment. Artificial intelligence, with its capacity to process and integrate high-dimensional data, is uniquely positioned to facilitate the discovery of such multi-marker panels in dermatology.

Artificial Intelligence in Biomedical Data Analysis

Artificial intelligence refers to computational

systems capable of performing tasks that require cognitive functions such as learning, reasoning, and decision-making. Within biomarker discovery, AI methods excel at recognizing patterns and correlations that may not be apparent through conventional statistical techniques. Machine learning, a subset of AI, includes supervised learning for prediction, unsupervised learning for pattern discovery, and semi-supervised learning for scenarios where labeled data is limited. Deep learning, based on multi-layer neural networks, has demonstrated remarkable capabilities in image analysis, natural language processing, and the integration of heterogeneous datasets. These strengths are particularly relevant to dermatology, where both visual and molecular data are crucial for understanding disease mechanisms and identifying reliable biomarkers.

Sources of Data for AI-driven Biomarker Discovery in Dermatology

The foundation of AI-based biomarker discovery lies in high-quality, diverse datasets. In dermatology, these sources include clinical records, laboratory tests, genomic and transcriptomic data, proteomic and metabolomic profiles, and high-resolution dermatological imaging. Skin biopsies provide valuable histopathological information, which can be

digitized for AI-based image analysis. Non-invasive imaging modalities such as dermoscopy, reflectance confocal microscopy, and optical coherence tomography offer rich datasets for extracting quantitative imaging biomarkers. Public repositories, disease registries, and multicenter research collaborations further expand the available data pool. Integrating these diverse datasets presents challenges, including differences in data formats, measurement protocols, and population characteristics. AI techniques such as feature embedding, normalization, and dimensionality reduction are critical for harmonizing datasets and enabling robust multi-modal biomarker discovery.

Machine Learning Approaches for Dermatological Biomarker Identification

Machine learning offers a versatile set of tools for identifying biomarkers in dermatology. Supervised learning methods, such as support vector machines, random forests, and gradient boosting algorithms, can classify skin lesions or predict disease outcomes based on molecular and imaging features. Unsupervised learning techniques, including clustering and principal component analysis, can reveal hidden subgroups within patient populations, potentially corresponding to distinct disease subtypes. Semi-supervised learning approaches are particularly

valuable in dermatology, where obtaining large annotated datasets can be challenging. These models can learn from a combination of labeled and unlabeled data, improving generalizability. The choice of algorithm depends on factors such as dataset size, feature dimensionality, and the need for interpretability in clinical contexts.

Deep Learning in Multi-omics Integration for Dermatology

Deep learning has shown particular promise in integrating multi-omics data for biomarker discovery in dermatological diseases. By leveraging architectures such as convolutional neural networks for imaging data and fully connected networks for genomic or proteomic data, deep learning enables the simultaneous analysis of diverse data types. Autoencoders can compress high-dimensional omics data into low-dimensional representations while preserving essential biological information, facilitating downstream predictive modeling. In dermatology, multi-omics integration has the potential to link genetic mutations, transcriptomic signatures, protein expression patterns, and metabolic profiles with specific disease phenotypes. This approach allows for the identification of complex biomarker signatures that reflect the multifactorial nature of skin diseases.

AI in Imaging Biomarker

Discovery for Skin Diseases

Visual examination remains central to dermatological diagnosis, making imaging data an invaluable resource for biomarker discovery. AI has revolutionized the analysis of skin images, with convolutional neural networks achieving dermatologist-level performance in lesion classification. Beyond diagnosis, AI can extract quantitative features from dermoscopic, histopathological, and confocal images to serve as imaging biomarkers. For example, texture, color distribution, vascular patterns, and lesion shape can all be quantified and correlated with disease stage or aggressiveness. In melanoma, radiomic features derived from high-resolution imaging have been associated with molecular subtypes and prognostic outcomes. The integration of imaging biomarkers with molecular and clinical data using AI can enhance the precision of dermatological diagnostics and treatment planning.

The Role of the Skin Microbiome in AI-based Biomarker Discovery

The skin microbiome, composed of bacteria, fungi, viruses, and mites, plays an important role in skin health and disease. Dysbiosis of the skin microbiota has been implicated in conditions such as atopic dermatitis, acne, and psoriasis. High-throughput sequencing technologies allow detailed characterization of the skin microbiome, generating large and complex datasets suitable

for AI analysis. Machine learning algorithms can identify microbial taxa or community structures that serve as biomarkers for disease diagnosis, prognosis, or treatment response. Furthermore, integrating microbiome data with host genetic, proteomic, and metabolomic profiles can yield composite biomarkers that provide deeper insights into disease mechanisms. AI-driven microbiome analysis may also inform personalized therapeutic strategies, including targeted antimicrobial or probiotic interventions.

Challenges in AI-based Dermatological Biomarker Discovery

Despite its potential, AI-based biomarker discovery in dermatology faces several challenges. Data scarcity is a common problem, particularly for rare skin diseases or specific patient demographics. Variability in image acquisition, sample processing, and measurement techniques can introduce biases that affect model performance. Deep learning models, while powerful, are often criticized for their lack of interpretability, which can hinder clinician trust and regulatory approval. Overfitting is another concern, especially when training on small datasets with high feature dimensionality. Addressing these challenges requires careful study design, standardized data collection protocols, rigorous validation procedures, and

the development of interpretable AI models that provide transparent reasoning for biomarker selection.

AI for Longitudinal Biomarker Tracking in Dermatological Diseases

Longitudinal biomarker tracking allows clinicians and researchers to monitor disease progression and treatment responses over extended periods. In dermatology, where diseases such as psoriasis, atopic dermatitis, vitiligo, and melanoma may evolve gradually or present intermittent flare-ups, tracking changes in biomarker levels or imaging characteristics can provide valuable insights. Artificial intelligence can process sequential datasets from clinical photographs, dermoscopic images, histopathology, and molecular profiles to identify patterns that indicate early signs of relapse, therapeutic resistance, or remission. Time-series models such as recurrent neural networks and temporal convolutional networks are capable of recognizing temporal dependencies in biomarker data, enabling proactive interventions before significant clinical deterioration occurs. The integration of wearable technologies and mobile applications that capture skin images or physiological signals in real time further enhances longitudinal monitoring, offering the possibility of more responsive and personalized patient care.

Personalized Medicine Enabled by AI-derived Biomarkers

The application of AI in biomarker discovery is closely aligned with the goals of personalized medicine, where treatment plans are tailored to the unique biological and clinical characteristics of each patient. In dermatology, personalized approaches can improve the effectiveness of therapies and reduce adverse effects. For example, AI-derived biomarkers can help identify patients with melanoma who are more likely to benefit from specific immunotherapies, or individuals with psoriasis who are most responsive to certain biologic agents. By integrating genetic data, immune signatures, imaging features, and environmental factors, AI can generate comprehensive profiles that inform individualized treatment strategies. Personalized medicine also extends to preventive care, where biomarkers can identify individuals at high risk for developing certain skin diseases, enabling targeted surveillance and lifestyle modifications to reduce risk.

Case Studies of AI in Dermatological Biomarker Research

Several studies have demonstrated the practical value of AI in dermatological biomarker discovery. In melanoma research, deep learning models trained on histopathological images

have identified features correlating with specific genetic mutations, offering non-invasive surrogates for molecular testing. Another study applied machine learning to cytokine profiles in patients with atopic dermatitis, revealing immune biomarkers that predicted disease severity and treatment response. In acne research, AI models have integrated skin microbiome data with clinical photography to identify microbial and morphological biomarkers that distinguish between subtypes and predict responsiveness to antibiotic or hormonal therapy. These examples illustrate that AI is not limited to diagnostic classification but can uncover mechanistic biomarkers that provide insight into disease biology and therapeutic targets.

Integrating AI-derived Biomarkers into Clinical Workflows

The successful translation of AI-discovered biomarkers into clinical practice requires seamless integration into existing workflows. This involves not only validating biomarkers in independent and diverse patient cohorts but also ensuring that the assays and measurement techniques used are practical for routine use. Clinical decision support systems can be enhanced with AI-derived biomarker data, providing clinicians with real-time recommendations during patient consultations. Integration with electronic health records enables the automatic retrieval and

analysis of biomarker results, streamlining the diagnostic process. Importantly, the presentation of biomarker information must be intuitive, with clear visualization tools and straightforward interpretative guidance to support clinician decision-making without adding unnecessary complexity.

The Role of Explainable AI in Dermatological Biomarker Discovery

Explainability is critical for the adoption of AI-based biomarker tools in dermatology. Clinicians need to understand why a particular biomarker or feature set has been flagged as significant, especially when such findings influence treatment decisions. Explainable AI techniques, such as feature attribution methods and heatmap visualizations, can highlight the regions of an image, molecular features, or microbiome taxa that contribute most strongly to the model's predictions. In practice, this might mean showing which parts of a dermoscopic image correspond to features linked with malignancy or which proteins in a serum profile are driving a prognosis prediction. By enhancing transparency, explainable AI builds trust among clinicians and supports regulatory compliance, while also aiding researchers in biological interpretation and hypothesis generation.

Ethical and Regulatory Considerations in AI-based Biomarker Research

The deployment of AI in biomarker discovery brings forward several ethical and regulatory considerations. Privacy protection is paramount, particularly when handling sensitive patient images, genetic data, and microbiome profiles. Compliance with legal frameworks such as the General Data Protection Regulation and the Health Insurance Portability and Accountability Act is essential for protecting patient rights. Another challenge lies in avoiding biases that can arise from unrepresentative datasets, which may lead to less accurate biomarker identification in underrepresented populations. Regulatory agencies require that AI-based diagnostic tools and biomarker panels demonstrate reproducibility, clinical validity, and a clear benefit over existing methods before approval. This means that developers must engage in rigorous, transparent validation processes and maintain thorough documentation of the model development pipeline.

Collaborative Research Models for AI in Dermatological Biomarkers

Progress in AI-based biomarker discovery for dermatology is accelerated by collaborative research models that bring together clinicians,

data scientists, molecular biologists, and bioinformaticians. Multi-institutional consortia and data-sharing initiatives can provide the large, diverse datasets required to train and validate robust AI models. Federated learning approaches are particularly valuable in this context, as they allow algorithms to learn from distributed datasets without requiring direct sharing of sensitive patient information. Collaborative projects also facilitate the development of standardized data collection and annotation protocols, which are essential for minimizing bias and enhancing reproducibility. Partnerships between academic institutions, healthcare providers, industry, and regulatory bodies can further streamline the translation of AI-discovered biomarkers into validated clinical tools.

Future Directions for AI in Dermatological Biomarker Discovery

The future of AI in dermatological biomarker research is likely to be shaped by several key trends. Advances in single-cell sequencing technologies will allow researchers to identify biomarkers at unprecedented resolution, distinguishing between cellular subtypes within skin lesions. Multi-omics integration will become more sophisticated, encompassing genomic, transcriptomic, proteomic, metabolomic, and

microbiome data, as well as spatial transcriptomics that reveal the organization of cells and molecules within tissue. The use of real-time data from wearable sensors and mobile health applications will enable continuous monitoring of skin health and disease progression, facilitating adaptive treatment strategies. Generative AI models may contribute to data augmentation, helping to overcome limitations in dataset size and diversity, although careful validation will be required. Education and training programs that bridge dermatology and computational science will be essential for cultivating a new generation of researchers capable of driving innovation in this field.

Conclusion

Artificial intelligence offers transformative potential for biomarker discovery in dermatological diseases by integrating complex datasets, uncovering subtle patterns, and identifying clinically actionable indicators. From early disease detection to personalized therapy selection and longitudinal monitoring, AI-derived biomarkers can enhance the precision and effectiveness of dermatological care. Challenges related to data quality, interpretability, and regulatory compliance remain, but ongoing advances in computational methods, collaborative research frameworks, and explainability tools are steadily addressing these obstacles. The ultimate

goal is the seamless incorporation of AI-derived biomarkers into clinical practice, where they can support timely diagnosis, guide targeted interventions, and improve patient outcomes. As the field continues to evolve, AI is set to redefine the landscape of dermatological research and patient management, fostering a more predictive, personalized, and preventative approach to skin health.

6. AI IN BIOMARKER DISCOVERY FOR ONCOLOGY

Background

Cancer remains one of the most formidable challenges in modern medicine, with its complexity demanding innovative approaches to improve diagnosis and treatment. Biomarkers, which are measurable indicators of biological processes, play a pivotal role in oncology by enabling early detection, precise diagnosis, and personalized therapy. However, traditional methods of biomarker discovery have been hindered by the vast and intricate nature of biological data, often requiring years of painstaking research. Artificial intelligence (AI) is now transforming this landscape, offering unprecedented capabilities to analyze massive datasets and uncover hidden patterns that conventional techniques fail to detect. By applying machine learning and deep learning, AI accelerates the identification of novel biomarkers from genomic, proteomic, and imaging data, ushering in a new era of precision oncology.

The integration of AI into biomarker discovery begins with its ability to process multi-omics data, including genomics, transcriptomics, proteomics, and metabolomics. While traditional approaches

might focus on individual genes or proteins, AI algorithms can simultaneously analyze thousands of molecular features, identifying subtle yet clinically significant patterns. For example, AI has been used to detect somatic mutations in cancer genomes, such as TP53 or BRCA1/2, which are critical for understanding tumor behavior and guiding targeted therapies. Beyond genomics, AI-powered tools examine proteomic and metabolomic datasets to identify protein or metabolite signatures that correlate with disease presence or progression. Liquid biopsy, a non-invasive method for detecting cancer through blood samples, has particularly benefited from AI's capability to analyze circulating tumor DNA (ctDNA) and exosomes, paving the way for earlier and more accurate diagnoses.

Medical imaging is another domain where AI is making profound contributions to biomarker discovery. Radiomics, an emerging field, uses AI to extract quantitative features from CT, MRI, and PET scans, features that may be imperceptible to the human eye but still hold predictive value. Deep learning models, particularly convolutional neural networks (CNNs), excel at segmenting tumors, quantifying their growth, and even predicting how they may respond to treatments such as immunotherapy. These imaging biomarkers are increasingly being combined with molecular data to create comprehensive profiles of tumors,

enabling more precise prognostication and treatment planning. The integration of AI-driven imaging analysis with molecular data is a strong example of how multimodal approaches are enhancing our understanding of cancer biology.

Despite these advancements, challenges remain in translating AI-discovered biomarkers into clinical practice. One major hurdle is data heterogeneity, as integrating diverse datasets from different institutions or platforms requires robust standardization and validation. In addition, the so-called black box nature of some AI models raises concerns about interpretability, since clinicians need to understand how a biomarker was identified in order to trust its application in patient care. Regulatory approval is another essential step, as agencies such as the FDA and EMA must ensure that AI-generated biomarkers meet rigorous standards for safety and efficacy. Nevertheless, the potential benefits are considerable. AI not only accelerates biomarker discovery but also enables personalized medicine, in which treatments are tailored to the unique molecular profile of each patient's cancer.

Looking ahead, the synergy between AI and biomarker discovery is expected to redefine oncology. As algorithms become more sophisticated and datasets grow larger and more diverse, AI will likely reveal biomarkers for rare cancers or subtypes that have historically been

difficult to study. Collaborative efforts among researchers, clinicians, and AI specialists will be essential to overcome existing barriers and translate these innovations into clinical use. The ultimate goal is a future in which cancer is detected at its earliest stages, treated with pinpoint accuracy, and monitored in real time, all made possible by the transformative power of AI in biomarker discovery. This convergence of technology and biology holds the potential to change the course of cancer, offering hope for more effective and individualized care.

In molecular biology, AI-based models are advancing our understanding of cancer biology by integrating high-dimensional datasets and combining biological sciences with computational methods, leading to novel insights and breakthroughs. These models generate information from diverse datasets, including tumor biopsy samples, blood, urine, semen, saliva, and other biological sources, to discover biomarkers associated with clinical outcomes. Molecular biomarkers serve as a foundation for studying the biological mechanisms of cancer, and the ability to investigate them has expanded significantly due to advances in high-throughput omics technologies in recent decades, including next-generation sequencing (NGS), RNA sequencing (RNA-seq), microarray analysis, and mass spectrometry.

AI-based multiomics analyses have facilitated the development of personalized cancer medicine, contributing to cancer detection and screening, diagnosis, prognosis, classification, grading, and evaluation of treatment response. Machine learning approaches make it easier to detect a wide range of oncogenic driver mutations and improve the discovery of novel molecular biomarkers. Artificial intelligence is also highly applicable in extracting quantitative imaging biomarkers and analyzing imaging data, such as tumor size, shape, intensity, and texture, from medical images including CT, PET, MRI, and molecular imaging. AI-driven image analysis, particularly through deep learning and radiomics, can extract valuable features from medical scans that are useful for building predictive models in oncology.

Clinical AI-Assisted Studies Based on Spectroscopy Methods

In cancer biology research, particularly for biomarker discovery, cancer screening, and drug development, analytical techniques such as mass spectrometry (MS) are widely used. Gas chromatography-MS (GC-MS), liquid chromatography-MS (LC-MS), and capillary electrophoresis-MS (CE-MS) have become standard strategies and have yielded numerous biomarker candidates. However, these techniques have limitations, such as restrictions on molecule size, chemical coverage, lack of visualization of

molecular distribution, and absence of spatial resolution.

Recent advances in proteomics, supported by AI and computational statistical algorithms, provide an alternative path for the next generation of high-performance diagnostic biomarkers. Proteomics-based biomarker discovery from body fluids can be applied easily in clinical samples and is more rapid than conventional methods such as gel electrophoresis. Breakthroughs in high-throughput MS-based proteomics now allow visualization and mapping of metabolite distributions for proteins, with large datasets and high-selectivity adsorption on protein chip arrays facilitating biomarker discovery.

The ability to handle high mass and spatial resolution datasets is ideal for AI-based clinical diagnosis using multidimensional data. This maximization of physicochemical characterization has been applied in multimodal imaging techniques, microscopy, spectroscopy, and electrochemistry, creating new possibilities for cancer diagnosis and monitoring.

Clinical AI-Assisted Studies Based on Electrochemistry Methods

Electrochemical sensors and biosensors can detect cancer biomarkers by monitoring molecular mechanisms and changes in electrical signals in body fluids. These sensors can screen for

changes in plasma that indicate cancer. However, challenges remain due to the nonhomogeneous physical and chemical properties of biological samples.

Recent advances in nanotechnology have led to the development of noninvasive and inexpensive electrochemical sensors. Their comparable size to biological molecules and high sensitivity make them highly effective in measuring biomarkers in plasma, bridging chemistry and medicine. While diagnosing disease from a single biomarker in complex biological systems is challenging, multiplex biomarker analysis in large datasets has become increasingly important. Reproducibility in biosensor measurements is a critical parameter, and integrating multivariable data using machine learning algorithms offers the highest efficiency and performance for analysis and biomarker discovery.

One example is a sensor developed by Mijin Kim and colleagues that used molecularly tunable quantum defects, also known as organic color centers (OCCs), on single-walled carbon nanotubes (SWCNTs). These OCCs produce a distinct fluorescence band (E11-) in response to the local environment, providing novel sensitivities. A nanosensor array composed of OCC-DNA elements combined with ML capabilities was used to detect high-grade serous ovarian carcinoma (HGSOC) in patient sera. This advanced detection method

outperformed conventional serum biomarker-based identification with high accuracy and sensitivity.

Research integrating chemistry and medicine continues to drive the discovery of new prognostic biomarkers. The extensive data gathered from electrochemical sensors, combined with their ability to modify systems in computer-aided biomarker discovery, is particularly valuable in multi-analyte testing and large-scale population monitoring.

The Role of Artificial Intelligence in the Discovery of Biomarkers

Artificial intelligence, particularly in the domains of machine learning and deep learning, has revolutionized the analysis of biological data. The discovery of cancer biomarkers has traditionally been a complex, costly, and time-consuming process that requires screening thousands of samples and conducting multi-layered data analysis. AI has made this process faster, more accurate, and more cost-effective.

Analyzing Complex Biometric Data with AI

One of the most important advantages of AI is its ability to process large volumes of multidimensional data, such as:

Genomic data, including DNA and RNA

sequencing information;

Transcriptomic data, involving the analysis of gene expression in cells;

Proteomic data, examining the structure and surface characteristics of proteins;

Metabolomic data, involving the investigation of cellular metabolites.

Machine learning algorithms can identify patterns in these datasets that are not visible to researchers. For example, subtle changes in gene expression patterns in certain patients may indicate the presence or progression of a specific type of cancer, and AI can detect such changes as potential biomarkers.

Identifying New and Unexpected Biomarkers

In numerous studies, deep learning models have successfully identified biomarkers that had not previously been reported. These biomarkers may be associated with previously unknown biological pathways involved in tumor growth, invasion, or metastasis. Such discoveries could lead to a deeper understanding of disease mechanisms and the development of more targeted therapies.

Discovering Hybrid Biomarkers

AI has the capability to define complex combinations of features as biomarkers. Unlike traditional methods that often focus on a single

biomarker, AI algorithms can extract multivariate patterns from the expression of genes, proteins, and metabolites and present them as molecular signatures. These hybrid biomarkers often demonstrate higher accuracy and sensitivity in cancer prediction and diagnosis.

Multi-Source Data Integration

Another significant capability of AI is its ability to integrate various types of data, such as omics data, pathological images, electronic medical records, and clinical information. Multimodal AI models can provide a more comprehensive understanding of a patient's condition and identify biomarkers that can only be detected through the overlap of multiple data types. For example:

An algorithm might identify a specific biomarker of metastasis by combining microscopic images with RNA sequencing data;

Another algorithm may detect a biomarker for drug resistance by integrating treatment history with genomic sequencing data.

Clinical Applications and Prognosis

AI is not only instrumental in the discovery phase of biomarkers but is also highly effective in predicting disease progression, guiding the selection of targeted treatments, and forecasting treatment responses. AI models can:

Classify patients according to their risk of cancer

recurrence;

Recommend the most suitable treatment, such as immunotherapy, chemotherapy, or targeted therapy, based on biomarker profiles;

Detect disease recurrence earlier through continuous monitoring of biological data.

Facilitating Population Screenings

In nationwide cancer screening programs, AI has improved accuracy, reduced false positives, and enhanced early detection rates. For instance, deep learning algorithms applied to mammography, colonoscopy, and CT scans can flag suspicious cases with high precision, significantly reducing detection time.

Optimizing the Design of Clinical Trials

Artificial intelligence can be used to identify patients suitable for participation in clinical trials based on their biomarker profiles. In addition, AI can help predict the success or failure of a new drug by analyzing the biological characteristics of the participant population.

Applications of Artificial Intelligence in the Discovery of Cancer Biomarkers

Breast Cancer

In breast cancer, biomarkers such as HER2,

estrogen receptor (ER), and progesterone receptor (PR) play essential roles in diagnosis and treatment. By analyzing genomic and proteomic data, AI can detect new biomarkers and assist in predicting treatment response.

Lung Cancer

In lung cancer, biomarkers such as EGFR and ALK are used to guide targeted therapies. AI algorithms can identify appropriate candidates for these treatments by analyzing sequencing data and medical images.

Colon Cancer

In colorectal cancer, biomarkers such as KRAS and BRAF are important for predicting responses to specific treatments. AI can uncover new biomarkers and aid in treatment decisions through the analysis of genomic and clinical data.

Ovarian Cancer

In ovarian cancer, biomarkers such as CA-125 and HE4 are used for diagnosis and monitoring. AI can identify new biomarkers by analyzing proteomic and genomic data, thereby improving early detection.

Liver Cancer

In liver cancer, biomarkers such as AFP are used for diagnosis and monitoring. AI algorithms can discover new biomarkers by analyzing

multimodal data, improving diagnostic accuracy.

Challenges of AI in Discovering Biomarkers

Data quality: Biological data may be incomplete or inconsistent, which can affect the accuracy of AI models.

Interpretability of models: Complex AI models may be difficult to interpret, limiting their adoption in clinical practice.

Ethical and privacy issues: The use of patient data requires strict adherence to ethical standards and privacy protection.

Conclusion

In recent years, the use of artificial intelligence in biomarker detection has emerged as a promising and innovative approach. As technology advances and access to high-quality biological data improves, AI is expected to play an increasingly important role in discovering new biomarkers and enhancing cancer diagnosis and treatment. Collaboration between data scientists, biologists, and clinicians is essential for developing interpretable, reliable, and clinically applicable models.

7. AI IN BIOMARKER DISCOVERY FOR ORAL DISEASES

Background

Oral diseases are among the most prevalent health conditions worldwide, ranging from dental caries and periodontal diseases to oral potentially malignant disorders and oral cancers. These conditions can significantly impair quality of life, affecting nutrition, speech, and overall well-being. Early detection and accurate diagnosis are essential for preventing disease progression, initiating timely treatment, and reducing the burden on healthcare systems. Biomarkers play a central role in this process by providing measurable indicators of physiological or pathological processes and responses to therapeutic interventions. In the context of oral diseases, biomarkers can include genetic alterations, protein expression levels, metabolites, microbiome shifts, and imaging features derived from advanced oral imaging modalities. Traditional methods for biomarker discovery, while valuable, are often limited by their inability to efficiently integrate the diverse and complex data generated in oral health research. Artificial intelligence offers a transformative approach, capable of processing large-scale, heterogeneous

datasets, detecting patterns invisible to the human eye, and identifying robust biomarker candidates that can revolutionize prevention, diagnosis, and personalized treatment strategies.

The Role of Biomarkers in Oral Disease Management

In oral medicine, biomarkers are critical for a wide range of applications, including disease screening, risk assessment, prognosis, and therapeutic monitoring. Salivary biomarkers, for instance, have gained considerable attention due to the non-invasive nature of saliva collection and its richness in diagnostic information, including DNA, RNA, proteins, metabolites, and microbiota. For example, elevated levels of interleukin-6 and matrix metalloproteinases in saliva have been linked to periodontal inflammation, while specific RNA signatures can serve as indicators of oral squamous cell carcinoma. Imaging biomarkers, derived from techniques such as optical coherence tomography, fluorescence imaging, and cone-beam computed tomography, provide structural and functional information about oral tissues. However, single biomarkers often lack sufficient sensitivity and specificity, making them less reliable when used alone. Combining multiple biomarkers from different biological domains offers the potential for more accurate and comprehensive disease assessment, and artificial intelligence provides the analytical

power necessary to integrate and interpret such multifaceted data.

Artificial Intelligence in Biomedical Data Analysis

Artificial intelligence refers to computational systems designed to perform tasks requiring human-like reasoning, pattern recognition, and decision-making. Within biomarker discovery, AI excels at analyzing large and complex datasets, identifying subtle correlations, and generating predictive models that can guide clinical decisions. Machine learning, a major branch of AI, includes supervised learning for prediction tasks, unsupervised learning for pattern detection, and semi-supervised learning for situations where labeled data are limited. Deep learning, based on multi-layer neural networks, has achieved remarkable success in image analysis, natural language processing, and multi-omics data integration. These capabilities are particularly relevant to oral disease research, which often involves both visual diagnostic data from imaging modalities and molecular data from saliva, blood, or tissue samples. By leveraging these approaches, AI can discover novel biomarker signatures and enable more precise disease classification and prognosis.

Sources of Data for AI- driven Biomarker Discovery

in Oral Diseases

Robust AI models for biomarker discovery depend on high-quality, diverse, and well-curated datasets. In oral diseases, relevant data sources include electronic health records containing dental and medical histories, laboratory and pathology reports, genomic and transcriptomic profiles, proteomic and metabolomic data from saliva or gingival crevicular fluid, and high-resolution oral imaging data. Advanced diagnostic tools such as digital intraoral scanners, hyperspectral imaging, and optical coherence tomography generate large volumes of image-based information that can be analyzed for quantitative biomarkers. Public databases and collaborative research networks contribute additional datasets, though integration across sources can be challenging due to differences in data formats, measurement protocols, and patient demographics. Artificial intelligence methods such as feature normalization, dimensionality reduction, and transfer learning can help harmonize these diverse inputs, enabling multi-modal biomarker discovery that captures the complexity of oral pathophysiology.

Machine Learning Approaches for Biomarker Identification in Oral Diseases

Machine learning offers a rich toolkit for biomarker discovery in oral diseases. Supervised

learning algorithms, including support vector machines, decision trees, random forests, and gradient boosting methods, can classify patients based on disease presence or severity using known biomarker profiles. Unsupervised learning approaches such as clustering, principal component analysis, and manifold learning can reveal hidden structures in the data, identifying patient subgroups that may share common biomarker signatures. Semi-supervised learning is particularly valuable in dental and oral research, where obtaining large labeled datasets can be resource-intensive. By combining labeled and unlabeled data, these models can improve predictive accuracy and generalizability. The selection of an appropriate algorithm depends on factors such as data type, feature dimensionality, sample size, and the balance between interpretability and predictive performance.

Deep Learning in Multi-omics Integration for Oral Health

Deep learning has become a powerful approach for integrating multi-omics datasets, which is essential for understanding the multifactorial nature of oral diseases. Convolutional neural networks are highly effective for processing image-based data from oral imaging techniques, detecting fine-grained patterns that correlate with disease states. Fully connected neural networks can handle genomic, transcriptomic,

and proteomic data, while autoencoders can reduce dimensionality and uncover latent features relevant to disease. In oral oncology, deep learning models have been used to combine gene expression profiles with histopathological images to identify biomarkers predictive of tumor aggressiveness and treatment response. Similarly, in periodontal research, multi-omics integration involving microbiome, proteome, and metabolome data has led to the identification of composite biomarkers that better reflect disease activity than single-analyte markers. This integrated approach facilitates a holistic understanding of oral diseases and supports the development of precision diagnostic tools.

AI in Imaging Biomarker Discovery for Oral Diseases

Imaging is a cornerstone of oral disease diagnosis and management, providing essential insights into tissue structure, pathology extent, and treatment response. AI has greatly enhanced the extraction of imaging biomarkers from modalities such as cone-beam computed tomography, optical coherence tomography, and intraoral photography. Through the use of convolutional neural networks, AI can detect minute changes in texture, color, and morphology that may indicate early disease, often before they are visible to the naked eye. Radiomic analysis quantifies features such as shape, intensity, and texture

from medical images, and when combined with machine learning, these features can serve as powerful biomarkers for disease classification and prognosis. In oral cancer detection, AI-enhanced analysis of hyperspectral imaging has shown promise in differentiating malignant from benign lesions with high accuracy, supporting early diagnosis and better treatment outcomes.

The Role of the Oral Microbiome in AI-based Biomarker Discovery

The oral microbiome plays a crucial role in oral and systemic health, influencing immune responses, inflammation, and even cancer development. Dysbiosis, or microbial imbalance, has been linked to conditions such as periodontitis, dental caries, and oral squamous cell carcinoma. High-throughput sequencing technologies enable comprehensive profiling of the oral microbiota, generating complex datasets that require advanced computational analysis. Machine learning and network analysis can identify microbial taxa or community patterns that serve as biomarkers for disease risk, progression, or therapeutic response. Furthermore, integrating microbiome profiles with host genomic, proteomic, and metabolomic data can yield multi-layer biomarker signatures with improved predictive value. AI-driven oral microbiome analysis not only enhances diagnostic accuracy but also opens the door to microbiome-

targeted interventions for disease prevention and management.

Challenges in AI-based Biomarker Discovery for Oral Diseases

Despite its promise, AI-based biomarker discovery in oral diseases faces several challenges. Data scarcity is a significant limitation, particularly for rare oral conditions and in underrepresented populations. Variability in sample collection methods, imaging equipment, and sequencing platforms can introduce biases that hinder model performance and reproducibility. Overfitting is a common risk in deep learning models trained on small datasets, potentially leading to poor generalization in real-world clinical settings. Additionally, the black-box nature of some AI models raises concerns about interpretability, which is critical for clinician trust and regulatory approval. Addressing these challenges will require larger, more diverse datasets, standardized data collection protocols, explainable AI techniques, and rigorous external validation of biomarker models before they can be integrated into routine practice.

AI for Longitudinal Biomarker Tracking in Oral Diseases

Longitudinal biomarker tracking provides essential information about how oral diseases evolve over time and how they respond

to treatment. Many oral conditions, such as periodontitis, oral potentially malignant disorders, and oral squamous cell carcinoma, have chronic or progressive courses that require continuous monitoring. Artificial intelligence can analyze sequential data from repeated saliva tests, imaging scans, microbiome sequencing, and clinical evaluations to detect subtle trends that may signal disease recurrence, progression, or remission. Time-series models like recurrent neural networks and temporal convolutional networks are capable of identifying temporal dependencies and patterns in biomarker data. By incorporating real-time data from point-of-care devices or wearable oral health sensors, AI systems can generate alerts for early intervention, potentially preventing irreversible tissue damage. This approach enables proactive and personalized care, allowing clinicians to adjust treatments based on the evolving biomarker profile of each patient.

Personalized Medicine Enabled by AI-derived Biomarkers

One of the most powerful outcomes of AI-based biomarker discovery in oral diseases is the facilitation of personalized medicine. By integrating data from genetic, proteomic, metabolomic, and microbiome analyses, along with imaging and clinical history, AI can generate comprehensive patient profiles that

guide individualized treatment plans. In oral oncology, such profiles can help determine which patients are more likely to respond to specific chemotherapeutic agents, targeted therapies, or immunotherapies. In periodontal therapy, AI can predict which individuals will respond best to scaling and root planing, adjunctive antimicrobial therapy, or surgical intervention based on their biomarker patterns. Personalized approaches extend beyond treatment selection to include prevention, where biomarker-driven risk assessment can inform targeted oral hygiene regimens, dietary recommendations, and lifestyle modifications aimed at reducing disease risk.

Case Studies of AI in Oral Biomarker Research

Several studies highlight the potential of AI in transforming biomarker discovery for oral diseases. In oral squamous cell carcinoma, deep learning models have been applied to histopathological images to identify morphological features correlated with specific genetic mutations and prognostic outcomes, offering non-invasive surrogates for molecular testing. In periodontitis research, machine learning algorithms integrating salivary proteomic and microbiome data have identified composite biomarkers that outperform conventional clinical indices in predicting disease severity and progression. Another study

combined optical coherence tomography imaging with AI-based feature extraction to identify structural biomarkers indicative of early caries development, enabling preventive intervention before cavitation occurs. These examples illustrate how AI can bridge molecular, imaging, and clinical data to generate biomarkers with direct clinical relevance.

Integrating AI-derived Biomarkers into Clinical Workflows

The integration of AI-derived biomarkers into clinical workflows is essential for their adoption in everyday practice. This process begins with rigorous validation of biomarkers in diverse patient populations to ensure generalizability and reliability. Once validated, these biomarkers can be incorporated into diagnostic platforms or decision support systems embedded within electronic health records. Such integration allows clinicians to access biomarker results and AI-driven interpretations during routine consultations, supporting informed decision-making. The success of this integration depends on the development of user-friendly interfaces that present complex biomarker information in a clear and interpretable manner. Training programs for dental and medical professionals are also necessary to ensure they understand how to use AI-generated insights effectively and responsibly in patient care.

The Role of Explainable AI in Oral Biomarker Discovery

Explainability is a critical factor for the clinical acceptance of AI-derived biomarkers. Clinicians must understand how an AI model arrives at its conclusions to trust and act upon its recommendations. Explainable AI techniques, such as SHAP values, feature importance rankings, and heatmap visualizations, can reveal which features in a dataset—whether specific molecular markers, microbial taxa, or imaging patterns—contributed most to a model's prediction. In practice, this might involve highlighting regions of an oral lesion image that correspond to features linked with malignancy or pinpointing the salivary proteins that drive a risk score for periodontal disease. By making AI models transparent and interpretable, explainable AI not only builds trust among clinicians but also provides valuable insights for researchers aiming to understand the biological underpinnings of discovered biomarkers.

Ethical and Regulatory Considerations in AI-based Oral Biomarker Research

The application of AI to biomarker discovery in oral diseases raises important ethical and regulatory questions. Patient privacy is paramount, particularly when handling

sensitive genomic, proteomic, and imaging data. Compliance with relevant data protection laws, such as the General Data Protection Regulation and the Health Insurance Portability and Accountability Act, is essential. Another concern is the potential for bias in AI models, which can arise from training on datasets that are not representative of the broader patient population. This could result in biomarkers that are less accurate or relevant for certain demographic groups, exacerbating healthcare disparities. Regulatory agencies require that AI-derived biomarkers undergo thorough validation to demonstrate accuracy, reproducibility, and clinical utility before they can be approved for clinical use. Developers must also ensure that these tools are accompanied by clear documentation of their design, training data, and intended use.

Collaborative Research Models for AI in Oral Biomarker Discovery

Advances in AI-based biomarker discovery for oral diseases are greatly facilitated by collaborative research efforts. Multi-institutional partnerships and data-sharing networks can provide the large, diverse datasets needed to train robust AI models. Federated learning is an emerging approach that enables the training of AI algorithms on distributed datasets without the need to transfer sensitive patient data, preserving privacy while

enhancing model performance. Collaborative projects also promote the standardization of data collection and annotation protocols, which is crucial for reducing variability and bias in biomarker studies. Partnerships between academia, industry, and healthcare organizations can accelerate the translation of AI-derived biomarkers into clinically validated diagnostic tests and decision support tools.

Future Directions for AI in Oral Biomarker Discovery

The future of AI in oral biomarker discovery is poised to be shaped by several emerging trends. Advances in single-cell sequencing and spatial transcriptomics will enable the identification of biomarkers at an unprecedented level of resolution, capturing cellular heterogeneity within oral lesions. Multi-omics integration will expand to include epigenomic and metabolomic layers, providing a more complete understanding of disease mechanisms. Real-time monitoring through wearable and at-home oral health devices will generate continuous biomarker data, allowing for dynamic risk assessment and adaptive treatment strategies. Generative AI models may contribute to data augmentation, addressing the limitations of small datasets, though careful validation will be required to ensure reliability. As these technologies evolve, interdisciplinary training programs that combine expertise in

oral biology, computational science, and clinical dentistry will be essential for driving innovation and translating discoveries into improved patient care.

Conclusion

Artificial intelligence is redefining the landscape of biomarker discovery for oral diseases by enabling the integration of diverse data types, uncovering complex patterns, and generating clinically actionable insights. From early detection to personalized therapy and longitudinal monitoring, AI-derived biomarkers have the potential to improve diagnostic accuracy, guide targeted interventions, and enhance patient outcomes. While challenges remain in terms of data quality, interpretability, and regulatory compliance, ongoing advancements in computational methods, collaborative research models, and explainable AI are steadily overcoming these barriers. The ultimate goal is to incorporate AI-based biomarker tools seamlessly into clinical workflows, transforming oral healthcare from a reactive to a proactive discipline. As the field progresses, AI will continue to open new avenues for precision dentistry and oral medicine, benefiting patients worldwide through earlier detection, more effective treatment, and improved long-term oral health.

8. AI IN BIOMARKER DISCOVERY FOR INFECTIOUS DISEASES

Background

Infectious diseases remain one of the most significant threats to global health, causing substantial morbidity and mortality despite advances in preventive measures, diagnostics, and therapeutics. They encompass a wide range of conditions caused by bacteria, viruses, fungi, and parasites, affecting populations across all geographic and socioeconomic boundaries. Rapid and accurate detection of infectious agents, along with the ability to monitor disease progression and treatment response, is essential for effective patient management and for controlling outbreaks. Biomarkers serve as measurable indicators of pathogenic presence, host response, or treatment efficacy, providing vital information for diagnosis, prognosis, and therapeutic monitoring. These biomarkers can be molecular, such as nucleic acids and proteins, or physiological, such as changes in immune cell counts or inflammatory markers. However, traditional biomarker discovery methods are often limited by the complexity and diversity of host-pathogen interactions and the need to integrate data from multiple

biological domains. Artificial intelligence offers a transformative approach, capable of processing vast, heterogeneous datasets, uncovering hidden patterns, and identifying robust biomarker candidates that can significantly enhance the management of infectious diseases.

The Role of Biomarkers in Infectious Disease Management

Biomarkers are integral to every stage of infectious disease management, from early detection and pathogen identification to monitoring disease progression and evaluating treatment efficacy. For example, procalcitonin levels are widely used to distinguish bacterial infections from viral ones, while HIV viral load and CD4 cell counts serve as critical biomarkers for monitoring disease stage and treatment success in HIV/AIDS. In tuberculosis, molecular biomarkers such as *Mycobacterium tuberculosis* DNA sequences can confirm diagnosis, while interferon-gamma release assays measure host immune response. However, single biomarkers often lack sufficient sensitivity or specificity, especially in diseases with variable presentations or in cases of co-infection. Combining multiple biomarkers into predictive models can improve diagnostic accuracy and enable earlier intervention. Artificial intelligence is uniquely positioned to facilitate this process by integrating diverse biomarker data, including genomic, transcriptomic, proteomic,

metabolomic, microbiome, and imaging information, into comprehensive and clinically useful signatures.

Artificial Intelligence in Biomedical Data Analysis

Artificial intelligence encompasses computational methods designed to replicate aspects of human cognition, such as learning, reasoning, and decision-making. In the context of biomarker discovery, AI excels at processing large and complex datasets, identifying subtle patterns, and building predictive models that outperform traditional statistical approaches. Machine learning, a core branch of AI, includes supervised methods for predicting specific outcomes, unsupervised techniques for uncovering hidden patterns, and semi-supervised approaches for scenarios with limited labeled data. Deep learning, a subset of machine learning based on neural networks with multiple layers, has demonstrated exceptional performance in fields such as image recognition, natural language processing, and multi-omics data integration. In infectious disease research, AI can link pathogen-specific molecular patterns with host immune responses, revealing biomarkers that improve diagnosis, predict severity, and guide targeted therapy.

Sources of Data for AI- driven Biomarker Discovery

in Infectious Diseases

High-quality and diverse datasets are the foundation for AI-based biomarker discovery. In infectious diseases, these datasets can include electronic health records containing clinical signs, symptoms, and laboratory results; genomic and transcriptomic sequences from pathogens and hosts; proteomic and metabolomic profiles from blood or other body fluids; and imaging data from modalities such as chest radiography, computed tomography, or ultrasound. Large-scale surveillance databases, clinical trial datasets, and public repositories such as the Gene Expression Omnibus or the Pathosystems Resource Integration Center provide additional resources. Microbiome sequencing data can also offer valuable insights, as shifts in microbial communities can signal infection or dysbiosis. Integrating these diverse data types presents challenges related to differences in scale, format, and completeness. Artificial intelligence methods, including feature extraction, dimensionality reduction, and data harmonization, are essential for managing these complexities and generating meaningful biomarker candidates.

Machine Learning Approaches for Biomarker Identification in Infectious Diseases

Machine learning provides a flexible and powerful set of tools for identifying biomarkers

in infectious diseases. Supervised learning algorithms, such as support vector machines, random forests, gradient boosting frameworks, and logistic regression, can be trained on labeled datasets to classify patients by infection type, predict disease severity, or forecast treatment outcomes. Unsupervised learning techniques, including clustering and principal component analysis, can reveal hidden structures in the data, identifying subgroups of patients who share common biomarker profiles. Semi-supervised learning is particularly valuable in infectious disease research, where obtaining large labeled datasets can be costly and time-consuming. These methods can leverage both labeled and unlabeled data to improve model performance and robustness. Selecting the most appropriate algorithm depends on factors such as the nature of the data, the desired balance between interpretability and predictive accuracy, and the computational resources available.

Deep Learning in Multi-omics Integration for Infectious Diseases

Deep learning has emerged as a powerful approach for integrating multi-omics data, which is essential for understanding the complex interactions between pathogens and their hosts. Convolutional neural networks are highly effective for analyzing image-based data, such as radiological scans or microscopic images of

infected tissues, while recurrent neural networks can handle time-series data from longitudinal studies. Fully connected neural networks can process genomic, transcriptomic, proteomic, and metabolomic data, uncovering patterns that may not be apparent through conventional analysis. Autoencoders and variational autoencoders can reduce dimensionality and highlight latent features that capture the essence of disease processes. In infectious disease research, multi-omics integration allows the combination of pathogen genome data with host immune profiles, enabling the identification of biomarkers that not only indicate infection but also predict disease severity and treatment response.

AI in Imaging Biomarker Discovery for Infectious Diseases

Imaging plays a critical role in diagnosing and monitoring many infectious diseases. In tuberculosis, chest radiographs and CT scans reveal lung abnormalities, while in parasitic infections, ultrasound can detect organ damage. AI has transformed imaging analysis by enabling the extraction of quantitative features, known as radiomics, which can serve as imaging biomarkers. Convolutional neural networks can identify subtle changes in texture, shape, or intensity that may escape human observation, providing early indicators of infection or treatment response. For example, AI models

trained on chest CT scans have been used to differentiate COVID-19 pneumonia from other causes of lung inflammation with high accuracy. Integrating imaging biomarkers with molecular and clinical data further enhances diagnostic precision and helps guide treatment decisions.

The Role of the Microbiome in AI-based Biomarker Discovery for Infectious Diseases

The human microbiome plays a significant role in susceptibility to infection, disease progression, and treatment outcomes. Dysbiosis in the gut, respiratory tract, or other body sites can predispose individuals to opportunistic infections or influence the severity of pathogen-induced disease. High-throughput sequencing technologies can generate comprehensive profiles of microbial communities, producing datasets that require advanced analytical techniques. AI can process these complex datasets to identify microbial taxa, community structures, or functional pathways that serve as biomarkers for infection risk or disease state. Combining microbiome data with host genomic and immune profiles can yield integrated biomarkers that provide a more complete picture of the host-pathogen relationship. Such insights can inform targeted interventions, including microbiome modulation through probiotics, diet, or antimicrobial stewardship.

Challenges in AI-based Biomarker Discovery for Infectious Diseases

While AI offers immense promise for biomarker discovery in infectious diseases, several challenges must be addressed. Data scarcity is a persistent issue, particularly for rare infections or emerging pathogens. The quality and consistency of data can vary widely, with differences in collection methods, sequencing platforms, or imaging protocols introducing biases. Overfitting is a risk in deep learning models trained on small or unbalanced datasets, potentially limiting their applicability to new populations. Interpretability is another challenge, as clinicians require clear explanations for how AI models arrive at their predictions to build trust and meet regulatory requirements. Addressing these challenges will require collaborative data-sharing initiatives, standardized data collection procedures, explainable AI methods, and rigorous validation of models across diverse populations and settings.

AI for Longitudinal Biomarker Tracking in Infectious Diseases

Longitudinal biomarker tracking is a powerful approach to understanding how infectious diseases evolve over time and how patients respond to treatment. Many infections, such as tuberculosis, hepatitis, and HIV, require months

or years of follow-up to assess treatment efficacy and detect relapse. Artificial intelligence can analyze sequential biomarker data from molecular tests, imaging studies, and clinical records to identify patterns that may not be apparent to human observers. Time-series analysis methods, including recurrent neural networks and temporal convolutional networks, can detect early warning signs of treatment failure or disease reactivation. For example, in HIV management, AI could track subtle fluctuations in viral load and immune cell counts to predict the risk of virologic rebound before it becomes clinically evident. By integrating wearable health monitoring devices and point-of-care diagnostic tools, AI-based systems can facilitate near real-time longitudinal tracking, enabling proactive interventions and improving patient outcomes.

Personalized Medicine Enabled by AI-derived Biomarkers

One of the most transformative applications of AI in infectious disease biomarker research is the advancement of personalized medicine. By integrating genomic, transcriptomic, proteomic, metabolomic, and microbiome data with clinical variables, AI can create individualized patient profiles that predict disease severity, treatment response, and potential adverse effects. In bacterial infections, such as sepsis, AI-derived biomarker panels could help determine which

patients are likely to benefit from specific antibiotic regimens, minimizing unnecessary exposure and reducing antimicrobial resistance. In viral infections, such as hepatitis C, AI could predict which patients will achieve sustained virologic response to particular antiviral therapies, guiding treatment selection. Personalized biomarker-based approaches also have implications for vaccination strategies, where AI could identify subpopulations that may require modified dosing or adjuvant formulations for optimal immune protection.

Case Studies of AI in Infectious Disease Biomarker Research

Several case studies illustrate the practical potential of AI in infectious disease biomarker discovery. In tuberculosis research, machine learning models combining gene expression profiles from host blood samples with clinical data have identified transcriptional signatures capable of predicting progression from latent to active disease. In COVID-19, deep learning applied to chest CT scans and laboratory parameters identified composite biomarkers that stratified patients by risk of severe disease and predicted the need for intensive care. Another example comes from malaria, where AI-based analysis of proteomic and metabolomic data from blood samples uncovered biomarkers that differentiated between severe and uncomplicated

cases, providing a foundation for early triage in resource-limited settings. These examples highlight how AI can integrate diverse datasets to generate actionable biomarkers that improve clinical decision-making.

Integrating AI-derived Biomarkers into Clinical Workflows

The translation of AI-derived biomarkers into routine clinical workflows requires careful consideration of both technical and practical factors. Biomarkers must be validated in independent and diverse patient populations to ensure generalizability. Once validated, they can be embedded into diagnostic platforms or decision support systems within electronic health record environments. These systems can deliver real-time biomarker-based recommendations during patient encounters, assisting clinicians in diagnosis, prognosis, and treatment planning. Effective integration also depends on user-friendly interfaces that present biomarker information clearly, along with training programs to ensure clinicians understand how to interpret and apply AI-generated outputs. Close collaboration between healthcare providers, data scientists, and software developers is essential to ensure these tools fit seamlessly into clinical practice without disrupting workflow.

The Role of Explainable

AI in Infectious Disease Biomarker Discovery

Explainability is crucial for the adoption of AI-based biomarker tools in infectious disease management. Clinicians and regulatory agencies need to understand the reasoning behind AI predictions, particularly when these influence high-stakes treatment decisions. Explainable AI techniques, such as SHAP values, LIME, and attention heatmaps, can reveal which biomarkers or features contributed most to a prediction. For example, in a model predicting sepsis mortality risk, explainable AI could identify the relative importance of specific cytokine levels, microbial DNA sequences, or imaging findings. This transparency fosters clinician trust, facilitates regulatory approval, and enables researchers to validate and refine biomarker models based on biological plausibility.

Ethical and Regulatory Considerations in AI-based Biomarker Research

AI applications in biomarker discovery raise significant ethical and regulatory considerations. Data privacy is paramount, especially when integrating sensitive genomic and clinical information from diverse sources. Compliance with regulations such as the General Data Protection Regulation and the Health Insurance Portability and Accountability Act is mandatory.

Algorithmic bias is another concern, as models trained on unrepresentative datasets may yield less accurate predictions for certain demographic groups, potentially exacerbating health disparities. Regulatory agencies require thorough validation, reproducibility, and clinical utility before AI-based biomarker tools can be approved for widespread use. Ethical frameworks also demand transparency in data usage and informed consent processes, ensuring patients understand how their data will contribute to AI-driven research and applications.

Collaborative Research Models for AI in Infectious Disease Biomarker Discovery

Collaboration is essential for advancing AI-based biomarker discovery in infectious diseases. Multi-institutional partnerships and global data-sharing initiatives can provide the large, diverse datasets needed to train and validate robust models. Federated learning offers a promising approach, enabling algorithms to learn from distributed data without transferring sensitive patient information. Collaborative efforts can also establish standardized protocols for data collection, processing, and annotation, reducing variability and bias in biomarker studies. Partnerships between academic institutions, industry, public health agencies, and non-governmental organizations can accelerate the

translation of AI-derived biomarkers into practical diagnostic tools, ensuring they address real-world healthcare needs.

Future Directions for AI in Infectious Disease Biomarker Discovery

The future of AI in infectious disease biomarker research will be shaped by several key trends. Advances in single-cell sequencing and spatial transcriptomics will provide unprecedented detail on host-pathogen interactions at the cellular level, enabling the discovery of highly specific biomarkers. Multi-omics integration will expand to include epigenomic and lipidomic data, offering a more comprehensive view of disease processes. Real-time data from wearable biosensors and portable diagnostic devices will enable continuous biomarker monitoring, supporting adaptive treatment strategies and outbreak surveillance. Generative AI models may help overcome data scarcity by producing synthetic datasets for model training, though rigorous validation will be essential to ensure their reliability. As these innovations emerge, interdisciplinary education will be critical to train researchers and clinicians capable of bridging computational methods with infectious disease biology.

Conclusion

Artificial intelligence is transforming biomarker

discovery for infectious diseases by integrating complex, multi-modal datasets to uncover clinically relevant indicators of disease presence, progression, and treatment response. From improving diagnostic accuracy to enabling personalized medicine and real-time monitoring, AI-derived biomarkers have the potential to revolutionize patient care and public health interventions. Despite challenges related to data quality, interpretability, and regulatory compliance, ongoing advances in computational techniques, collaborative research frameworks, and explainability tools are steadily overcoming these barriers. The ultimate goal is to integrate AI-derived biomarker tools seamlessly into clinical and public health workflows, enabling earlier detection, targeted therapy, and improved patient outcomes. As the field evolves, AI is poised to play an increasingly central role in the fight against infectious diseases, contributing to more precise, proactive, and effective healthcare strategies worldwide.

9. AI IN BIOMARKER DISCOVERY FOR RHEUMATOLOGICAL DISEASES

Background

Rheumatological diseases are complex, multifactorial conditions that involve chronic inflammation, autoimmunity, and progressive joint or tissue damage. Accurate diagnosis, together with reliable prognostic assessment, is essential for guiding effective treatment strategies and improving long-term outcomes in patients with rheumatic diseases. Biomarkers serve as measurable indicators of physiological and pathological processes and are essential tools in both clinical practice and research.

In rheumatology, biomarkers are typically derived from blood, synovial fluid, or tissue samples and include a variety of proteins, antibodies, genetic markers, and inflammatory mediators. These biomarkers assist in diagnosing specific diseases, predicting disease activity, assessing prognosis, and monitoring therapeutic responses.

Imaging in rheumatology, particularly synovial fluid and tissue imaging, serves as a crucial complement to biomarker analysis in diagnosing and predicting rheumatic diseases. While biomarkers provide valuable biochemical

insights into inflammatory activity, autoantibody presence, and disease progression, imaging offers a direct visual assessment of joint structures and pathological changes. Techniques such as ultrasound and magnetic resonance imaging (MRI) enable the detection of synovial hypertrophy, effusion, and early erosive changes that might not yet be reflected in serum markers. By integrating imaging with biomarker data, clinicians can gain a more comprehensive understanding of disease activity and structural damage, enabling earlier diagnosis, risk classification, and more targeted medical decisions.

Imaging in Rheumatology: Synovial Fluid and Tissue

Advanced imaging modalities significantly enhance the early detection and monitoring of rheumatologic diseases. Imaging enables the visualization of synovial inflammation, joint effusion, erosions, and bone marrow edema, often before clinical symptoms become pronounced.

Ultrasound, particularly power Doppler ultrasound (PDUS), is used to detect synovial hypertrophy and increased vascularity indicative of active inflammation. It is valuable in identifying subclinical synovitis, thereby facilitating early diagnosis and intervention.

MRI provides superior soft tissue contrast and allows visualization of bone marrow edema,

early erosions, and cartilage loss. These features are highly predictive of disease progression, especially in early rheumatoid arthritis (RA) and spondyloarthropathies. MRI also assists in differentiating inflammatory from non-inflammatory joint conditions.

Detecting early biomarkers such as synovial hypertrophy, effusion, and erosive changes is challenging due to their subtle and often nonspecific presentation. These signs may be missed on physical examination or standard imaging, and their variability among patients further complicates diagnosis. This underscores the need for sensitive imaging techniques and combined diagnostic approaches to improve early detection.

Role of AI in Imaging-Based Diagnosis and Prognosis

Artificial intelligence (AI), particularly through image processing and machine learning techniques, holds transformative potential in rheumatology. AI can analyze vast amounts of imaging data, identify subtle patterns, and provide objective, reproducible assessments that may be challenging for human observers.

Deep learning, especially convolutional neural networks (CNNs), has demonstrated remarkable capabilities in interpreting imaging modalities such as MRI, ultrasound, and X-rays. AI algorithms can automate the detection of synovitis, bone

erosions, joint effusions, and other pathological features with high sensitivity and specificity.

Segmentation models such as U-Net are employed to localize and quantify regions of interest, including inflamed synovium or Doppler signal regions in ultrasound. Radiomics, a subfield of AI, extracts quantitative imaging features that can serve as advanced imaging biomarkers. These features can be correlated with clinical and serological data to enhance disease characterization.

Multimodal AI models combine imaging data with clinical and laboratory parameters, improving the accuracy of differential diagnosis. For example, combining MRI features with anti-CCP and CRP levels in early arthritis patients can improve the prediction of progression to RA.

Predictive analytics using AI can stratify patients based on their risk of disease progression, flare, or response to therapy. AI models can forecast radiographic progression and identify patients who would benefit from early aggressive treatment. This is particularly important in conditions such as RA, where early intervention significantly alters the disease trajectory.

A comprehensive review noted that most research in RA imaging has focused on hand and wrist X-rays, ultrasound, and MRI, employing architectures such as VGG, ResNet, DenseNet, U-Net, and Vision Transformers (ViTs) for classification, segmentation, and damage

quantification. For instance, CNN-based systems have been developed to automatically score joint damage in RA X-rays using the modified Total Sharp Score (mTSS), achieving high localization accuracy exceeding 99 percent and classification performance of approximately 88 percent through multi-stage pipelines enhanced with attention layers.

Segmentation tasks in MRI and ultrasound, such as delineating inflamed synovium, effusion, or cartilage, often rely on U-Net and its variants. U-Net is widely recognized for its ability to segment medical images accurately with limited data, and architectures like U-Net++ have been successfully applied to wrist radiographs to detect synovitis with high Dice coefficients. A recent study introduced RA-XTNet, which combines U-Net++ segmentation with CNN, transformer (ViT), and quantum support vector machine (QSVM) classifiers to diagnose RA from hand X-rays and thermal images. This system achieved approximately 90 percent accuracy for X-rays and around 93 percent for thermal imaging, with ViT reaching approximately 80–90 percent, demonstrating the potential of hybrid architectures.

Vision Transformers are also gaining ground, particularly in non-traditional imaging. A ViT model analyzing nailfold capillaroscopy images, used for detecting microangiopathic changes in systemic sclerosis, achieved AUC values between

81.8 percent and 84.5 percent, rivaling human performance and assisting rheumatologists in screening. Similar transformer-based methods have been recognized for improving consistency and reducing bias in the assessment of capillaroscopy changes.

Despite these advances, challenges persist. Many models are trained on relatively small datasets, which can affect generalizability, and fewer than 15 percent implement explainability frameworks, which is a limitation for clinical integration. To address these issues, researchers are increasingly integrating radiomics with deep learning, using multimodal datasets and incorporating explainable AI methods to enhance trust, transparency, and performance in clinical practice.

Tools and Techniques

Several open-source frameworks and libraries provide essential foundations for deep learning in medical imaging. TensorFlow and PyTorch remain the leading deep learning libraries, offering comprehensive tools for model building, training, and deployment. To address the unique requirements of medical image analysis, such as multi-dimensional images, spatial metadata, and reproducible preprocessing, specialized toolkits have been developed. MONAI (Medical Open Network for AI) is a PyTorch-based framework created collaboratively by NVIDIA, King's College

London, and the National Institutes of Health. It offers domain-optimized building blocks, including data loaders, augmentation pipelines, sliding-window inference, medical-specific loss functions, and standard model architectures tailored for imaging tasks in healthcare.

Similarly, SimpleITK, an accessible interface to the Insight Toolkit, supports robust image preprocessing, registration, and filtering, enabling reproducible medical image workflows across programming languages such as Python and R.

For radiomics, which involves the extraction of quantitative imaging features, PyRadiomics is widely used to compute hundreds of engineered features, including texture, shape, and intensity, from imaging data. These features can then be incorporated into machine learning pipelines. High-dimensional radiomics features often complement deep learning models or serve as standalone predictors in classification or prognostic tasks.

Regarding network architectures, U-Net and its variants, such as U-Net++, are considered gold standards for segmentation in MRI, ultrasound, and other modalities. Their encoder-decoder design enables precise delineation of anatomical structures like synovium, cartilage, and inflammatory regions. These models are frequently integrated into hybrid systems that combine feature extraction, deep learning, and post-processing.

Off-the-shelf convolutional neural networks, including ResNet, DenseNet, EfficientNet, and YOLOv7, can be fine-tuned on rheumatology imaging datasets such as X-rays of hands or wrists. These pretrained models excel at classification tasks like detecting erosions or grading joint space narrowing, and they often incorporate attention mechanisms or function as components in multi-stage pipelines.

Beyond segmentation and classification, advanced model variants such as Squeeze-and-Excitation CNNs, hybrids combining CNNs with Vision Transformers or quantum support vector machines (QSVM), and transformer-based frameworks are gaining prominence. For example, RA-XTNet integrates U-Net++ segmentation with CNN, Vision Transformer, and QSVM classifiers to diagnose rheumatoid arthritis using X-ray and thermal images, achieving accuracy rates of 90 to 93 percent.

Verification and Validation

Verification of AI models in rheumatology requires rigorous validation protocols to ensure reliable performance across diverse patient populations and imaging conditions. This process begins with the use of external test datasets obtained from different institutions or demographics and the implementation of cross-validation techniques such as k-fold or nested cross-validation to prevent overfitting

and provide robust estimates of generalizability. Models are assessed using a comprehensive array of performance metrics, including accuracy, sensitivity, specificity, precision, recall, and the area under the receiver operating characteristic curve (AUC-ROC). These measures help ensure that the true positive and false positive rates are adequately balanced for clinical utility.

However, statistical validation alone is not sufficient; clinical validation is equally critical. AI-generated predictions must be compared with expert consensus among trained rheumatologists and radiologists and, where possible, correlated with real-world outcomes such as disease progression or treatment response. To encourage adoption, transparent reporting standards are vital. Guidelines such as TRIPOD-AI (Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis-AI) and CONSORT-AI (Consolidated Standards of Reporting Trials-AI) require detailed documentation of data sources, model architecture, versioning, input-output handling, and human-AI interaction. Adhering to these protocols enhances reproducibility, reduces bias, and is essential for the responsible translation of AI models into clinical rheumatology practice.

Conclusion

The integration of biomarkers, imaging, and artificial intelligence is transforming

rheumatologic diagnosis and prognosis. Biomarkers derived from blood, synovial fluid, and tissue provide critical insights into disease mechanisms, while imaging modalities such as ultrasound and MRI allow early visualization of pathological changes including synovitis and bone erosion. Together, these tools support more accurate and timely clinical decision-making.

Artificial intelligence advances this integration by enabling automated, objective analysis of medical images. Deep learning models such as convolutional neural networks, U-Net, and Vision Transformers have demonstrated strong performance in detecting and quantifying disease features. Radiomics further enhances this approach by extracting quantitative imaging biomarkers that complement clinical and serological data.

For successful clinical adoption, AI models must undergo robust validation using external datasets and expert review, with transparent reporting guided by standards such as TRIPOD-AI and CONSORT-AI. When combined, these approaches offer a powerful, data-driven framework for improving outcomes in rheumatologic care.

10. AI IN BIOMARKER DISCOVERY FOR OTHER DISEASES

AI in Biomarker Discovery for Ophthalmology

Artificial intelligence (AI) integration is highly promising in ophthalmology, as the field relies heavily on imaging techniques and objective metrics. Combining imaging data with medical records through AI can enhance diagnostic accuracy, improve therapy monitoring, and optimize treatment outcomes for patients with ocular diseases. Ocular biomarkers are detectable in biosamples such as tears, blood, and eye tissues using invasive methods (such as testing ocular fluids and blood sampling) or non-invasive methods (such as optical coherence tomography (OCT) and fundus photography). Integrating ophthalmic biomarkers with AI provides valuable insights into physiologic and pathologic eye conditions, supports systemic risk assessment, and facilitates personalized treatment in both clinical and research settings.

Glaucoma

Glaucoma is a progressive optic neuropathy that can lead to irreversible vision loss. Screening, early detection of at-risk patients, appropriate

diagnostic workups, and timely treatment are essential to reduce morbidity and slow disease progression. AI has significant potential in glaucoma for classification, screening, diagnosis, prognosis, and treatment planning. Diagnosis and prognosis generally rely on clinical examination, visual field (VF) testing, intraocular pressure (IOP) measurement, optic disc photography, and OCT. Identifying glaucoma-relevant biomarkers to improve diagnosis and disease monitoring is an important goal.

AI has been applied to enhance visual field analysis. Andersson and colleagues compared a trained artificial neural network (ANN) with physicians for glaucoma diagnosis based on VF assessments. The ANN achieved 91% specificity and 93% sensitivity, performing at least as well as physicians. Wang and colleagues used an unsupervised AI method to quantify patterns of central VF loss in glaucoma patients. Shuldiner and collaborators evaluated machine learning algorithms (MLAs) to identify eyes at risk for rapid glaucoma progression using initial VF tests. Herbert and colleagues trained deep learning models (DLMs) with early clinical data, VF, and OCT to predict rapid glaucomatous VF deterioration. Wang, Bradley, and colleagues developed a DLM using initial clinical data, OCT, and VF, or even a second VF, to predict eyes with low VF variability, suggesting that DLMs could

simplify the design of glaucoma clinical trials.

OCT is a key tool in glaucoma management. OCT parameters such as retinal nerve fiber layer (RNFL) thickness, macular retinal nerve fiber layer (mRNFL), inner plexiform layer (IPL), disc size, cupping, ganglion cell layer (GCL), and ganglion cell complex (GCC) thickness are important in assessment. AI-driven image segmentation can estimate these parameters with high accuracy. Wu, Shen, Lu, and colleagues applied machine learning methods to build robust classifiers and assess OCT metrics in glaucoma of varying severities. Omodaka and collaborators developed a machine learning algorithm for open-angle glaucoma (OAG) patients, classifying swept-source OCT images into Nicolela's four optic disc types. Asaoka and colleagues created a deep learning model for glaucoma diagnosis using spectral-domain OCT images, improving diagnostic performance. Koornwinder, Zhang, and colleagues aimed to predict which glaucoma patients would require surgery within 12 months based on clinical exams, demographic data, and RNFL OCT scans, either individually or in combination. Fusion models outperformed single-data-type models. Riina and collaborators applied neural networks using VF, heart rate, IOP, blood pressure, and one of several listed biomarkers derived from OCT or OCTA, including RNFL thickness, GCC thickness, macular thickness, optic

nerve parameters, or choroidal thickness. Their results indicated that OCTA-derived vascular biomarkers of the optic nerve head are as effective as OCT-derived structural biomarkers for machine learning-based diagnosis of primary open-angle glaucoma (POAG).

In the domain of fundus photography, Cerentini and colleagues trained a neural network (GoogLeNet) to automate glaucoma classification from fundus photographs. Liu, Lee, Wormstone, and collaborators developed a deep learning system (DLS) using retinal fundus images to automatically classify glaucomatous optic neuropathy (GON), demonstrating high generalizability, specificity, and sensitivity. Li and colleagues created a DLS based on color fundus photographs for automated GON categorization, achieving high specificity and sensitivity for referable GON detection. Sidhu and Mansoori used a DLM based on Residual Network (ResNet) 50V2 to classify GON from color fundus images, showing good accuracy and potential for clinical application. Common false negatives included early glaucoma in a small disc, coexisting glaucoma in high myopia, and misclassification by software. False positives were often due to myopic or tilted discs, physiological large cupping in large discs, and software misinterpretation of normal optic discs. Chen and colleagues proposed a method combining fundus photographs

with enhanced depth imaging OCT (EDI-OCT) parameters to screen for glaucoma, achieving high sensitivity and accuracy.

AI in Biomarker Discovery for Obstetrics and Gynecology Diseases

Background

Biomarkers are essential in the diagnosis, prognosis, and management of obstetric and gynecological (OB/GYN) diseases. Despite decades of research, discovering reliable biomarkers remains challenging due to the complex nature of these conditions and the heterogeneity of patient populations. The emergence of artificial intelligence offers new opportunities to address these challenges by enabling the analysis of large, complex datasets to uncover novel biomarkers. This review explores the current role of artificial intelligence in biomarker discovery for OB/GYN diseases, outlines the methods employed, and discusses existing challenges and future directions.

The Role of Biomarkers in OB/GYN Diseases

OB/GYN diseases such as preeclampsia, endometriosis, polycystic ovary syndrome (PCOS), cervical cancer, and ovarian cancer have a profound impact on women's health worldwide. Early detection and effective treatment are critical

to improving patient outcomes. Biomarkers, defined as biological molecules that indicate physiological or pathological states, can serve as diagnostic, prognostic, and predictive tools. However, many candidate biomarkers identified using traditional methods have failed to translate into clinical practice due to limitations such as small sample sizes, lack of reproducibility, and limited generalizability.

AI as a Transformative Tool for Biomarker Discovery

Artificial intelligence, particularly machine learning and deep learning, has revolutionized biomarker discovery by offering powerful tools for processing high-dimensional data derived from genomics, transcriptomics, proteomics, metabolomics, and imaging studies. AI algorithms excel at detecting complex, nonlinear patterns that may not be apparent through traditional statistical approaches.

In preeclampsia, machine learning models have been applied to proteomic and metabolomic datasets to identify potential biomarkers such as soluble fms-like tyrosine kinase-1 (sFlt-1), placental growth factor (PlGF), and other angiogenic factors, improving early detection and risk stratification. In ovarian cancer, machine learning approaches analyzing gene expression datasets have identified biomarker panels with greater sensitivity and specificity than single-

biomarker methods.

Regression Models in AI- Driven Biomarker Research

Regression analysis remains fundamental in AI applications for biomarker discovery. Logistic regression is frequently used to assess associations between biomarker concentrations and disease status, as seen in studies on endometriosis. Advanced regression methods, including LASSO, Ridge regression, and Elastic Net, are often integrated within machine learning workflows for feature selection and dimensionality reduction. These approaches are particularly effective when handling large omics datasets with thousands of variables but limited sample sizes. LASSO regression, by shrinking irrelevant coefficients to zero, facilitates the identification of the most promising biomarkers while minimizing overfitting.

Deep Learning Applications

Deep learning techniques, such as convolutional neural networks and recurrent neural networks, are increasingly used in biomarker discovery, particularly when integrating imaging and sequential data. In OB/GYN, convolutional neural networks have been applied to ultrasound and MRI images for detecting placental abnormalities, fetal anomalies, and cervical insufficiency. When combined with molecular datasets, these models

can generate multimodal biomarkers that are more predictive than any single modality.

In cervical cancer research, deep learning models have been developed to analyze digital Pap smear images alongside HPV genotype data, enhancing risk assessment and enabling earlier detection.

Challenges and Limitations

While promising, AI-based biomarker discovery faces notable challenges. Data quality often varies between institutions, which can result in biased or non-generalizable models. The opaque nature of many AI algorithms raises concerns about interpretability, limiting clinical acceptance. Ethical considerations, including data privacy, algorithmic bias, and equitable access to AI technologies, also require attention.

Furthermore, many studies to date are retrospective, with limited prospective validation across diverse populations. Regulatory frameworks for AI-driven biomarker development are still evolving, presenting additional hurdles for clinical implementation.

Future Directions

Future research should prioritize the development of explainable AI methods to enhance model transparency and clinical trust. Federated learning could enable multicenter collaborations without the need to share sensitive patient data, thereby improving dataset diversity and

model robustness. Successful integration of AI into clinical workflows will require strong collaboration between data scientists, clinicians, and regulatory authorities.

Conclusion

Artificial intelligence has become a powerful tool in biomarker discovery for obstetric and gynecological diseases, capable of analyzing complex multi-omics and imaging data to identify novel and clinically relevant biomarkers. Although significant challenges remain, advancements in AI methodology, interpretability, and data integration hold the potential to greatly improve diagnosis, treatment, and outcomes for women worldwide.

AI in Biomarker Discovery for Autoimmune Diseases

Background

Autoimmune diseases represent a diverse group of chronic disorders in which the immune system mistakenly attacks the body's own cells and tissues. Conditions such as rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, type 1 diabetes, and inflammatory bowel disease are complex, multifactorial disorders with varied clinical presentations and unpredictable courses. Early diagnosis and accurate assessment of disease activity are critical for preventing

irreversible tissue damage and optimizing treatment strategies. Biomarkers are measurable indicators that can help detect disease, predict prognosis, and monitor treatment response. They can be derived from genetic, transcriptomic, proteomic, metabolomic, and immunologic data, as well as from imaging and physiological measurements. However, the identification of robust and clinically useful biomarkers in autoimmune diseases is particularly challenging due to their heterogeneity, overlapping symptoms, and fluctuating disease activity. Artificial intelligence offers a powerful solution to these challenges by enabling the integration and analysis of large, complex, and multi-modal datasets to uncover hidden patterns and identify biomarker signatures with high diagnostic and prognostic value.

The Role of Biomarkers in Autoimmune Disease Management

Biomarkers are essential tools for guiding the diagnosis, classification, and management of autoimmune diseases. For example, anti-citrullinated protein antibodies are widely used in the diagnosis of rheumatoid arthritis, while anti-double-stranded DNA antibodies and complement levels are key indicators in systemic lupus erythematosus. In multiple sclerosis, imaging biomarkers such as brain lesion load on MRI are critical for disease monitoring. However,

single biomarkers often lack the specificity or sensitivity required to capture the complexity of these disorders. Multi-marker panels that combine molecular, cellular, imaging, and clinical data can offer a more comprehensive assessment. Artificial intelligence is uniquely suited to handle this complexity, integrating diverse datasets to develop predictive models that improve early detection, stratify patients into disease subtypes, and monitor treatment efficacy over time.

Artificial Intelligence in Biomedical Data Analysis

Artificial intelligence encompasses computational techniques that mimic aspects of human reasoning, learning, and decision-making. In biomarker discovery, AI enables the detection of complex patterns in high-dimensional datasets that may be invisible to traditional statistical methods. Machine learning methods, including supervised algorithms for prediction, unsupervised methods for pattern recognition, and semi-supervised techniques for working with limited labeled data, are widely applied in this field. Deep learning, a subset of machine learning based on multi-layer neural networks, can extract hierarchical representations from raw data, making it highly effective for integrating multi-modal datasets such as genomic profiles, proteomic measurements, and imaging scans. In autoimmune disease research, these approaches

can reveal novel biomarker candidates that reflect disease mechanisms and predict clinical outcomes.

Sources of Data for AI-driven Biomarker Discovery in Autoimmune Diseases

The foundation of AI-driven biomarker discovery lies in access to high-quality, diverse, and well-annotated datasets. In autoimmune disease research, relevant data sources include electronic health records with detailed clinical histories, laboratory test results, imaging data from modalities such as MRI or ultrasound, and multi-omics datasets encompassing genomics, transcriptomics, proteomics, metabolomics, and epigenomics. Immunophenotyping data, obtained through technologies such as flow cytometry or mass cytometry, provide detailed insights into immune cell populations and activation states. Public repositories and disease-specific biobanks, as well as large-scale cohort studies, contribute valuable resources for AI model training and validation. Integrating these heterogeneous datasets presents challenges related to data standardization, batch effects, and missing values. AI methods such as feature normalization, dimensionality reduction, and transfer learning are critical for harmonizing diverse data types and enabling multi-modal biomarker discovery.

Machine Learning Approaches for Biomarker Identification in Autoimmune Diseases

Machine learning offers a versatile toolkit for identifying biomarkers that can differentiate between autoimmune disease subtypes, predict flares, or guide therapy. Supervised algorithms such as support vector machines, random forests, and gradient boosting methods can be trained to classify patients or predict disease outcomes based on known biomarker profiles. Unsupervised learning techniques, including clustering and principal component analysis, can uncover previously unrecognized disease subgroups that share common biomarker patterns. Semi-supervised learning, which combines small amounts of labeled data with large volumes of unlabeled data, is particularly valuable in autoimmune disease research where obtaining annotated datasets is often resource-intensive. The choice of algorithm depends on data dimensionality, the need for interpretability, and the specific clinical question being addressed.

Deep Learning in Multi-omics Integration for Autoimmune Diseases

Deep learning has proven especially effective for integrating data from multiple omics layers, which is essential for understanding the

complex pathogenesis of autoimmune diseases. Convolutional neural networks can analyze imaging data such as MRI scans in multiple sclerosis or ultrasound images in rheumatoid arthritis, extracting quantitative imaging biomarkers. Fully connected neural networks and transformer-based architectures can process genomic, transcriptomic, and proteomic data, uncovering patterns that correspond to disease activity or treatment response. Autoencoders can reduce the dimensionality of high-throughput datasets while preserving critical biological information, facilitating the discovery of latent biomarker features. Integrating omics data with imaging and clinical parameters through deep learning enables the development of comprehensive biomarker profiles that reflect the multifactorial nature of autoimmune diseases.

AI in Imaging Biomarker Discovery for Autoimmune Diseases

Medical imaging plays a central role in the diagnosis and monitoring of many autoimmune conditions. In multiple sclerosis, MRI is used to detect and quantify brain and spinal cord lesions, while in rheumatoid arthritis, ultrasound and MRI assess joint inflammation and structural damage. AI has revolutionized the extraction of imaging biomarkers through techniques such as radiomics, which quantify features like shape, texture, and intensity from medical images.

Convolutional neural networks can identify subtle imaging patterns that correlate with disease activity or predict progression. Integrating imaging biomarkers with molecular and clinical data enhances diagnostic accuracy and supports personalized treatment planning. For example, combining MRI-derived lesion characteristics with serum biomarkers and genetic profiles could improve predictions of relapse risk in multiple sclerosis.

The Role of the Immune System Profile in AI-based Biomarker Discovery

Autoimmune diseases are fundamentally disorders of the immune system, making immune profiling a rich source of potential biomarkers. High-dimensional immune profiling using flow cytometry, mass cytometry, and single-cell RNA sequencing generates complex datasets detailing immune cell composition, activation states, and functional responses. AI can analyze these datasets to identify immune cell subsets or activation signatures associated with specific disease states, severity levels, or treatment responses. Integrating immune profiling data with other omics layers can reveal multi-faceted biomarker signatures that provide a deeper understanding of disease mechanisms. These insights can guide the development of targeted therapies aimed at modulating specific immune

pathways.

***Challenges in AI-based Biomarker
Discovery for Autoimmune Diseases***

Despite its promise, AI-based biomarker discovery for autoimmune diseases faces several challenges. Data scarcity is a major issue, especially for rare autoimmune disorders. The heterogeneity of these diseases, both between patients and within the same patient over time, complicates biomarker identification. Variability in data acquisition methods, such as differences in sequencing platforms or imaging protocols, can introduce noise and bias. Deep learning models, while powerful, are often criticized for their lack of interpretability, which can hinder clinical acceptance and regulatory approval. Overfitting is another concern, particularly when models are trained on small datasets. Addressing these challenges requires collaborative data-sharing initiatives, standardized protocols, explainable AI techniques, and rigorous external validation of identified biomarkers.

REFERENCES

1. Adeoye J, Su YX. Artificial intelligence in salivary biomarker discovery and validation for oral diseases. *Oral Dis.* 2024;30(1):23-37.
2. Anghelescu A, Munteanu C, Spinu A, Ciobanu V, Popescu C, Cioca IE, et al. Standardized clinical assessments and advanced AI-driven instruments used to evaluate neurofunctional deficits, including within biomarker based framework, in Parkinson's disease - human intelligence made vs. AI models - systematic review. *Front Med (Lausanne).* 2025;12:1565275.
3. Aswathy R, Chalos VA, Suganya K, Sumathi S. Advancing miRNA cancer research through artificial intelligence: from biomarker discovery to therapeutic targeting. *Med Oncol.* 2024;42(1):30.
4. Baeseman L, Gunning S, Koyner JL. Biomarker Enrichment in Sepsis-Associated Acute Kidney Injury: Finding High-Risk Patients in the Intensive Care Unit. *Am J Nephrol.* 2024;55(1):72-85.
5. Bäuerle T, Dietzel M, Pinker K, Bonekamp D, Zhang KS, Schlemmer HP, et al. Identification of impactful imaging biomarker: Clinical applications for breast and prostate carcinoma. *Rofo.* 2024;196(4):354-62.
6. Beheshti I, Albensi BC, Freitas A, Ghafourian T. Advancements and challenges

- in using AI for biomarker detection in early Alzheimer's disease. *Drug Discov Today.* 2025;30(7):104415.
7. Behler A, Müller HP, Ludolph AC, Kassubek J. Diffusion Tensor Imaging in Amyotrophic Lateral Sclerosis: Machine Learning for Biomarker Development. *Int J Mol Sci.* 2023;24(3).
 8. Bekbossynova M, Saliev T, Mukarov M, Sugralimova M, Batpen A, Kozhakhmetova A, et al. Longitudinal Myocardial Deformation as an Emerging Biomarker for Post-Traumatic Cardiac Dysfunction. *Life (Basel).* 2025;15(7).
 9. Bhatia V, Chandel A, Minhas Y, Kushawaha SK. "Advances in biomarker discovery and diagnostics for alzheimer's disease". *Neurol Sci.* 2025;46(6):2419-36.
 10. Borkowski P, Singh N, Borkowska N. Advancements in Heart Transplantation: Donor-Derived Cell-Free DNA as Next-Generation Biomarker. *Cureus.* 2024;16(2):e54018.
 11. Burra P, Cammà C, Invernizzi P, Marra F, Pompili M. Does the hepatologist still need to rely on aminotransferases in clinical practice? A reappraisal of the role of a classic biomarker in the diagnosis and clinical management of chronic liver diseases. *Ann Hepatol.* 2025;30(1):101900.
 12. Çalışkan M, Tazaki K. AI/ML advances in non-small cell lung cancer biomarker discovery. *Front Oncol.* 2023;13:1260374.
 13. Caputo A, Angerilli V, Gambella A, L'Imperio V, Perrone G, Taffon C, et al.

Immunohistochemical biomarker scoring in gastroesophageal cancers: Can computers help us? *Pathol Res Pract*. 2025;272:156068.

14. Chang L, Liu J, Zhu J, Guo S, Wang Y, Zhou Z, et al. Advancing precision medicine: the transformative role of artificial intelligence in immunogenomics, radiomics, and pathomics for biomarker discovery and immunotherapy optimization. *Cancer Biol Med*. 2025;22(1):33-47.

15. Conte L, Caruso G, Philip AK, Cucci F, De Nunzio G, Cascio D, et al. Artificial Intelligence-Assisted Drug and Biomarker Discovery for Glioblastoma: A Scoping Review of the Literature. *Cancers (Basel)*. 2025;17(4).

16. Cui X, Gu X, Li D, Wu P, Sun N, Zhang C, et al. Tertiary lymphoid structures as a biomarker in immunotherapy and beyond: Advancing towards clinical application. *Cancer Lett*. 2025;613:217491.

17. Dakal TC, Xu C, Kumar A. Advanced computational tools, artificial intelligence and machine-learning approaches in gut microbiota and biomarker identification. *Front Med Technol*. 2024;6:1434799.

18. Dana J, Venkatasamy A, Saviano A, Lupberger J, Hoshida Y, Vilgrain V, et al. Conventional and artificial intelligence-based imaging for biomarker discovery in chronic liver disease. *Hepatol Int*. 2022;16(3):509-22.

19. El Abiad E, Al-Kuwari A, Al-Aani U, Al Jaidah Y, Chaari A. Navigating the Alzheimer's

Biomarker Landscape: A Comprehensive Analysis of Fluid-Based Diagnostics. *Cells*. 2024;13(22).

20. Evangelista EG, Bélisle-Pipon JC, Naunheim MR, Powell M, Gallois H, Bensoussan Y. Voice as a Biomarker in Health-Tech: Mapping the Evolving Landscape of Voice Biomarkers in the Start-Up World. *Otolaryngol Head Neck Surg*. 2024;171(2):340-52.

21. Faldu KG, Shah JS. Alzheimer's disease: a scoping review of biomarker research and development for effective disease diagnosis. *Expert Rev Mol Diagn*. 2022;22(7):681-703.

22. Fazlali M, Nasira M, Moravej A. AI-Driven Biomarker Discovery and Personalized Allergy Treatment: Utilizing Machine Learning and NGS. *Curr Allergy Asthma Rep*. 2025;25(1):27.

23. Fitzgerald J, Higgins D, Mazo Vargas C, Watson W, Mooney C, Rahman A, et al. Future of biomarker evaluation in the realm of artificial intelligence algorithms: application in improved therapeutic stratification of patients with breast and prostate cancer. *J Clin Pathol*. 2021;74(7):429-34.

24. Forghani R, Savadjiev P, Chatterjee A, Muthukrishnan N, Reinhold C, Forghani B. Radiomics and Artificial Intelligence for Biomarker and Prediction Model Development in Oncology. *Comput Struct Biotechnol J*. 2019;17:995-1008.

25. Galati F, Rizzo V, Trimboli RM, Kripa E, Maroncelli R, Pediconi F. MRI as a biomarker for

breast cancer diagnosis and prognosis. *BJR Open*. 2022;4(1):20220002.

26. Golestan A, Zareinejad M, Ramezani A. Comprehensive biomarker profiles in hematological malignancies: improving diagnosis, prognosis, and treatment. *Biomark Med*. 2025;19(6):223-38.

27. Haghayegh F, Norouziyazad A, Haghani E, Feygin AA, Rahimi RH, Ghavamabadi HA, et al. Revolutionary Point-of-Care Wearable Diagnostics for Early Disease Detection and Biomarker Discovery through Intelligent Technologies. *Adv Sci (Weinh)*. 2024;11(36):e2400595.

28. Hai L, Jiang Z, Zhang H, Sun Y. From multi-omics to predictive biomarker: AI in tumor microenvironment. *Front Immunol*. 2024;15:1514977.

29. He K, Baniasad M, Kwon H, Caval T, Xu G, Lebrilla C, et al. Decoding the glycoproteome: a new frontier for biomarker discovery in cancer. *J Hematol Oncol*. 2024;17(1):12.

30. Hermawan A, Amrillah T, Riapanitra A, Ong WJ, Yin S. Prospects and Challenges of MXenes as Emerging Sensing Materials for Flexible and Wearable Breath-Based Biomarker Diagnosis. *Adv Healthc Mater*. 2021;10(20):e2100970.

31. Huss R, Raffler J, Märkl B. Artificial intelligence and digital biomarker in precision pathology guiding immune therapy selection and precision oncology. *Cancer Rep (Hoboken)*. 2023;6(7):e1796.

32. Kalia A, Boyer M, Fagherazzi G, Bélisle-Pipon JC, Bensoussan Y. Master protocols in vocal biomarker development to reduce variability and advance clinical precision: a narrative review. *Front Digit Health*. 2025;7:1619183.

33. Kitaoka Y, Uchihashi T, Kawata S, Nishiura A, Yamamoto T, Hiraoka SI, et al. Role and Potential of Artificial Intelligence in Biomarker Discovery and Development of Treatment Strategies for Amyotrophic Lateral Sclerosis. *Int J Mol Sci*. 2025;26(9).

34. Krishna S, Abdelbaki A, Hart PA, Machicado JD. Endoscopic Ultrasound-Guided Needle-Based Confocal Endomicroscopy as a Diagnostic Imaging Biomarker for Intraductal Papillary Mucinous Neoplasms. *Cancers (Basel)*. 2024;16(6).

35. Kulshreshtha P, Deepak KK. Personality construct as a biomarker in fibromyalgia: A narrative review from an autonomic rehabilitation perspective. *J Back Musculoskelet Rehabil*. 2023;36(6):1251-60.

36. Lau RP, Kim TH, Rao J. Advances in Imaging Modalities, Artificial Intelligence, and Single Cell Biomarker Analysis, and Their Applications in Cytopathology. *Front Med (Lausanne)*. 2021;8:689954.

37. Levitt J, Saab CY. What does a pain 'biomarker' mean and can a machine be taught to measure pain? *Neurosci Lett*. 2019;702:40-3.

38. Lin Y, Zhao X, Miao Z, Ling Z, Wei X, Pu J, et al. Data-driven translational prostate cancer

research: from biomarker discovery to clinical decision. *J Transl Med.* 2020;18(1):119.

39. Liu L, Zhong X, Zhong Y, Li L. Recent advances in biomarker detection of oral squamous cell carcinoma. *Front Oncol.* 2025;15:1597086.

40. Liu S, Xu L, Xu G, Wang Y, Zhang G, He L. A systematic review: Brain age gap as a promising early diagnostic biomarker for Alzheimer's disease. *J Neurol Sci.* 2025;475:123563.

41. Liu Z, Zhou Y, Lu J, Gong T, Ibáñez E, Cifuentes A, et al. Microfluidic biosensors for biomarker detection in body fluids: a key approach for early cancer diagnosis. *Biomark Res.* 2024;12(1):153.

42. Llitjos JF, Carrol ED, Osuchowski MF, Bonneville M, Scicluna BP, Payen D, et al. Enhancing sepsis biomarker development: key considerations from public and private perspectives. *Crit Care.* 2024;28(1):238.

43. Lu M, Zhang J, Zhang L. Emerging Concepts and Methodologies in Cancer Biomarker Discovery. *Crit Rev Oncog.* 2017;22(5-6):371-88.

44. Mann M, Kumar C, Zeng WF, Strauss MT. Artificial intelligence for proteomics and biomarker discovery. *Cell Syst.* 2021;12(8):759-70.

45. Maréchal E. Chemogenomics: a discipline at the crossroad of high throughput technologies, biomarker research, combinatorial chemistry, genomics, cheminformatics, bioinformatics and artificial intelligence. *Comb Chem High Throughput Screen.* 2008;11(8):583-6.

46. Mikdadi D, O'Connell KA, Meacham PJ, Dugan MA, Ojiere MO, Carlson TB, et al. Applications of artificial intelligence (AI) in ovarian cancer, pancreatic cancer, and image biomarker discovery. *Cancer Biomark.* 2022;33(2):173-84.

47. Mukherjee S, Mukherjee A, Bytesnikova Z, Ashrafi AM, Richtera L, Adam V. 2D graphene-based advanced nanoarchitectonics for electrochemical biosensors: Applications in cancer biomarker detection. *Biosens Bioelectron.* 2024;250:116050.

48. Nandi A, Singh K, Sharma K. Advancement in early diagnosis of polycystic ovary syndrome: biomarker-driven innovative diagnostic sensor. *Mikrochim Acta.* 2025;192(5):331.

49. Ng S, Masarone S, Watson D, Barnes MR. The benefits and pitfalls of machine learning for biomarker discovery. *Cell Tissue Res.* 2023;394(1):17-31.

50. Pandey SN, Afzal M, Ali H, Malathi H, Maharana L, Goyal K, et al. AZGP1: A proteomic biomarker in cancer. *Clin Chim Acta.* 2025;577:120481.

51. Pang Y, Wang H, Li H. Medical Imaging Biomarker Discovery and Integration Towards AI-Based Personalized Radiotherapy. *Front Oncol.* 2021;11:764665.

52. Plou J, Valera PS, García I, de Albuquerque CDL, Carracedo A, Liz-Marzán LM. Prospects of Surface-Enhanced Raman Spectroscopy for

Biomarker Monitoring toward Precision Medicine. *ACS Photonics*. 2022;9(2):333-50.

53. Pokushalov E, Ponomarenko A, Shrainer E, Kudlay D, Miller R. Biomarker-Guided Dietary Supplementation: A Narrative Review of Precision in Personalized Nutrition. *Nutrients*. 2024;16(23).

54. Pourakbar N, Motamedi A, Pashapour M, Sharifi ME, Sharabiani SS, Fazlollahi A, et al. Effectiveness of Artificial Intelligence Models in Predicting Lung Cancer Recurrence: A Gene Biomarker-Driven Review. *Cancers (Basel)*. 2025;17(11).

55. Prelaj A, Miskovic V, Zanitti M, Trovo F, Genova C, Viscardi G, et al. Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review. *Ann Oncol*. 2024;35(1):29-65.

56. Qamar T, Ansari MS, Masihuddin, Mukherjee S. MicroRNAs as Biomarker in Rheumatoid Arthritis: Pathogenesis to Clinical Relevance. *J Cell Biochem*. 2025;126(2):e30690.

57. Rajasekar SJS, Saleem M, Kannan N, Narayanasamy K, Varalakshmi P. Artificial Intelligence Powered Audiomics: The Futuristic Biomarker in Pulmonary Medicine - A State-of-the-Art Review. *Stud Health Technol Inform*. 2025;327:884-5.

58. Ramesh D, Manickavel P, Ghosh S, Bhat M. The Integration of Multi-omics With Artificial Intelligence in Hepatology: A Comprehensive Review of Personalized Medicine, Biomarker

Identification, and Drug Discovery. *J Clin Exp Hepatol*. 2025;15(6):102611.

59. Ren AH, Fiala CA, Diamandis EP, Kulasingam V. Pitfalls in Cancer Biomarker Discovery and Validation with Emphasis on Circulating Tumor DNA. *Cancer Epidemiol Biomarkers Prev*. 2020;29(12):2568-74.

60. Ristori MV, Mortera SL, Marzano V, Guerrera S, Vernocchi P, Ianiro G, et al. Proteomics and Metabolomics Approaches towards a Functional Insight onto AUTISM Spectrum Disorders: Phenotype Stratification and Biomarker Discovery. *Int J Mol Sci*. 2020;21(17).

61. Rogers HP, Hseu A, Kim J, Silberholz E, Jo S, Dorste A, et al. Voice as a Biomarker of Pediatric Health: A Scoping Review. *Children (Basel)*. 2024;11(6).

62. Rossini PM, Miraglia F, Alù F, Cotelli M, Ferreri F, Iorio RD, et al. Neurophysiological Hallmarks of Neurodegenerative Cognitive Decline: The Study of Brain Connectivity as A Biomarker of Early Dementia. *J Pers Med*. 2020;10(2).

63. Sepúlveda M, Arauna D, García F, Albala C, Palomo I, Fuentes E. Frailty in Aging and the Search for the Optimal Biomarker: A Review. *Biomedicines*. 2022;10(6).

64. Shang S, Xia J, He G, Zheng Y, Zhang J, Lu H, et al. Advances in precision medicine for lupus nephritis: biomarker- and AI-driven diagnosis and treatment response prediction and targeted

therapies. *EBioMedicine*. 2025;117:105785.

65. Shang W, Wei G, Li H, Zhao G, Wang D. Advances in High-Resolution Mass Spectrometry-Based Metabolomics: Applications in Food Analysis and Biomarker Discovery. *J Agric Food Chem*. 2025;73(6):3305-25.

66. Shaw JR, Nopp S, Stavik B, Youkhana K, Michels AL, Kennes S, et al. Thrombosis, Translational Medicine, and Biomarker Research: Moving the Needle. *J Am Heart Assoc*. 2025;14(1):e038782.

67. Song J, Wang C, Zhao T, Zhang Y, Xing J, Zhao X, et al. Multi-omics approaches for biomarker discovery and precision diagnosis of prediabetes. *Front Endocrinol (Lausanne)*. 2025;16:1520436.

68. Vo DK, Trinh KTL. Polymerase Chain Reaction Chips for Biomarker Discovery and Validation in Drug Development. *Micromachines (Basel)*. 2025;16(3).

69. Wager K, Wang Y, Liew A, Campbell D, Liu F, Martini JF, et al. Using bioinformatics and artificial intelligence to map the cyclin-dependent kinase 4/6 inhibitor biomarker landscape in breast cancer. *Future Oncol*. 2024;20(40):3519-37.

70. Wang J, Wang YX, Zeng D, Zhu Z, Li D, Liu Y, et al. Artificial intelligence-enhanced retinal imaging as a biomarker for systemic diseases. *Theranostics*. 2025;15(8):3223-33.

71. Wang X, Li X, Dong T, Yu W, Jia Z, Hou Y, et al. Global biomarker trends in triple-negative

breast cancer research: a bibliometric analysis. *Int J Surg*. 2024;110(12):7962-83.

72. Wengler K, Trujillo P, Cassidy CM, Horga G. Neuromelanin-sensitive MRI for mechanistic research and biomarker development in psychiatry. *Neuropsychopharmacology*. 2024;50(1):137-52.

73. Weselá P, Eid M, Moravčík P, Vlažný J, Hlavsa J, Procházka V, et al. Artificial intelligence in pancreatic cancer histopathology and diagnostics - implications for clinical decisions and biomarker discovery? *Cell Div*. 2025;20(1):15.

74. Winchester LM, Harshfield EL, Shi L, Badhwar A, Khleifat AA, Clarke N, et al. Artificial intelligence for biomarker discovery in Alzheimer's disease and dementia. *Alzheimers Dement*. 2023;19(12):5860-71.

75. Xiao Q, Zhang F, Xu L, Yue L, Kon OL, Zhu Y, et al. High-throughput proteomics and AI for cancer biomarker discovery. *Adv Drug Deliv Rev*. 2021;176:113844.

76. Yadav AK, Verma D, Kumar A, Kumar P, Solanki PR. The perspectives of biomarker-based electrochemical immunosensors, artificial intelligence and the Internet of Medical Things toward COVID-19 diagnosis and management. *Mater Today Chem*. 2021;20:100443.

77. Yang Z, Guan F, Bronk L, Zhao L. Multi-omics approaches for biomarker discovery in predicting the response of esophageal cancer to neoadjuvant therapy: A multidimensional

perspective. *Pharmacol Ther.* 2024;254:108591.

78. Zehra, Bakhtiyar A, Islam A, Ishrat R, Hassan MI. AI-driven approaches in therapeutic interventions: Transforming RNA-seq analysis into biomarker discovery and drug development. *Drug Discov Today.* 2025;30(7):104391.

79. Zhang J, Choi H, Kim Y, Park J, Cho S, Kim E, et al. Artificial intelligence-based digital pathology using H&E-stained whole slide images in immuno-oncology: from immune biomarker detection to immunotherapy response prediction. *J Immunother Cancer.* 2025;13(8).

80. Acs B, Rantalainen M, Hartman J. Artificial intelligence as the next step towards precision pathology. *J Intern Med.* 2020;288(1):62-81.

81. Ahn JS, Shin S, Yang SA, Park EK, Kim KH, Cho SI, et al. Artificial Intelligence in Breast Cancer Diagnosis and Personalized Medicine. *J Breast Cancer.* 2023;26(5):405-35.

82. Ashraf AA, Rai S, Alva S, Alva PD, Naresh S. Revolutionizing clinical laboratories: The impact of artificial intelligence in diagnostics and patient care. *Diagn Microbiol Infect Dis.* 2025;111(4):116728.

83. Asleh K, Dery V, Taylor C, Davey M, Djeungoue-Petga MA, Ouellette RJ. Extracellular vesicle-based liquid biopsy biomarkers and their application in precision immuno-oncology. *Biomark Res.* 2023;11(1):99.

84. Athanasopoulou K, Michalopoulou VI, Scorilas A, Adamopoulos PG. Integrating Artificial

Intelligence in Next-Generation Sequencing: Advances, Challenges, and Future Directions. *Curr Issues Mol Biol.* 2025;47(6).

85. Attia AM, Rezaee-Zavareh MS, Hwang SY, Kim N, Adetyan H, Yalda T, et al. Novel Biomarkers for Early Detection of Hepatocellular Carcinoma. *Diagnostics (Basel).* 2024;14(20).

86. Azadi Moghadam P, Bashashati A, Goldenberg SL. Artificial Intelligence and Pathomics: Prostate Cancer. *Urol Clin North Am.* 2024;51(1):15-26.

87. Azzam M, Xu Z, Liu R, Li L, Meng Soh K, Challagundla KB, et al. A review of artificial intelligence-based brain age estimation and its applications for related diseases. *Brief Funct Genomics.* 2025;24.

88. Balasubramaniam NK, Penberthy S, Fenyo D, Viessmann N, Russmann C, Borchers CH. Digitalomics - digital transformation leading to omics insights. *Expert Rev Proteomics.* 2024;21(9-10):337-44.

89. Barberis E, Khoso S, Sica A, Falasca M, Gennari A, Dondero F, et al. Precision Medicine Approaches with Metabolomics and Artificial Intelligence. *Int J Mol Sci.* 2022;23(19).

90. Bassi A, Krance SH, Pucchio A, Pur DR, Miranda RN, Felfeli T. The Application of Artificial Intelligence in the Analysis of Biomarkers for Diagnosis and Management of Uveitis and Uveal Melanoma: A Systematic Review. *Clin Ophthalmol.* 2022;16:2895-908.

91. Baxi V, Edwards R, Montalto M, Saha S. Digital pathology and artificial intelligence in translational medicine and clinical practice. *Mod Pathol*. 2022;35(1):23-32.
92. Baydili İ, Tasci B, Tasci G. Artificial Intelligence in Psychiatry: A Review of Biological and Behavioral Data Analyses. *Diagnostics (Basel)*. 2025;15(4).
93. Bera K, Schalper KA, Rimm DL, Velcheti V, Madabhushi A. Artificial intelligence in digital pathology - new tools for diagnosis and precision oncology. *Nat Rev Clin Oncol*. 2019;16(11):703-15.
94. Bhat AA, Nisar S, Mukherjee S, Saha N, Yarravarapu N, Lone SN, et al. Integration of CRISPR/Cas9 with artificial intelligence for improved cancer therapeutics. *J Transl Med*. 2022;20(1):534.
95. Bjerkén LV, Rønborg SN, Jensen MT, Ørting SN, Nielsen OW. Artificial intelligence enabled ECG screening for left ventricular systolic dysfunction: a systematic review. *Heart Fail Rev*. 2023;28(2):419-30.
96. Boehm KM, Khosravi P, Vanguri R, Gao J, Shah SP. Harnessing multimodal data integration to advance precision oncology. *Nat Rev Cancer*. 2022;22(2):114-26.
97. Boniolo F, Dorigatti E, Ohnmacht AJ, Saur D, Schubert B, Menden MP. Artificial intelligence in early drug discovery enabling precision medicine. *Expert Opin Drug Discov*. 2021;16(9):991-1007.
98. Bordukova M, Makarov N, Rodriguez-

- Esteban R, Schmich F, Menden MP. Generative artificial intelligence empowers digital twins in drug discovery and clinical trials. *Expert Opin Drug Discov*. 2024;19(1):33-42.
99. Bougea A. Digital biomarkers in Parkinson's disease. *Adv Clin Chem*. 2024;123:221-53.
100. Bourcier S, Klug J, Nguyen LS. Non-occlusive mesenteric ischemia: Diagnostic challenges and perspectives in the era of artificial intelligence. *World J Gastroenterol*. 2021;27(26):4088-103.
101. Broza YY, Haick H. Biodiagnostics in an era of global pandemics-From biosensing materials to data management. *View (Beijing)*. 2022;3(2):20200164.
102. Bruhm DC, Vulpescu NA, Foda ZH, Phallen J, Scharpf RB, Velculescu VE. Genomic and fragmentomic landscapes of cell-free DNA for early cancer detection. *Nat Rev Cancer*. 2025;25(5):341-58.
103. Cao Y, Xu Y, Cao M, Chen N, Zeng Q, Lai MKP, et al. Fluid-based biomarkers for neurodegenerative diseases. *Ageing Res Rev*. 2025;108:102739.
104. Castagnaro E, Felici E, Spaccapelo R, Amoroso M, Moretti D, Saab JP, et al. Systematic Review: Use of Artificial Intelligence and Unmet Needs in Eosinophilic Oesophagitis. *Aliment Pharmacol Ther*. 2025;62(2):110-27.
105. Chaitanu Wong P, Singhanetr P, Chainakul

M, Arjkonharn N, Ruamviboonsuk P, Grzybowski A. Potential Ocular Biomarkers for Early Detection of Alzheimer's Disease and Their Roles in Artificial Intelligence Studies. *Neurol Ther.* 2023;12(5):1517-32.

106. Chang CH, Lin CH, Lane HY. Machine Learning and Novel Biomarkers for the Diagnosis of Alzheimer's Disease. *Int J Mol Sci.* 2021;22(5).

107. Charvériat M, Lafon V, Mouthon F, Zimmer L. Innovative approaches in CNS drug discovery. *Thérapie.* 2021;76(2):101-9.

108. Chen ZS, Kulkarni PP, Galatzer-Levy IR, Bigio B, Nasca C, Zhang Y. Modern views of machine learning for precision psychiatry. *Patterns (N Y).* 2022;3(11):100602.

109. Chidurala S, Charkhchi P, Komirisetty R, Ching K, Rozanitis K, Jha T, et al. A Review of Artificial Intelligence Models for Detecting Breast Arterial Calcification on Mammograms and Their Clinical Implications. *Cureus.* 2025;17(6):e86894.

110. Chiu FY, Yen Y. Imaging biomarkers for clinical applications in neuro-oncology: current status and future perspectives. *Biomark Res.* 2023;11(1):35.

111. Choi S, Kim S. Artificial Intelligence in the Pathology of Gastric Cancer. *J Gastric Cancer.* 2023;23(3):410-27.

112. Christie JR, Lang P, Zelko LM, Palma DA, Abdelrazek M, Mattonen SA. Artificial Intelligence in Lung Cancer: Bridging the Gap Between Computational Power and Clinical Decision-

Making. *Can Assoc Radiol J.* 2021;72(1):86-97.

113. Cifci D, Foersch S, Kather JN. Artificial intelligence to identify genetic alterations in conventional histopathology. *J Pathol.* 2022;257(4):430-44.

114. Classe M, Lerousseau M, Scoazec JY, Deutsch E. Perspectives in pathomics in head and neck cancer. *Curr Opin Oncol.* 2021;33(3):175-83.

115. Corcoran CM, Cecchi GA. Using Language Processing and Speech Analysis for the Identification of Psychosis and Other Disorders. *Biol Psychiatry Cogn Neurosci Neuroimaging.* 2020;5(8):770-9.

116. Crombé A, Spinnato P, Italiano A, Brisse HJ, Feydy A, Fadli D, et al. Radiomics and artificial intelligence for soft-tissue sarcomas: Current status and perspectives. *Diagn Interv Imaging.* 2023;104(12):567-83.

117. Das KP, J C. Nanoparticles and convergence of artificial intelligence for targeted drug delivery for cancer therapy: Current progress and challenges. *Front Med Technol.* 2022;4:1067144.

118. Datwani S, Khan H, Niazi MKK, Parwani AV, Li Z. Artificial intelligence in breast pathology: Overview and recent updates. *Hum Pathol.* 2025;105819.

119. Dennis AP, Strafella AP. The identification of cognitive impairment in Parkinson's disease using biofluids, neuroimaging, and artificial intelligence. *Front Neurosci.* 2024;18:1446878.

120. Dlamini Z, Francies FZ, Hull R, Marima R.

Artificial intelligence (AI) and big data in cancer and precision oncology. *Comput Struct Biotechnol J*. 2020;18:2300-11.

121. Du Y, Niu J, Xing Y, Li B, Calhoun VD. Neuroimage Analysis Methods and Artificial Intelligence Techniques for Reliable Biomarkers and Accurate Diagnosis of Schizophrenia: Achievements Made by Chinese Scholars Around the Past Decade. *Schizophr Bull*. 2025;51(2):325-42.

122. Duranti L, Tavecchio L, Rolli L, Solli P. New Perspectives on Lung Cancer Screening and Artificial Intelligence. *Life (Basel)*. 2025;15(3).

123. Egger K, Rijntjes M. [Big data and artificial intelligence for diagnostic decision support in atypical dementia]. *Nervenarzt*. 2018;89(8):875-84.

124. Fanciullo C, Gitto S, Carlicchi E, Albano D, Messina C, Sconfienza LM. Radiomics of Musculoskeletal Sarcomas: A Narrative Review. *J Imaging*. 2022;8(2).

125. Fiocchi C. Omics and Multi-Omics in IBD: No Integration, No Breakthroughs. *Int J Mol Sci*. 2023;24(19).

126. Forghani R. Precision Digital Oncology: Emerging Role of Radiomics-based Biomarkers and Artificial Intelligence for Advanced Imaging and Characterization of Brain Tumors. *Radiol Imaging Cancer*. 2020;2(4):e190047.

127. Gandhewar R, Guimaraes T, Sen S, Pontikos N, Moghul I, Empeslidis T, et al.

Imaging biomarkers and artificial intelligence for diagnosis, prediction, and therapy of macular fibrosis in age-related macular degeneration: Narrative review and future directions. *Graefes Arch Clin Exp Ophthalmol*. 2025.

128. Gangwal A, Lavecchia A. AI-Driven Drug Discovery for Rare Diseases. *J Chem Inf Model*. 2025;65(5):2214-31.

129. Garberis I, Andre F, Lacroix-Triki M. [Not Available]. *Bull Cancer*. 2021;108(11s):11s35-11s45.

130. Gholap AD, Omri A. Advances in artificial intelligence-envisioned technologies for protein and nucleic acid research. *Drug Discov Today*. 2025;30(5):104362.

131. Goggins M. The role of biomarkers in the early detection of pancreatic cancer. *Fam Cancer*. 2024;23(3):309-22.

132. Gomes CPC, Salgado-Somoza A, Creemers EE, Dieterich C, Lustrek M, Devaux Y. Circular RNAs in the cardiovascular system. *Noncoding RNA Res*. 2018;3(1):1-11.

133. Gruson D, Helleputte T, Rousseau P, Gruson D. Data science, artificial intelligence, and machine learning: Opportunities for laboratory medicine and the value of positive regulation. *Clin Biochem*. 2019;69:1-7.

134. Guo T, Steen JA, Mann M. Mass-spectrometry-based proteomics: from single cells to clinical applications. *Nature*. 2025;638(8052):901-11.

135. Gupta R, Srivastava D, Sahu M, Tiwari S, Ambasta RK, Kumar P. Artificial intelligence to deep learning: machine intelligence approach for drug discovery. *Mol Divers*. 2021;25(3):1315-60.
136. Hampel H, Vergallo A, Perry G, Lista S. The Alzheimer Precision Medicine Initiative. *J Alzheimers Dis*. 2019;68(1):1-24.
137. Hanna MG, Pantanowitz L, Dash R, Harrison JH, Deebajah M, Pantanowitz J, et al. Future of Artificial Intelligence-Machine Learning Trends in Pathology and Medicine. *Mod Pathol*. 2025;38(4):100705.
138. Hartl D, de Luca V, Kostikova A, Laramie J, Kennedy S, Ferrero E, et al. Translational precision medicine: an industry perspective. *J Transl Med*. 2021;19(1):245.
139. Hayashi D, Roemer FW, Guermazi A. Osteoarthritis year in review 2024: Imaging. *Osteoarthritis Cartilage*. 2025;33(1):88-93.
140. He N, Chen Y, LeWitt PA, Yan F, Haacke EM. Application of Neuromelanin MR Imaging in Parkinson Disease. *J Magn Reson Imaging*. 2023;57(2):337-52.
141. Ho D, Quake SR, McCabe ERB, Chng WJ, Chow EK, Ding X, et al. Enabling Technologies for Personalized and Precision Medicine. *Trends Biotechnol*. 2020;38(5):497-518.
142. Hokken TW, Ribeiro JM, De Jaegere PP, Van Mieghem NM. Precision Medicine in Interventional Cardiology. *Interv Cardiol*. 2020;15:e03.

143. Hormel TT, Hwang TS, Bailey ST, Wilson DJ, Huang D, Jia Y. Artificial intelligence in OCT angiography. *Prog Retin Eye Res*. 2021;85:100965.
144. Huemer F, Leisch M, Geisberger R, Melchardt T, Rinnerthaler G, Zaborsky N, et al. Combination Strategies for Immune-Checkpoint Blockade and Response Prediction by Artificial Intelligence. *Int J Mol Sci*. 2020;21(8).
145. Huss R, Coupland SE. Software-assisted decision support in digital histopathology. *J Pathol*. 2020;250(5):685-92.
146. Hussain MS, Ramalingam PS, Chellasamy G, Yun K, Bisht AS, Gupta G. Harnessing Artificial Intelligence for Precision Diagnosis and Treatment of Triple Negative Breast Cancer. *Clin Breast Cancer*. 2025;25(5):406-21.
147. Infante T, Cavaliere C, Punzo B, Grimaldi V, Salvatore M, Napoli C. Radiogenomics and Artificial Intelligence Approaches Applied to Cardiac Computed Tomography Angiography and Cardiac Magnetic Resonance for Precision Medicine in Coronary Heart Disease: A Systematic Review. *Circ Cardiovasc Imaging*. 2021;14(12):1133-46.
148. Jamthikar AD, Puvvula A, Gupta D, Johri AM, Nambi V, Khanna NN, et al. Cardiovascular disease and stroke risk assessment in patients with chronic kidney disease using integration of estimated glomerular filtration rate, ultrasonic image phenotypes, and artificial intelligence: a narrative review. *Int Angiol*. 2021;40(2):150-64.

149. Janitri V, ArulJothi KN, Ravi Mythili VM, Singh SK, Prasher P, Gupta G, et al. The roles of patient-derived xenograft models and artificial intelligence toward precision medicine. *MedComm* (2020). 2024;5(10):e745.
150. Jha AK, Mithun S, Sherkhane UB, Dwivedi P, Puts S, Osong B, et al. Emerging role of quantitative imaging (radiomics) and artificial intelligence in precision oncology. *Explor Target Antitumor Ther*. 2023;4(4):569-82.
151. Jin X, Liu C, Xu T, Su L, Zhang X. Artificial intelligence biosensors: Challenges and prospects. *Biosens Bioelectron*. 2020;165:112412.
152. Kang CY, Duarte SE, Kim HS, Kim E, Park J, Lee AD, et al. Artificial Intelligence-based Radiomics in the Era of Immuno-oncology. *Oncologist*. 2022;27(6):e471-e83.
153. Kannan S, Chellappan DK, Kow CS, Ramachandram DS, Pandey M, Mayuren J, et al. Transform diabetes care with precision medicine. *Health Sci Rep*. 2023;6(11):e1642.
154. Khatib M, Haick H. Sensors for Volatile Organic Compounds. *ACS Nano*. 2022;16(5):7080-115.
155. Khosravi P, Fuchs TJ, Ho DJ. Artificial Intelligence-Driven Cancer Diagnostics: Enhancing Radiology and Pathology through Reproducibility, Explainability, and Multimodality. *Cancer Res*. 2025;85(13):2356-67.
156. Klauschen F, Dippel J, Keyl P, Jurmeister P, Bockmayr M, Mock A, et al. [Explainable artificial

- intelligence in pathology]. *Pathologie (Heidelb)*. 2024;45(2):133-9.
157. Klauschen F, Dippel J, Keyl P, Jurmeister P, Bockmayr M, Mock A, et al. Toward Explainable Artificial Intelligence for Precision Pathology. *Annu Rev Pathol*. 2024;19:541-70.
158. Kuntz S, Kriehoff-Henning E, Kather JN, Jutzi T, Höhn J, Kiehl L, et al. Gastrointestinal cancer classification and prognostication from histology using deep learning: Systematic review. *Eur J Cancer*. 2021;155:200-15.
159. Lad EM, Finger RP, Guymer R. Biomarkers for the Progression of Intermediate Age-Related Macular Degeneration. *Ophthalmol Ther*. 2023;12(6):2917-41.
160. Lan CH, Chiu TH, Yen WT, Lu DW. Artificial Intelligence in Glaucoma: Advances in Diagnosis, Progression Forecasting, and Surgical Outcome Prediction. *Int J Mol Sci*. 2025;26(10).
161. Lancellotti C, Cancian P, Savevski V, Kotha SRR, Fraggetta F, Graziano P, et al. Artificial Intelligence & Tissue Biomarkers: Advantages, Risks and Perspectives for Pathology. *Cells*. 2021;10(4).
162. Li H, Jia W, Vujosevic S, Sabanayagam C, Grauslund J, Sivaprasad S, et al. Current research and future strategies for the management of vision-threatening diabetic retinopathy. *Asia Pac J Ophthalmol (Phila)*. 2024;13(5):100109.
163. Li LR, Du B, Liu HQ, Chen C. Artificial Intelligence for Personalized Medicine in Thyroid

Cancer: Current Status and Future Perspectives. *Front Oncol.* 2020;10:604051.

164. Lin B, Ma Y, Wu S. Multi-Omics and Artificial Intelligence-Guided Data Integration in Chronic Liver Disease: Prospects and Challenges for Precision Medicine. *Omics.* 2022;26(8):415-21.

165. Lin CY, Sung HY, Chen YJ, Yeh HI, Hou CJ, Tsai CT, et al. Personalized Management for Heart Failure with Preserved Ejection Fraction. *J Pers Med.* 2023;13(5).

166. Lin E, Lin CH, Lane HY. Precision Psychiatry Applications with Pharmacogenomics: Artificial Intelligence and Machine Learning Approaches. *Int J Mol Sci.* 2020;21(3).

167. Liu Y. HER2-low breast cancer: insights on pathological testing. *Transl Breast Cancer Res.* 2023;4:15.

168. Lu MY, Chuang WL, Yu ML. The role of artificial intelligence in the management of liver diseases. *Kaohsiung J Med Sci.* 2024;40(11):962-71.

169. Lüscher TF, Wenzl FA, D'Ascenzo F, Friedman PA, Antoniades C. Artificial intelligence in cardiovascular medicine: clinical applications. *Eur Heart J.* 2024;45(40):4291-304.

170. Lyall DM, Kormilitzin A, Lancaster C, Sousa J, Petermann-Rocha F, Buckley C, et al. Artificial intelligence for dementia-Applied models and digital health. *Alzheimers Dement.* 2023;19(12):5872-84.

171. Magrabi F, Ammenwerth E, McNair

JB, De Keizer NF, Hyppönen H, Nykänen P, et al. Artificial Intelligence in Clinical Decision Support: Challenges for Evaluating AI and Practical Implications. *Yearb Med Inform.* 2019;28(1):128-34.

172. Mamoshina P, Vieira A, Putin E, Zhavoronkov A. Applications of Deep Learning in Biomedicine. *Mol Pharm.* 2016;13(5):1445-54.

173. Mane PP, Ambekar RS, Kandasubramanian B. Electrospun nanofiber-based cancer sensors: A review. *Int J Pharm.* 2020;583:119364.

174. Mansur A, Vrionis A, Charles JP, Hancel K, Panagides JC, Moloudi F, et al. The Role of Artificial Intelligence in the Detection and Implementation of Biomarkers for Hepatocellular Carcinoma: Outlook and Opportunities. *Cancers (Basel).* 2023;15(11).

175. Mao Y, Shangguan D, Huang Q, Xiao L, Cao D, Zhou H, et al. Emerging artificial intelligence-driven precision therapies in tumor drug resistance: recent advances, opportunities, and challenges. *Mol Cancer.* 2025;24(1):123.

176. Marra A, Morganti S, Pareja F, Campanella G, Bibeau F, Fuchs T, et al. Artificial intelligence entering the pathology arena in oncology: current applications and future perspectives. *Ann Oncol.* 2025;36(7):712-25.

177. Martins D, Martins T, Schor P. The use of artificial intelligence to identify ophthalmic biomarkers in cardiovascular disease and stroke: a narrative review. *Sao Paulo Med J.*

2025;143(3):e2023369.

178. Mazer BL, Lee JW, Roberts NJ, Chu LC, Lennon AM, Klein AP, et al. Screening for pancreatic cancer has the potential to save lives, but is it practical? *Expert Rev Gastroenterol Hepatol.* 2023;17(6):555-74.

179. McCaffrey C, Jahangir C, Murphy C, Burke C, Gallagher WM, Rahman A. Artificial intelligence in digital histopathology for predicting patient prognosis and treatment efficacy in breast cancer. *Expert Rev Mol Diagn.* 2024;24(5):363-77.

180. McElroy SJ, Lueschow SR. State of the art review on machine learning and artificial intelligence in the study of neonatal necrotizing enterocolitis. *Front Pediatr.* 2023;11:1182597.

181. Mei T, Wang T, Zhou Q. Multi-omics and artificial intelligence predict clinical outcomes of immunotherapy in non-small cell lung cancer patients. *Clin Exp Med.* 2024;24(1):60.

182. Messika J, Belousova N, Parquin F, Roux A. Antibody-Mediated Rejection in Lung Transplantation: Diagnosis and Therapeutic Armamentarium in a 21st Century Perspective. *Transpl Int.* 2024;37:12973.

183. Michelhaugh SA, Januzzi JL, Jr. Using Artificial Intelligence to Better Predict and Develop Biomarkers. *Heart Fail Clin.* 2022;18(2):275-85.

184. Michelhaugh SA, Januzzi JL, Jr. Using Artificial Intelligence to Better Predict and Develop Biomarkers. *Clin Lab Med.*

2023;43(1):99-114.

185. Miller C, Manious M, Portnoy J. Artificial intelligence and machine learning for anaphylaxis algorithms. *Curr Opin Allergy Clin Immunol.* 2024;24(5):305-12.

186. Moingeon P. Artificial intelligence-driven drug development against autoimmune diseases. *Trends Pharmacol Sci.* 2023;44(7):411-24.

187. Moldogazieva NT, Mokhosoev IM, Zavadskiy SP, Terentiev AA. Proteomic Profiling and Artificial Intelligence for Hepatocellular Carcinoma Translational Medicine. *Biomedicines.* 2021;9(2).

188. Mooghal M, Anjum S, Khan W, Tariq H, Babar A, Vohra LM. Artificial intelligence-powered optimization of KI-67 assessment in breast cancer: enhancing precision and workflow efficiency. a literature review. *J Pak Med Assoc.* 2024;74(4 (Supple-4)):S109-s16.

189. Moreau NN, Valable S, Jaudet C, Dessoude L, Thomas L, Hérault R, et al. Early characterization and prediction of glioblastoma and brain metastasis treatment efficacy using medical imaging-based radiomics and artificial intelligence algorithms. *Front Oncol.* 2025;15:1497195.

190. Murray K, Oldfield L, Stefanova I, Gentiluomo M, Aretini P, O'Sullivan R, et al. Biomarkers, omics and artificial intelligence for early detection of pancreatic cancer. *Semin Cancer Biol.* 2025;111:76-88.

191. Nahar JK, Lopez-Jimenez F. Utilizing Conversational Artificial Intelligence, Voice, and Phonocardiography Analytics in Heart Failure Care. *Heart Fail Clin.* 2022;18(2):311-23.
192. Naik K, Goyal RK, Foschini L, Chak CW, Thielscher C, Zhu H, et al. Current Status and Future Directions: The Application of Artificial Intelligence/Machine Learning for Precision Medicine. *Clin Pharmacol Ther.* 2024;115(4):673-86.
193. Nejatie A, Yee SS, Jeter A, Saragovi HU. The cancer glycode as a family of diagnostic biomarkers, exemplified by tumor-associated gangliosides. *Front Oncol.* 2023;13:1261090.
194. Noor J, Chaudhry A, Batool S. Microfluidic Technology, Artificial Intelligence, and Biosensors As Advanced Technologies in Cancer Screening: A Review Article. *Cureus.* 2023;15(5):e39634.
195. Ochi M, Komura D, Ishikawa S. Pathology Foundation Models. *Jmaj.* 2025;8(1):121-30.
196. Ong W, Lee A, Tan WC, Fong KTD, Lai DD, Tan YL, et al. Oncologic Applications of Artificial Intelligence and Deep Learning Methods in CT Spine Imaging-A Systematic Review. *Cancers (Basel).* 2024;16(17).
197. Park JH, Kim EY, Luchini C, Eccher A, Tizaoui K, Shin JI, et al. Artificial Intelligence for Predicting Microsatellite Instability Based on Tumor Histomorphology: A Systematic Review. *Int J Mol Sci.* 2022;23(5).
198. Park Y, Park S, Lee M. Effectiveness of

- artificial intelligence in detecting and managing depressive disorders: Systematic review. *J Affect Disord.* 2024;361:445-56.
199. Pham TD, Teh MT, Chatzopoulou D, Holmes S, Coulthard P. Artificial Intelligence in Head and Neck Cancer: Innovations, Applications, and Future Directions. *Curr Oncol.* 2024;31(9):5255-90.
200. Piloizzi A, Huang X. Overcoming Alzheimer's Disease Stigma by Leveraging Artificial Intelligence and Blockchain Technologies. *Brain Sci.* 2020;10(3).
201. Pritzker KPH. Blood-based biomarkers of chronic inflammation. *Expert Rev Mol Diagn.* 2023;23(6):495-504.
202. Prudinnik DS, Kussanova A, Vorobjev IA, Tikhonov A, Ataullakhanov FI, Barteneva NS. Deformability of Heterogeneous Red Blood Cells in Aging and Related Pathologies. *Aging Dis.* 2024;16(3):1242-64.
203. Pucchio A, Krance SH, Pur DR, Bhatti J, Bassi A, Manichavagan K, et al. Applications of artificial intelligence and bioinformatics methodologies in the analysis of ocular biofluid markers: a scoping review. *Graefes Arch Clin Exp Ophthalmol.* 2024;262(4):1041-91.
204. Pur DR, Krance SH, Pucchio A, Miranda RN, Felfeli T. Current uses of artificial intelligence in the analysis of biofluid markers involved in corneal and ocular surface diseases: a systematic review. *Eye (Lond).* 2023;37(10):2007-19.

205. Rashid M. Artificial Intelligence Effecting a Paradigm Shift in Drug Development. *SLAS Technol.* 2021;26(1):3-15.
206. Restrepo JC, Dueñas D, Corredor Z, Liscano Y. Advances in Genomic Data and Biomarkers: Revolutionizing NSCLC Diagnosis and Treatment. *Cancers (Basel).* 2023;15(13).
207. Rittman T. Neurological update: neuroimaging in dementia. *J Neurol.* 2020;267(11):3429-35.
208. Roemer FW, Wirth W, Demehri S, Kijowski R, Jarraya M, Hayashi D, et al. Imaging Biomarkers of Osteoarthritis. *Semin Musculoskelet Radiol.* 2024;28(1):14-25.
209. Sadee W, Wang D, Hartmann K, Toland AE. Pharmacogenomics: Driving Personalized Medicine. *Pharmacol Rev.* 2023;75(4):789-814.
210. Sarvepalli S, Vadarevu S. Role of artificial intelligence in cancer drug discovery and development. *Cancer Lett.* 2025;627:217821.
211. Savadjiev P, Chong J, Dohan A, Agnus V, Forghani R, Reinhold C, et al. Image-based biomarkers for solid tumor quantification. *Eur Radiol.* 2019;29(10):5431-40.
212. Šebestová G, Klinger T, Švajdler M, Jr., Daum O, Jirásek T. Utilization of Artificial Intelligence Algorithms for the Diagnosis of Breast, Lung, and Prostate Cancer. *Cesk Patol.* 2025;61(2):70-90.
213. Sekaran K, Gnanasambandan R, Thirunavukarasu R, Iyyadurai R, Karthik G,

- George Priya Doss C. A systematic review of artificial intelligence-based COVID-19 modeling on multimodal genetic information. *Prog Biophys Mol Biol.* 2023;179:1-9.
214. Sen P, Lamichhane S, Mathema VB, McGlinchey A, Dickens AM, Khoomrung S, et al. Deep learning meets metabolomics: a methodological perspective. *Brief Bioinform.* 2021;22(2):1531-42.
215. Shah M, Naik N, Somani BK, Hameed BMZ. Artificial intelligence (AI) in urology-Current use and future directions: An iTRUE study. *Turk J Urol.* 2020;46(Supp. 1):S27-s39.
216. Shojaei S, Mousavi A, Kazemian S, Armani S, Maleki S, Fallahtafti P, et al. Artificial Intelligence in Risk Stratification and Outcome Prediction for Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-Analysis. *J Pers Med.* 2025;15(7).
217. Singh M, Babbarwal A, Pushpakumar S, Tyagi SC. Interoception, cardiac health, and heart failure: The potential for artificial intelligence (AI)-driven diagnosis and treatment. *Physiol Rep.* 2025;13(1):e70146.
218. Singh S, Kumar R, Payra S, Singh SK. Artificial Intelligence and Machine Learning in Pharmacological Research: Bridging the Gap Between Data and Drug Discovery. *Cureus.* 2023;15(8):e44359.
219. Siontis KC, Noseworthy PA, Attia ZI, Friedman PA. Artificial intelligence-enhanced

- electrocardiography in cardiovascular disease management. *Nat Rev Cardiol*. 2021;18(7):465-78.
220. Srivastav AK, Mishra MK, Lillard JW, Jr., Singh R. Transforming Pharmacogenomics and CRISPR Gene Editing with the Power of Artificial Intelligence for Precision Medicine. *Pharmaceutics*. 2025;17(5).
221. Sun J, Dong QX, Wang SW, Zheng YB, Liu XX, Lu TS, et al. Artificial intelligence in psychiatry research, diagnosis, and therapy. *Asian J Psychiatr*. 2023;87:103705.
222. Swinney DC, Lee JA. Recent advances in phenotypic drug discovery. *F1000Res*. 2020;9.
223. Tang HS, Ebriani J, Yan MJ, Wongvibulsin S, Farshchian M. Artificial Intelligence in Patch Testing: Comprehensive Review of Current Applications and Future Prospects in Dermatology. *JMIR Dermatol*. 2025;8:e67154.
224. Tătaru OS, Vartolomei MD, Rassweiler JJ, Virgil O, Lucarelli G, Porpiglia F, et al. Artificial Intelligence and Machine Learning in Prostate Cancer Patient Management-Current Trends and Future Perspectives. *Diagnostics (Basel)*. 2021;11(2).
225. Theodoros E, Nagaraju GP. Artificial Intelligence and Precision Medicine: Outcome of Immunotherapy in Hepatocellular Carcinoma. *Crit Rev Immunol*. 2022;42(6):1-8.
226. Tripathi D, Hajra K, Mulukutla A, Shreshtha R, Maity D. Artificial Intelligence in Biomedical Engineering and Its Influence

- on Healthcare Structure: Current and Future Prospects. *Bioengineering (Basel)*. 2025;12(2).
227. Uchikov P, Khalid U, Dedaj-Salad GH, Ghale D, Rajadurai H, Kraeva M, et al. Artificial Intelligence in Breast Cancer Diagnosis and Treatment: Advances in Imaging, Pathology, and Personalized Care. *Life (Basel)*. 2024;14(11).
228. Vicino A, Veltsista D, van Alfen N. Muscle ultrasound in myopathies. *Curr Opin Neurol*. 2024;37(5):549-57.
229. Vidiyala N, Parupathi P, Sunkishala P, Muppavarapu CS, Gujja A, Kanagala P, et al. Artificial intelligence: a new era in prostate cancer diagnosis and treatment. *Int J Pharm*. 2025;683:126024.
230. Viet CT, Zhang M, Dharmaraj N, Li GY, Pearson AT, Manon VA, et al. Artificial Intelligence Applications in Oral Cancer and Oral Dysplasia. *Tissue Eng Part A*. 2024;30(19-20):640-51.
231. Vigdorovits A, Köteles MM, Olteanu GE, Pop O. Breaking Barriers: AI's Influence on Pathology and Oncology in Resource-Scarce Medical Systems. *Cancers (Basel)*. 2023;15(23).
232. Vrahatis AG, Skolariki K, Krokidis MG, Lazaros K, Exarchos TP, Vlamos P. Revolutionizing the Early Detection of Alzheimer's Disease through Non-Invasive Biomarkers: The Role of Artificial Intelligence and Deep Learning. *Sensors (Basel)*. 2023;23(9).
233. Wagner MW, Bilbily A, Beheshti M, Shammass A, Vali R. Artificial intelligence

and radiomics in pediatric molecular imaging. *Methods*. 2021;188:37-43.

234. Wang MH. Integrating Artificial Intelligence and Precision Therapeutics for Advancing the Diagnosis and Treatment of Age-Related Macular Degeneration. *Bioengineering (Basel)*. 2025;12(5).

235. Wang YL, Gao S, Xiao Q, Li C, Grzegorzec M, Zhang YY, et al. Role of artificial intelligence in digital pathology for gynecological cancers. *Comput Struct Biotechnol J*. 2024;24:205-12.

236. Wijntjes J, van Alfen N. Muscle ultrasound: Present state and future opportunities. *Muscle Nerve*. 2021;63(4):455-66.

237. Wilczok D. Deep learning and generative artificial intelligence in aging research and healthy longevity medicine. *Aging (Albany NY)*. 2025;17(1):251-75.

238. Wu Y, Szymanska M, Hu Y, Fazal MI, Jiang N, Yetisen AK, et al. Measures of disease activity in glaucoma. *Biosens Bioelectron*. 2022;196:113700.

239. Xu D, Liu B, Wang J, Zhang Z. Bibliometric analysis of artificial intelligence for biotechnology and applied microbiology: Exploring research hotspots and frontiers. *Front Bioeng Biotechnol*. 2022;10:998298.

240. Yao J, Lin X, Zhang X, Xie M, Ma X, Bao X, et al. Predictive biomarkers for immune checkpoint inhibitors therapy in lung cancer. *Hum Vaccin Immunother*. 2024;20(1):2406063.

241. Yates J, Van Allen EM. New horizons at the

interface of artificial intelligence and translational cancer research. *Cancer Cell*. 2025;43(4):708-27.

242. Yoshida H, Kiyuna T. Requirements for implementation of artificial intelligence in the practice of gastrointestinal pathology. *World J Gastroenterol*. 2021;27(21):2818-33.

243. Yuan L, Shen Z, Shan Y, Zhu J, Wang Q, Lu Y, et al. Unveiling the landscape of pathomics in personalized immunotherapy for lung cancer: a bibliometric analysis. *Front Oncol*. 2024;14:1432212.

244. Zhavoronkov A, Mamoshina P, Vanhaelen Q, Scheibye-Knudsen M, Moskalev A, Aliper A. Artificial intelligence for aging and longevity research: Recent advances and perspectives. *Ageing Res Rev*. 2019;49:49-66.

245. Zimmer AJ, Ugarte-Gil C, Pathri R, Dewan P, Jaganath D, Cattamanchi A, et al. Making cough count in tuberculosis care. *Commun Med (Lond)*. 2022;2:83.

246. Abadi SAH, Atbaei R, Forouhi M, Falaverjani HG, Moazamiyanfar R, Rezaei M, et al. Preventive and Therapeutic Approaches in Medical Departments During the COVID-19 Pandemic. *Kindle*. 2022;2(1):1-216.

247. Ahadiat S-A, Atighi J, Forouhi M, Mashatan N, Ghahremaniyeh Z, Radmanesh M, et al. Diagnosis and Management of Complications of COVID-19. *Kindle*. 2022;2(1):1-113.

248. Ahadiat S-A, Barati R, Moghadam NS, Samami E, Ghiabi S, Alyari M, et al.

Role of Oxidative Stress and Antioxidants in Malignancies. *Kindle*. 2022;2(1):1-122.

249. Ahadiat S-A, Falaverjani HG, Shabani M, Abadi SAH, Moazamiyanfar R, Rajabi SK, et al. The Role of Stem Cells in Treatment of Autoimmune Diseases. *Kindle*. 2022;2(1):1-136.

250. Ahadiat S-A, Ghazalگو A, Abadi SAH, Falaverjani HG, Bagherianlemraski M, Namazifar F, et al. Role of Vitamin D in Pathogenesis, Diagnosis, and Treatment of Inflammatory Diseases. *Kindle*. 2022;2(1):1-119.

251. Ahadiat S-A, Kamrani K, Fard AM, Bagherianlemraski M, Rahimpour E, Jamali M, et al. Role of Blood Groups in Risk, Severity, Prognosis, and Response to Treatment of the Diseases. *Kindle*. 2022;2(1):1-130.

252. Ahadiat S-A, Shirazinia M, Shirazinia S, Garousi S, Mottahedi M, Jalali AB, et al. Role of Telemedicine in Management of Patients During the COVID-19 Pandemic. *Kindle*. 2022;2(1):1-191.

253. Amini N, Azimzadeh M, Dosar MD, Fard AM, Habibzadeh N, Yahyazadehjasour S, et al. Role of Microbiome, Infection, and Inflammation in Autoimmune Diseases. *Kindle*. 2023;3(1):1-102.

254. Babaheidarian P, Soltanattar A, Sajadi SK, Rostamian L, Foroutani L, Soleymanpourshamsi T, et al. Robotics in Healthcare. *Kindle*. 2025;5(1):1-178.

255. Fard AM, Nikbakht T, Babaei N, Pouyamanesh M, Afzalian A, Kharazmkia A, et al. Role of medicinal plants in treatment of

inflammatory diseases. *Kindle*. 2022;2(1):1-139.

256. Farrokhi M, Ghalamkarpour N, Nouri S, Babaei M, Rajabloo Y, Sattari M, et al. Innovative Vaccination: A New Era in Cancer Prevention. *Kindle*. 2025;5(1):1-194.

257. Farrokhi M, Khouzani SJ, Farrokhi M, Jalayeri H, Faranoush P, Babaei M, et al. Artificial Intelligence and Deep Learning for Screening and Risk Assessment of Cancers. *Kindle*. 2024;4(1):1-140.

258. Farrokhi M, Moeini A, Taheri F, Farrokhi M, Khodashenas M, Babaei M, et al. AI-assisted Screening and Prevention Programs for Diseases. *Kindle*. 2023;3(1):1-209.

259. Farrokhi M, Moeini A, Taheri F, Farrokhi M, Mostafavi M, Ardakan AK, et al. Artificial Intelligence in Cancer Care: From Diagnosis to Prevention and Beyond. *Kindle*. 2023;3(1):1-149.

260. Farrokhi M, Rigi A, Mangouri A, Fadaei M, Shabani E, Mashouf P, et al. Role of Antioxidants in Autoimmune Diseases. *Kindle*. 2021;1(1):1-107.

261. Farrokhi M, Shabani S, Rigi A, Seighalani HH, Pazhooha M, Bagheri S, et al. Academic Textbook: Anatomy, Pathophysiology, and Treatment of Pain. *Kindle*. 2021;1(1):1-123.

262. Farrokhi M, Taheri F, Bayat Z, Damiri M, Farrokhi M, Ghadirzadeh E, et al. Role of Lifestyle Medicine in the Prevention and Treatment of Diseases. *Kindle*. 2024;4(1):1-219.

263. Farrokhi M, Taheri F, Farrokhi M, Emtiazi N, Talebi M, Akbari A, et al. Human and AI:

Collaborative Medicine in the Age of Technology. Kindle. 2024;4(1):1-160.

264. Farrokhi M, Taheri F, Farrokhi M, Heydari Z, Darbani R, Salbi M, et al. Advancements and Innovations in Cancer Management: A Comprehensive Perspective. Kindle. 2024;4(1):1-161.

265. Farrokhi M, Taheri F, Farrokhi M, Moeini A, Tooyserkani SH, Shahali A, et al. Anti-Aging Strategies to Prevent Diseases: Promoting Longevity and Optimal Health. Kindle. 2024;4(1):1-194.

266. Farrokhi M, Taheri F, Farrokhi M, Tosi YEK, Ghadirzadeh E, Bagheri M, et al. Nanomedicine: Technologies and Applications. Kindle. 2024;4(1):1-196.

267. Farrokhi M, Taheri F, Karami E, Khorram R, Sarnaghy FJ, Mirbolook A, et al. Effects of Environmental Factors and Epigenetic on Health and the Development of Diseases. Kindle. 2023;3(1):1-186.

268. Farrokhi M, Taheri F, Khouzani PJ, Rahmani E, Tavakoli R, Fard AM, et al. Role of precision medicine and personalized medicine in the treatment of diseases. Kindle. 2023;3(1):1-164.

269. Farrokhi M, Taheri F, Moeini A, Farrokhi M, Alireza MZS, Farahmandsadr M, et al. Artificial Intelligence for Remote Patient Monitoring: Advancements, Applications, and Challenges. Kindle. 2024;4(1):1-261.

270. Farrokhi M, Taheri F, Moeini A, Farrokhi

M, Khouzani PJ, Ghadirzadeh E, et al. Artificial Intelligence for Drug Development, Personalized Prescriptions, and Adverse Event Prediction. Kindle. 2024;4(1):1-180.

271. Farrokhi M, Taheri F, Moeini A, Farrokhi M, Rabiei S, Farahmandsadr M, et al. Sex and Gender Differences in the Pathogenesis and Treatment of Diseases. Kindle. 2023;3(1):1-168.

272. Farrokhi M, Vafaei S, Bidares M, Siami H, Rigi A, Hannaniyan M, et al. Diagnosis and Treatment of Manifestations of COVID-19. Kindle. 2021;1(1):1-170.

273. Ghalamkarpour N, Fard AM, Babazadeh A, Nikseresht H, Feyzmanesh A, Soltani R, et al. Role of Biomarkers in Risk, Diagnosis, Response to Treatment, and Prognosis of the Autoimmune Diseases. Kindle. 2022;2(1):1-124.

274. Harati K, Abbasmoftad H, Ebrahimi M, Hashemlu L, Chelan RJ, Hashemzadeh A, et al. Intelligent Patient Engagement: Education and Follow-Up through AI and Telemedicine. Kindle. 2025;5(1):1-185.

275. Harati K, Mosaddeghi-Heris R, Kiani K, Saligheh Rad M, Morovatshoar R, Kamali M, et al. The AI Revolution: Predicting and Managing the Next Global Health Challenges and Emerging Disease Outbreaks. Kindle. 2025;5(1):1-326.

276. Harati K, Tahernejad M, Saddam SMS, Farshi M, Saeedfar M, Gheibi M, et al. The Future of Prosthetics and Organ Transplantation: A Therapeutic Approach Across Various Medical

Disciplines. Kindle. 2025;5(1):1-193.

277. Javadzadeh A, Shafiei D, Amlash RS, Mehrvar R, Sepehrian S, Shafiee A, et al. The Brain-Body Connection: Neuroscience's Role Across Medical Sciences Disciplines. Kindle. 2025;5(1):1-210.

278. Karimian S, Taheri F, Farrokhi M, Farrokhi M, Bayat Z, Zadeh SAM, et al. Digital Health and Wearable Technologies. Kindle. 2024;4(1):1-240.

279. Louia S, Mosaddeghi-Heris R, Kamvar R, Zahmatkesh N, Damiri M, Esfahani MA, et al. Artificial Intelligence in Cancer Genomics: Transforming Diagnosis, Treatment, and Precision Medicine. Kindle. 2025;5(1):1-234.

280. Niakosari V, Mosaddeghi-Heris R, Hezarani HB, Farrokhi M, Safaei P, Nikseresht H, et al. AI in Medical Imaging and Early Disease Detection. Kindle. 2025;5(1):1-203.

281. Poudineh M, Poudineh S, Hosseini Z, Pouramini S, Fard SS, Fadavian H, et al. Risk Factors for the Development of Cancers. Kindle. 2023;3(1):1-118.

282. Poudineh S, Poudineh M, Roohinezhad R, Khorram R, Fard AM, Barzegar F, et al. Role of Vitamins in Pathogenesis and Treatment of Cancers. Kindle. 2023;3(1):1-110.

283. Rahmani E, Fard AM, Baghsheikhi H, Hosseini Z, Mashaollahi A, Atighi J, et al. Role of Selenium in Pathogenesis and Treatment of the Autoimmune Diseases. Kindle. 2022;2(1):1-131.

284. Rahmani E, Farrokhi M, Aghajan A,

Gholampour G, Ghoojani E, Shemshadigolafzani R, et al. AI-Driven Strategies for Improving Patient Quality of Life. Kindle. 2025;5(1):1-214.

285. Rahmani E, Farrokhi M, Nemati P, Riahi S, Rostami ME, Golafzani RS, et al. Global Health Challenges. Kindle. 2024;4(1):1-218.

286. Rahmani E, Rezaei M, Tavakoli R, Ghadirzadeh E, Sarnaghy FJ, Khorram R, et al. Role of Regenerative Medicine in the Treatment of Diseases. Kindle. 2023;3(1):1-184.

287. Ramezani M, Benis DS, Nikakhtar R, Gorjizadeh N, Asadi F, Bagherianlemraski M, et al. Artificial Intelligence in Genomic Medicine: Improving Diagnostic Accuracy and Treatment Outcomes. Kindle. 2025;5(1):1-215.

288. Rezaei M, Rahmani E, Khouzani SJ, Rahmannia M, Ghadirzadeh E, Bashghareh P, et al. Role of artificial intelligence in the diagnosis and treatment of diseases. Kindle. 2023;3(1):1-160.

289. Rezaei M, Saei S, Khouzani SJ, Rostami ME, Rahmannia M, Manzelat AMR, et al. Emerging Technologies in Medicine: Artificial Intelligence, Robotics, and Medical Automation. Kindle. 2023;3(1):1-184.

290. Rezaei T, Khouzani PJ, Khouzani SJ, Fard AM, Rashidi S, Ghazalgoo A, et al. Integrating Artificial Intelligence into Telemedicine: Revolutionizing Healthcare Delivery. Kindle. 2023;3(1):1-161.

291. Rigi A, Harati K, Abbaspour M, Fattahpour SF, Hosseini P, Fard AM, et al. AI and Deep Learning

in Understanding the Etiology and Pathogenesis of Autoimmune Diseases. Kindle. 2024;4(1):1-182.

292. Tabatabaei SOH, Moazamiyanfar R, Fard AM, Salemi MH, Masjedi MNK, Yazdani Y, et al. Academic Textbook: The Role of Melatonin in Pathogenesis and Treatment of Autoimmune Diseases. Kindle. 2022;2(1):1-126.

293. Taheri F, Farrokhi M, Fard AM, Rahmani E, Soltani R, Shamsedanesh S, et al. Role of Micronutrients and Nutrition in Prevention and Treatment of Cancers. Kindle. 2023;3(1):1-102.

294. Taheri F, Farrokhi M, Rajabloo Y, Razavi N, Shirdel E, Hooshir MH, et al. Complementary and alternative medicine (CAM). Kindle. 2024;4(1):1-193.

295. Taheri F, Rahmani E, Fard SS, Rezaei M, Ayati A, Farhoudian A, et al. Aging Process and Related Diseases. Kindle. 2023;3(1):1-117.

296. Talaie R, Fard SS, Forouhi M, Fard AM, Fard TM, Dadashzadehasl N, et al. Applications, Limitations, and Guidelines for the Use of Telemedicine in Medical Departments. Kindle. 2022;2(1):1-118.

297. Yarmohammadi B, Rigi A, Sahebkar F, Ahadiat S-A, Ghareh F, Heydarian P, et al. Guidelines for Providing Services in Medical Departments During the COVID-19 Pandemic. Kindle. 2022;2(1):1-193.

298. Zahmatkesh N, Babaei SS, Manesh SH, Abbaspour M, Ghadirzadeh E, Salimian N, et al. Artificial Intelligence for Prediction of Metastasis

Risk and Survival. Kindle. 2024;4(1):1-205.

Proof